U.S. SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
1-A
Dated: January
30, 2024
REGULATION A OFFERING
CIRCULAR UNDER THE SECURITIES ACT OF 1933
Sino Bioenergy
Corp.
(Exact name of issuer as specified in its charter)
Nevada
(State of other jurisdiction of incorporation or organization)
370 Amapola Ave.,
Suite 200A
Torrance, CA 90501
404-661-2389
(Address, including zip code, and telephone number,
including area code of issuer’s principal executive office)
Udo
Ekekeulu, Esq.
Alpha Advocate Law Group PC
11432 South
Street, #373
Cerritos, CA
90703
310-866-6018
Alphaadvocatelaw@gmail.com |
(Name, address, including
zip code, and telephone number,
including area code, of agent for service)
1531 |
|
76-0616470 |
(Primary
Standard Industrial
Classification Code Number) |
|
(I.R.S.
Employer
Identification Number) |
This Preliminary Offering Circular shall
only be qualified upon order of the Commission, unless a subsequent amendment is filed indicating the intention to become qualified by
operation of the terms of Regulation A.
This Offering Circular is following the
Offering Circular format described in Part II (a)(1)(ii) of Form 1-A.
PART II – PRELIMINARY
OFFERING CIRCULAR - FORM 1-A: TIER II
An Offering statement pursuant to Regulation
A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary
Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the
Offering statement filed with the Securities and Exchange Commission is qualified. This Preliminary Offering Circular shall not constitute
an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer,
solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy
our obligation to deliver a Final Offering circular by sending you a notice within two business days after the completion of our sale
to you that contains the URL where the Final Offering Circular or the Offering statement in which such Final Offering Circular was filed
may be obtained.
PRELIMINARY OFFERING
CIRCULAR
Dated: January
30, 2024
Subject to Completion
PURSUANT TO REGULATION A OF THE SECURITIES ACT OF 1933
Sino Bioenergy
Corp.
370 Amapola Ave.,
Suite 200A
Torrance, CA 90501
424-358-1046
2,000,000,000 Shares
of Common Stock
at a price range of
$0.001 to $0.005 per Share
Minimum Investment: $1,000
Maximum Offering:
$10,000,000
See The Offering - Page 9 and Securities
Being Offered - Page 29 for further details. None of the securities offered are being sold by present security holders. This Offering
will commence upon qualification of this Offering by the Securities and Exchange Commission and will terminate 365 days from the date
of qualification by the Securities and Exchange Commission, unless extended or terminated earlier by the Company.
PLEASE REVIEW ALL RISK FACTORS ON PAGES
3 THROUGH PAGE 17 BEFORE MAKING AN INVESTMENT IN THIS COMPANY. AN INVESTMENT IN THIS COMPANY SHOULD ONLY BE MADE IF YOU ARE CAPABLE OF
EVALUATING THE RISKS AND MERITS OF THIS INVESTMENT AND IF YOU HAVE SUFFICIENT RESOURCES TO BEAR THE ENTIRE LOSS OF YOUR INVESTMENT, SHOULD
THAT OCCUR.
THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT
PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE. THESE SECURITIES ARE OFFERED PURSUANT TO
AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES
OFFERED HEREUNDER ARE EXEMPT FROM REGISTRATION.
Because these securities are being offered
on a “best efforts” basis, the following disclosures are hereby made:
|
|
Price
to Public |
|
|
Commissions
(1) |
|
|
Proceeds
to
Company (2) |
|
|
Proceeds
to
Other Persons (3) |
|
Per
Share |
|
$ |
TBD |
|
|
$ |
0 |
|
|
$ |
TBD |
|
|
|
None |
|
Minimum
Investment |
|
$ |
1,000 |
|
|
$ |
0 |
|
|
$ |
1,000 |
|
|
|
None |
|
Maximum
Offering |
|
$ |
10,000,000 |
|
|
$ |
0 |
|
|
$ |
10,000,000 |
|
|
|
None |
|
|
(1) |
The
Company has not presently engaged an underwriter for the sale of securities under this Offering. |
|
(2) |
Does
not reflect payment of expenses of this Offering, which are estimated to not exceed $240,000 and which include, among other things,
legal fees, accounting costs, reproduction expenses, due diligence, marketing, consulting, administrative services other costs of
blue-sky compliance, and actual out-of-pocket expenses incurred by the Company selling the Shares. This amount represents the proceeds
of the offering to the Company, which will be used as set out in “USE OF PROCEEDS TO ISSUER.” |
|
(3) |
There
are no finder’s fees or other fees being paid to third parties from the proceeds. See ‘PLAN OF DISTRIBUTION.’ |
|
(4) |
Assumes
a minimum price of $0.001 per share and maximum offering price of $0.005 per share. |
This Offering (the “Offering”)
consists of Common Stock (the “Shares” or individually, each a “Share”) that is being offered on a “best
efforts” basis, which means that there is no guarantee that any minimum amount will be sold. The Shares are being offered and sold
by Sino Bioenergy Corp., a Nevada corporation (the “Company”). We are offering up to 2,000,000,000 being offered at a price
to be determined after qualification pursuant to Rule 253(b). We have provided a bona fide estimate of $0.001-$0.005 per Share. This
Offering has a minimum purchase of $1,000 per investor. We may waive the minimum purchase requirement on a case-by-case basis at our
sole discretion. The Shares are being offered only by the Company on a best-efforts basis to an unlimited number of accredited investors
and to an unlimited number of non-accredited investors subject to the limitations of Regulation A. Under Rule 251(d)(2)(i)(C) of Regulation
A+, non-accredited, non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10%
of the greater of the purchaser’s revenue or net assets (as of the purchaser’s most recent fiscal year end). A non-accredited,
natural person may only invest funds which do not exceed 10% of the greater of the purchaser’s annual income or net worth (please
see below on how to calculate your net worth). The maximum aggregate amount of the Shares that will be offered is 2,000,000,000 of Common
Stock with a Maximum Offering of $10,000,000. There is no minimum number of Shares that need to be sold for funds to be released to the
Company and for this Offering to close.
Our Common Stock is currently quoted on
the OTC Expert tier of the OTC Market Group, Inc. under the symbol “SFBE”. As of January 30, 2024, the Company’s common
stock has no bid or ask.
The Shares are being offered pursuant
to Regulation A of Section 3(b) of the Securities Act of 1933, as amended, for Tier II offerings. The Shares will only be issued to purchasers
who satisfy the requirements set forth in Regulation A. The offering is expected to expire on the first of: (i) all of the Shares offered
are sold; or (ii) the close of business 365 days from the date of qualification by the Commission, unless sooner terminated or extended
by the Company’s CEO. Pending each closing, payments for the Shares will be paid directly to the Company. Funds will be immediately
transferred to the Company where they will be available for use in the operations of the Company’s business in a manner consistent
with the “USE OF PROCEEDS TO ISSUER” in this Offering Circular.
THIS OFFERING CIRCULAR DOES NOT CONSTITUTE
AN OFFER OR SOLICITATION IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO PERSON HAS BEEN AUTHORIZED
TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS CONCERNING THE COMPANY OTHER THAN THOSE CONTAINED IN THIS OFFERING CIRCULAR, AND
IF GIVEN OR MADE, SUCH OTHER INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON.
PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE
THE CONTENTS OF THIS OFFERING CIRCULAR, OR OF ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE COMPANY OR ANY OF ITS EMPLOYEES, AGENTS
OR AFFILIATES, AS INVESTMENT, LEGAL, FINANCIAL OR TAX ADVICE.
GENERALLY, NO SALE MAY BE MADE TO YOU
IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT
RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE
THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(d)(2)(i)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO
REFER TO WWW.INVESTOR.GOV (WHICH IS NOT INCORPORATED BY REFERENCE INTO THIS OFFERING CIRCULAR).
This Offering is inherently risky. See
“Risk Factors” beginning on page 3.
Sales of these securities will commence
within two calendar days of the qualification date and the filing of a Form 253(g)(2) Offering Circular AND it will be a continuous Offering
pursuant to Rule 251(d)(3)(i)(F).
The Company is following the “Offering
Circular” format of disclosure under Regulation A.
AN OFFERING STATEMENT PURSUANT TO REGULATION
A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY
OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED BEFORE THE
OFFERING STATEMENT FILED WITH THE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AN OFFER TO SELL OR
THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR
SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF SUCH STATE. THE COMPANY MAY ELECT TO SATISFY ITS OBLIGATION
TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION OF THE COMPANY’S SALE
TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR WAS FILED
MAY BE OBTAINED.
IN MAKING AN INVESTMENT DECISION INVESTORS
MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS
AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY.
FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
NOTICE TO FOREIGN
INVESTORS
IF THE PURCHASER LIVES OUTSIDE THE
UNITED STATES, IT IS THE PURCHASER’S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE
THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS OR OBSERVING
ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES BY ANY FOREIGN PURCHASER.
PATRIOT ACT RIDER
The Investor hereby represents and warrants
that Investor is not, nor is it acting as an agent, representative, intermediary or nominee for, a person identified on the list of blocked
persons maintained by the Office of Foreign Assets Control, U.S. Department of Treasury. In addition, the Investor has complied with
all applicable U.S. laws, regulations, directives, and executive orders relating to anti-money laundering , including but not limited
to the following laws: (1) the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001, Public Law 107-56, and (2) Executive Order 13224 (Blocking Property and Prohibiting Transactions with Persons Who Commit,
Threaten to Commit, or Support Terrorism) of September 23, 2001.
NO DISQUALIFICATION
EVENT (“BAD ACTOR” DECLARATION)
NONE OF THE COMPANY, ANY OF ITS PREDECESSORS,
ANY AFFILIATED ISSUER, ANY DIRECTOR, EXECUTIVE OFFICER, OTHER OFFICER OF THE COMPANY PARTICIPATING IN THE OFFERING CONTEMPLATED HEREBY,
ANY BENEFICIAL OWNER OF 20% OR MORE OF THE COMPANY’S OUTSTANDING VOTING EQUITY SECURITIES, CALCULATED ON THE BASIS OF VOTING POWER,
NOR ANY PROMOTER (AS THAT TERM IS DEFINED IN RULE 405 UNDER THE SECURITIES ACT OF 1933) CONNECTED WITH THE COMPANY IN ANY CAPACITY AT
THE TIME OF SALE (EACH, AN “ISSUER COVERED PERSON”) IS SUBJECT TO ANY OF THE “BAD ACTOR” DISQUALIFICATIONS
DESCRIBED IN RULE 506(D)(1)(I) TO (VIII) UNDER THE SECURITIES ACT OF 1933 (A “DISQUALIFICATION EVENT”), EXCEPT
FOR A DISQUALIFICATION EVENT COVERED BY RULE 506(D)(2) OR (D)(3) UNDER THE SECURITIES ACT. THE COMPANY HAS EXERCISED REASONABLE CARE
TO DETERMINE WHETHER ANY ISSUER COVERED PERSON IS SUBJECT TO A DISQUALIFICATION EVENT.
Continuous Offering
Under Rule 251(d)(3) to Regulation A,
the following types of continuous or delayed Offerings are permitted, among others: (1) securities offered or sold by or on behalf of
a person other than the issuer or its subsidiary or a person of which the issuer is a subsidiary; (2) securities issued upon conversion
of other outstanding securities; or (3) securities that are part of an Offering which commences within two calendar days after the qualification
date. These may be offered on a continuous basis and may continue to be offered for a period of more than 30 days from the date of initial
qualification. They may be offered in an amount that, at the time the Offering statement is qualified, is reasonably expected to be offered
and sold within one year from the initial qualification date. No securities will be offered or sold “at the market.” The
Shares will be sold at a fixed price to be determined after qualification. We have provided a bona fide estimate of the price range of
the Offering, pursuant to Rule 253(b)(2). The Offering Price will be filed by the Company via an offering circular supplement pursuant
to Rule 253(c). The supplement will not, in the aggregate, represent any change from the maximum aggregate Offering Price calculable
using the information in the qualified Offering statement. This information will be filed no later than two business days following the
earlier of the date of determination of such pricing information or the date of first use of the Offering Circular after qualification.
Sale of these shares will commence
within two calendar days of the qualification date, and it will be a continuous Offering pursuant to Rule 251(d)(3)(i)(F).
Subscriptions are irrevocable and the
purchase price is non-refundable as expressly stated in this Offering Circular. The Company, by determination of the Board of Directors,
in its sole discretion, may issue the Securities under this Offering for cash, promissory notes, services, and/or other consideration
without notice to subscribers. All proceeds received by the Company from subscribers for this Offering will be available for use by the
Company upon acceptance of subscriptions for Securities by the Company.
Forward Looking
Statement Disclosure
This Form 1-A, Offering Circular, and
any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties.
All statements other than statements of historical fact or relating to present facts or current conditions included in this Form 1-A,
Offering Circular, and any documents incorporated by reference are forward-looking statements. Forward-looking statements give the Company’s
current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future
performance, and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or
current facts. These statements may include words such as ‘anticipate,’ ‘estimate,’ ‘expect,’ ‘project,’
‘plan,’ ‘intend,’ ‘believe,’ ‘may,’ ‘should,’ ‘can have,’ ‘likely’
and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial
performance or other events. The forward-looking statements contained in this Form 1-A, Offering Circular, and any documents incorporated
by reference herein or therein are based on reasonable assumptions the Company has made considering its industry experience, perceptions
of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances.
As you read and consider this Form 1-A, Offering Circular, and any documents incorporated by reference, you should understand that these
statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company’s
control) and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you
should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially
from the performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize or
should any of these assumptions prove incorrect or change, the Company’s actual operating and financial performance may vary in
material respects from the performance projected in these forward- looking statements. Any forward-looking statement made by the Company
in this Form 1-A, Offering Circular or any documents incorporated by reference herein speaks only as of the date of this Form 1-A, Offering
Circular or any documents incorporated by reference herein. Factors or events that could cause our actual operating and financial performance
to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation
to update any forward-looking statement, whether because of new information, future developments or otherwise, except as may be required
by law.
About This Form 1-A and
Offering Circular
In making an investment decision, you
should rely only on the information contained in this Form 1-A and Offering Circular. The Company has not authorized anyone to provide
you with information different from that contained in this Form 1-A and Offering Circular. We are offering to sell, and seeking offers
to buy the Shares only in jurisdictions where offers and sales are permitted. You should assume that the information contained in this
Form 1-A and Offering Circular is accurate only as of the date of this Form 1-A and Offering Circular, regardless of the time of delivery
of this Form 1-A and Offering Circular. Our business, financial condition, results of operations, and prospects may have changed since
that date. The statements contained herein as to the content of any agreements or other documents are summaries and, therefore, are necessarily
selective and incomplete and are qualified in their entirety by the actual agreements or other documents.
TABLE OF CONTENTS
|
Page |
|
|
OFFERING
SUMMARY, PERKS AND RISK FACTORS |
9 |
Offering
Circular Summary |
9 |
The
Offering |
10 |
Investment
Analysis |
10 |
RISK
FACTORS |
11 |
DILUTION |
22 |
PLAN
OF DISTRIBUTION |
23 |
USE
OF PROCEEDS TO ISSUER |
26 |
DESCRIPTION
OF BUSINESS |
27 |
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
31 |
DIRECTORS,
EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES |
37 |
COMPENSATION
OF DIRECTORS AND EXECUTIVE OFFICERS |
38 |
SECURITY
OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS |
40 |
INTEREST
OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS |
41 |
DESCRIPTION
OF SECURITIES |
42 |
SECURITIES
BEING OFFERED |
42 |
DISQUALIFYING
EVENTS DISCLOSURE |
44 |
ERISA
CONSIDERATIONS |
44 |
SHARES
ELIGIBLE FOR FUTURE SALE |
46 |
INVESTOR
ELIGIBILITY STANDARDS & ADDITIONAL INFORMATION ABOUT THE OFFERING |
47 |
WHERE
YOU CAN FIND MORE INFORMATION |
49 |
SIGNATURES |
50 |
INDEX
TO EXHIBITS |
III-1 |
PART
F/S FINANCIAL STATEMENTS |
F-1 |
OFFERING CIRCULAR
SUMMARY, PERKS AND RISK FACTORS
OFFERING CIRCULAR
SUMMARY
The following summary is qualified
in its entirety by the more detailed information appearing elsewhere in this Offering Circular and/or incorporated by reference in this
Offering Circular. For full offering details, please (1) thoroughly review this Form 1-A filed with the Securities and Exchange Commission
(2) thoroughly review this Offering Circular and (3) thoroughly review any attached documents to or documents referenced in, this Form
1-A and Offering Circular.
Unless otherwise indicated, the terms
“SFBE Global” “SFBE,” “the Company,” we,” “our,” and “us” are used
in this Offering Circular to refer to Sino Bioenergy Corp. and its subsidiaries.
Business Overview
Historically, Sino Bioenergy Corp., a
Nevada corporation, owns the rights to several domain names, all related to the supplements industry including: VitaminSales.us VitaminsPrime.com,
VitaminChoices.com, HerbsPrime.com, SupplementsPrime.com and NewHealthReview.com. Subsequent to its revival of business operations and
revival of its charter with the State of Nevada, the Company wants to enter the Electric Vehicles Charge point business through acquisition
or leasing of spots in or near multi-family residential complexes or convenient stores to install changepoints where EV users could conveniently
recharge their vehicles for a fee.
For a further description of the Company
and its plan of operations, see the section entitled “Description of Business” beginning on Page 13.
Issuer: |
Sino
Bioenergy Corp. |
|
|
Type
of Stock Offering: |
Common
Stock |
|
|
Price
Per Share: |
To
be determined after qualification. We have provided a bona fide estimate of the expected range of the price per share of $0.001-
0.005. |
|
|
Minimum
Investment: |
$1,000
per investor. We may waive the minimum purchase requirement on a case-by-case basis in our sole discretion. |
|
|
Maximum
Offering: |
$10,000,000.
The Company will not accept investments that would be, in aggregate, greater than the Maximum Offering amount. |
|
|
Maximum
Shares Offered: |
2,000,000,000
of Common Stock |
|
|
Investment
Amount Restrictions: |
Generally,
no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual
income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that
your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(c) of Regulation A. For general
information on investing, we encourage you to refer to www.investor.gov. |
|
|
Method
of Subscription: |
After
the qualification by the SEC of the Offering Statement of which this Offering Circular is a part, investors can subscribe to purchase
the Shares by completing the Subscription Agreement and sending payment by check, wire transfer, ACH, credit card, or any other payment
method accepted by the Company. Upon the approval of any subscription, the Company shall immediately deposit said proceeds
into the bank account of the Company and may dispose of the proceeds in accordance with the Use of Proceeds. Subscriptions
are irrevocable and the purchase price is non-refundable. |
|
|
Use
of Proceeds: |
See
the description in the section entitled “USE OF PROCEEDS TO ISSUER” on page 12 herein. |
|
|
Voting
Rights: |
The
Shares have full voting rights. |
|
|
Trading
Symbols: |
Our
common stock is directly quoted on the OTC Pink tier of the OTC Market Group, Inc. under the symbol “SFBE”. |
|
|
Transfer
Agent and Registrar: |
Transfer
Online, Inc. is our transfer agent and registrar in connection with the Offering. |
|
|
Length
of Offering: |
Shares
will be offered on a continuous basis until either (1) the maximum number of Shares are sold; (2) 365 days from the date of qualification
by the Commission; (3) the Company in its sole discretion extends the offering beyond 365 days from the date of qualification by
the Commission, or (4) the Company in its sole discretion withdraws this Offering. |
The Offering
Common
Stock Outstanding (1) |
|
51,251,321
Shares |
|
Common
Stock in this Offering |
|
2,000,000,000
Shares |
|
Stock
to be outstanding after the offering (2) |
|
2,051,251,321
Shares |
|
|
(1) |
As
of the date of this Offering Circular. |
|
(2) |
The
total number of Shares of Common Stock assumes that the maximum number of Shares are sold in this Offering. The Company may not be
able to sell the Maximum Offering Amount. The Company will conduct one or more closings on a rolling basis as funds are received
from investors. |
Investment Analysis
There is no assurance the Company will
be profitable, or that the management’s opinion of the Company’s prospects will not be outweighed by the unanticipated losses,
adverse regulatory developments and other risks. Investors should carefully consider the various risk factors below before investing
in the Shares.
Risk Factor Summary
We are subject to a variety of risks and
uncertainties, including risks related to our operations and business, financial risks, risks related to our industry, environmental
and climate risks, risks related to the jurisdictions in which we operate, risks related to our workforce, legal risks and risks related
to our common stock, which could have a material adverse effect on our business, financial condition, results of operations and cash
flows. Risks that we deem material are described in Item 1A, Risk Factors of this report. These risks include, but are not limited to,
the following:
• Our operations and business have
been affected by the COVID-19 pandemic and may be materially and adversely impacted in the future by pandemics, epidemics, or other health
emergencies.
• Our results could be significantly
impacted by impairments.
• Our operations are subject to
risks of doing business in multiple jurisdictions, including political, economic and other risks.
• Our business depends on good relations
with our employees, and if we are unable to attract and retain additional highly skilled employees, our business and future operations
may be adversely affected
• Title to some of the properties
of our target acquisition may be insufficient, defective, or subject to legal challenge in the future.
• The price of our common stock
may be volatile, and holders of our common stock may not receive dividends in the future.
Additional risks and uncertainties not
presently known to us or that we currently deem immaterial also may impair our business, financial condition, results of operations and
cash flows.
RISK FACTORS
The purchase of the Company’s Common
Stock involves substantial risks. You should carefully consider the following risk factors in addition to any other risks associated
with this investment. The Shares offered by the Company constitute a highly speculative investment and you should be in an economic position
to lose your entire investment. The risks listed do not necessarily comprise all those associated with an investment in the Shares and
are not set out in any order of priority. Additional risks and uncertainties may also have an adverse effect on the Company’s business
and your investment in the Shares. An investment in the Company may not be suitable for all recipients of this Offering Circular. You
are advised to consult an independent professional adviser or attorney who specializes in investments of this kind before making any
decision to invest. You should consider carefully whether an investment in the Company is suitable in the light of your personal circumstances
and the financial resources available to you.
The discussions and information in this
Offering Circular may contain both historical and forward- looking statements. To the extent that the Offering Circular contains forward-looking
statements regarding the financial condition, operating results, business prospects, or any other aspect of the Company’s business,
please be advised that the Company’s actual financial condition, operating results, and business performance may differ materially
from that projected or estimated by the Company in forward-looking statements. The Company has attempted to identify, in context, certain
of the factors it currently believes may cause actual future experience and results may differ from the Company’s current expectations.
Before investing, you should carefully
read and carefully consider the following risk factors:
Risks Relating to Our
Company
Our
financial condition and results of operations will fluctuate from quarter to quarter, which makes them difficult to predict and they
may not fully reflect the underlying performance of our business.
Our quarterly results
of operations have fluctuated in the past and will fluctuate in the future, both based on the seasonality of our business as well as
external factors impacting the global economy, our industry and our company. Additionally, the current scale of our business makes it
difficult to forecast our future results. As a result, you should not rely on our past quarterly results of operations as indicators
of future performance. You should consider the risks and uncertainties frequently encountered by companies in rapidly evolving market
segments. Our financial condition and results of operations in any given quarter can be influenced by numerous factors, many of which
we are unable to predict or are outside of our control, including:
Our business is affected by
seasonal demands, and our quarterly operations results fluctuate as a result.
•
Our accountant has included a “going concern” note in its review report. We may not have enough funds to sustain the
business until it becomes profitable. Our ability to remain in business is reliant on either generating sufficient cash flows, raising
additional capital, or likely a combination of the two. Additionally, even if targeted funds are raised, it is likely that we will need
to raise additional funds soon.
•
We depend on a small management team. We depend on the skill and experience of our President, Frank Igwealor. Mr. Igwealor has
responsibilities to other companies and is not currently a paid employee. If demand for our product is high, our ability to raise sufficient
capital may have an impact on our ability to attract and hire the right talent.
•
We are controlled by our officer, director and a majority shareholder. Frank Igwealor holds most of our voting stock, and at the
conclusion of this offering will continue to hold most of the company’s common stock. Investors in this offering will not have
the ability to control a vote by the stockholders or the board of directors.
•
The company will need to raise additional money in the future. We might not sell enough securities in this offering to meet our
operating needs and fulfill our plans, in which case we will cease operating and you will lose your investment. Even if we raise everything
at or above our targeted funds, it is likely that we will need to raise additional funds in the future. The ability to raise funds will
always be a risk until we achieve sustainable profitability, which we currently cannot predict. Even if we do successfully raise more
funds after this offering, the terms of that offering could result in a reduction in the value of your investment in the company, as
later stage investors may get more favorable terms.
•
It is difficult for us to accurately predict our earnings potential. Because of our short operating history, it is more difficult
to accurately assess growth rate and earnings potential. It is possible that our company will face many difficulties typical for early-stage
companies.
As a
new company we have a limited operating history.
The Company was organized
in Nevada. Our business and prospects must be considered considering the risk, expense and difficulties frequently encountered by pre-revenue
companies in the early stages of development, particularly companies in highly competitive and evolving markets. If we are unable to
effectively allocate our resources, our business operating results and financial condition would be adversely affected and we may be
unable to execute our business plan, and our business could fail. Investors could therefore be at risk of losing their investment.
We expect
losses in the foreseeable future.
Excluding the effect
of any future non-operating gains, we expect to incur losses in the foreseeable future and, if we ever generate revenues, or have profits,
we may not be able to sustain them. Our expenses will increase as we build an infrastructure to implement our business model. For example,
we may hire additional employees, expand information technology systems, and lease more space for our corporate offices. In addition,
we plan to significantly increase our operating expenses to:
| ● | acquire
properties or leases. |
| ● | explore
opportunities and alliances with other landlords;
and |
| ● | facilitate
business arrangements. |
Our success
is dependent on our key personnel.
We believe that our
success will depend on the continued employment of our senior management and key personnel. If one or more members of our senior management
were unable or unwilling to continue in their present positions,
our business and
operations could be disrupted, and this could put the overall business at risk, and therefore investors could be at risk of losing their
investments.
Projections
are speculative and are based upon several assumptions.
Any projected financial
results prepared by or on behalf of the Company have not been independently reviewed, analyzed, or otherwise passed upon. Such “forward-looking”
statements are based on various assumptions, which assumptions may prove to be incorrect. Such assumptions include but are not limited
to (i) the future status of local, regional and international economies, (ii) anticipated demand for EV-Chargers, (iii) anticipated costs
associated with the acquisition and retrofitting of the properties, marketing of our models,
and (iv) anticipated and retention of a customer base. Accordingly, there can be no assurance that such projections, assumptions, and
statements will accurately predict future events or actual performance. Any projections of cash flow should be considered speculative
and are qualified in their entirety by the assumptions, information and risks disclosed in this Memorandum. Investors are advised to
consult with their own independent tax and business advisors concerning the validity and reasonableness of the factual, accounting and
tax assumptions. No representations or warranties whatsoever are made by the Company, its affiliates or any other person or entity as
to the future profitability of the Company or the results of making an investment in the Shares. If our future projections end up being
significantly different to those currently projected, our business could be greatly impacted. Our business therefore may not be able
to sustain itself without the projected future revenues. The business could be at risk of closing, and investors may therefore be at
risk of losing their investments.
We may
not effectively manage growth.
The
anticipated growth of the Company’s business will result in a corresponding growth in the demands on the Company’s management
and its operating infrastructure and internal controls. While we are planning for managed growth, any future growth may strain resources
and operational, financial, human and management information systems, which may not be adequate to support the Company’s operations
and will require the Company to develop further management systems and procedures. There can be no guarantee that the Company will be
able to develop such systems or procedures effectively on a timely basis. The failure to do so could have a material adverse effect upon
the Company’s business, operating results and financial condition. Investors could therefore be at risk of losing their investments
if growth is not managed effectively.
Our
efficiency may be limited while our current employees and future employees are being integrated into our operations.
In
addition, we may be unable to find and hire additional qualified management and professional personnel to help lead us. There is competition
for qualified personnel in the Company’s activities, and there can be no assurance that the Company will be able to attract and
retain the qualified personnel necessary for the development of our business. If this business cannot effectively hire employees to help
the company grow, the business could be at risk overall of failing, and investors therefore may be at risk of losing their investment.
We expect
our expenses to grow as the Company grows.
Our
expenses will increase as we build infrastructure to implement our business plan. For example, we may hire additional employees, expand
our product offerings, and lease more space for our corporate offices. This poses a risk to the financial forecasts and current financial
model of the Company.
The Company may not
reach its revenue goals.
The Company has forecasted
its capitalization requirements based on revenue goals and cost measures; any reduction to these forecasts could make it difficult for
the company to achieve its projected growth, which would affect available cash and working capital, ultimately affecting the Company’s
financial condition. This could put the investor at risk of losing their investment.
The Company
may require additional financing to support working capital needs.
The Company may need
to explore additional financing transactions that management determines are in the best interest of the Company, including, without limitation,
commercial debt transactions, private offerings of debt or equity securities, a right offering, and other strategic alternatives. Such
additional financing may not be available to the Company, or, if available, the Company may be unable to undertake such additional financing
on terms that are advantageous to the Company. If the Company fails to raise additional capital in such an offering, or through other
fund-raising efforts, such a failure could have a material adverse effect on the Company,
and investors in this Offering could be at greater risk of losing their investments due to the inability of the business to proceed with
enough working capital to effectively run the Company.
If the
Company incurs commercial debt, there may be risks associated with such borrowing.
If the Company incurs
commercial indebtedness, a portion of its cash flow will have to be dedicated to the payment of principal and interest on such indebtedness.
Typical loan agreements also might contain restrictive covenants, which may impair the Company’s operating flexibility. Such loan
agreements would also provide for default under certain circumstances, such as failure to meet certain financial covenants. A default
under a loan agreement could result in the loan becoming immediately due and payable and, if unpaid, a judgment in favor of such lender
which would be senior to the rights of shareholders of the Company. A judgment creditor would have the right to foreclose on any of the
Company’s assets resulting in a material adverse effect on the Company’s business, operating results or financial condition.
Public
health epidemics or outbreaks could adversely impact our business.
In
December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely
concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections
have been reported globally. The extent to which the coronavirus impacts our operations will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak,
new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact,
among others. In particular, the continued spread of the coronavirus globally could adversely impact our operations and could have an
adverse impact on our business and our financial results.
Risks
Relating to Our Operation and Properties.
There
are inherent risks associated with real estate investments and with the real estate industry, each of which could have an adverse impact
on our financial performance and the value of our properties.
Real
estate investments are subject to various risks and fluctuations and cycles in value and demand, many of which are beyond our control.
Our financial performance and the value of our properties can be affected by many of these factors, including the following:
|
• |
|
adverse
changes in financial conditions of buyers, sellers and tenants of our properties, including bankruptcies, financial difficulties
or lease defaults by our tenants; |
|
• |
|
the
national, regional and local economy, which may be negatively impacted by concerns about inflation, government deficits or government
budgets, unemployment rates, decreased consumer confidence, industry slowdowns, reduced corporate profits, liquidity concerns in
our markets and other adverse business concerns; |
|
• |
|
local
real estate conditions, such as an oversupply of, or a reduction in, demand for office space and the availability and creditworthiness
of current and prospective tenants; |
|
• |
|
vacancies
or ability to rent space on favorable terms, including possible market pressures to offer tenants rent abatements, tenant improvements,
early termination rights or below-market renewal options; |
|
• |
|
changes
in operating costs and expenses, including, without limitation, increasing labor and material costs, insurance costs, energy prices,
environmental restrictions, real estate taxes and costs of compliance with laws, regulations and government policies, which we may
be restricted from passing on to our tenants; |
|
• |
|
fluctuations
in interest rates, which could adversely affect our ability, or the ability of buyers and tenants of our properties, to obtain financing
on favorable terms or at all, or impact the market price of our properties we own or target for investment; |
|
• |
|
competition
from other real estate investors with significant capital, including other real estate operating companies; |
|
• |
|
inability
to refinance our indebtedness, which could result in a default on our obligation and trigger cross default provisions that could
result in a default on other indebtedness; |
|
• |
|
the
convenience and quality of competing office properties; |
|
• |
|
inability
to collect rent from tenants; |
|
• |
|
our
ability to secure adequate insurance; |
|
• |
|
our
ability to secure adequate management services and to maintain our properties; |
|
• |
|
changes
in, and changes in enforcement of, laws, regulations and governmental policies, including, without limitation, health, safety, environmental,
zoning, immigration and tax laws, government fiscal, monetary and trade policies and the Americans with Disabilities Act of 1990
(the “ADA”); and |
|
• |
|
civil
unrest, acts of war, cyber-attacks, terrorist attacks and natural disasters, including earthquakes, wind damage and floods, which
may result in uninsured and underinsured losses. |
In
addition, because the yields available from equity investments in real estate depend in large part on the amount of rental income earned,
as well as property operating expenses and other costs incurred, a period of economic slowdown or recession, or declining demand for
real estate, or the public perception that any of these.
We
may be unable to complete acquisitions and, even if acquisitions are completed, we may fail to successfully operate acquired properties.
Our
business plan includes, among other things, growth through identifying suitable acquisition opportunities, consummating acquisitions
and leasing such properties. We will evaluate the market of available properties and may acquire properties when we believe strategic
opportunities exist. Our ability to acquire properties on favorable terms and successfully develop or operate them is subject to, among
others, the following risks:
|
• |
|
we
may be unable to acquire a desired property because of competition from other real estate investors with substantial capital; |
|
• |
|
even
if we can acquire a desired property, competition from other potential acquirers may significantly increase the purchase price; |
|
• |
|
even
if we enter into agreements for the acquisition of properties, these agreements are subject to customary conditions to closing, including
completion of due diligence investigations to our satisfaction; |
|
• |
|
we
may incur significant costs in connection with evaluation and negotiation of potential acquisitions, including acquisitions that
we are subsequently unable to complete; |
|
• |
|
we
may acquire properties that are not initially accretive to our results upon acquisition, and we may not successfully lease those
properties to meet our expectations; |
|
• |
|
we
may be unable to finance the acquisition on favorable terms in the time we desire, or at all; |
|
• |
|
even
if we can finance the acquisition, our cash flows may be insufficient to meet our required principal and interest payments; |
|
• |
|
we
may spend more than budgeted to make necessary improvements or renovations to acquired properties; |
|
• |
|
we
may be unable to quickly and efficiently integrate new acquisitions, particularly the acquisition of portfolios of properties, into
our existing operations; market conditions may result in higher-than-expected vacancy rates and lower than expected rental rates;
and |
|
• |
|
we
may acquire properties subject to liabilities and without any recourse, or with only limited recourse, with respect to unknown liabilities
for clean-up of undisclosed environmental contamination, claims by tenants or other persons dealing with former owners
of the properties and claims for indemnification by general partners, directors, officers and others indemnified by the former owners
of the properties. |
Acquired
properties may be in new markets where we may face risks associated with investing in an unfamiliar market.
We
may acquire properties in markets that are new to us. When we acquire properties located in new markets, we may face risks associated
with a lack of market knowledge or understanding of the local economy, forging new business relationships in the area and unfamiliarity
with local government and permitting procedures. We work to mitigate such risks through extensive diligence and research and associations
with experienced service providers. However, there can be no guarantee that all such risks will be eliminated.
We
may be limited in our ability to diversify our investments, making us more vulnerable economically than if our investments were diversified.
Our
ability to diversify our portfolio may be limited both as to the number of investments owned and the geographic regions in which our
investments are located. While we seek to diversify our portfolio by geographic location, we focus on our specified target markets that
we believe offer the opportunity for attractive returns and, accordingly, our actual investments may result in concentrations in a limited
number of geographic regions. As a result, there is an increased likelihood that the performance of any single property, or the economic
performance of a particular region in which our properties are located, could materially affect our operating results.
We
may acquire properties with lock-out provisions or agree to such provisions in connection with obtaining financing, which may
prohibit us from selling or refinancing a property during the lock-out period.
We
may acquire properties in exchange for common units and agree to restrictions on sales or refinancing, called “lock-out” provisions,
which are intended to preserve favorable tax treatment for the owners of such properties who sell them to us. In addition, we may agree
to lock-out provisions in connection with obtaining financing for the acquisition of properties. Lock-out provisions
could materially restrict us from selling, otherwise disposing of or refinancing properties. These restrictions could affect our ability
to turn our investments into cash and thus affect the cash available for distributions to our stockholders. Lock-out provisions
could impair our ability to take actions during the lock-out period that would otherwise be in the best interests of our stockholders
and, therefore, could adversely impact the market value of our common stock. Lock-out provisions could preclude us from participating
in major transactions that could result in a disposition of our assets or a change in control even though that disposition or change
in control might be in the best interests of our stockholders.
Illiquidity
of real estate investments could significantly impede our ability to respond to adverse changes in the performance of our properties
and harm our financial condition.
The
real estate investments made, and to be made, by us are relatively difficult to sell quickly. As a result, our ability to promptly sell
one or more properties in our portfolio in response to changing economic, financial and investment conditions is limited. Return
of capital and realization of gains, if any, from an investment generally will occur upon disposition or refinancing of the underlying
property. We may be unable to realize our investment objectives by sale, other disposition or refinancing at attractive prices within
any given period or may otherwise be unable to complete any exit strategy. Our ability to dispose of one or more properties is subject
to weakness in or even the lack of an established market for a property, changes in the financial condition or prospects of prospective
purchasers, changes in national or international economic conditions and changes in laws, regulations or fiscal policies of jurisdictions
in which the property is located.
If
we sell properties by providing financing to purchasers, we will bear the risk of default by the purchaser.
If
we decide to sell any of our properties, we intend to use commercially reasonable efforts to sell them for cash. However, in some instances
we may sell our properties by providing financing to purchasers. If we provide financing to purchasers, we will bear the risk of default
by the purchasers which would reduce the value of our assets, impair our ability to make distributions to our stockholders and reduce
the price of our common stock.
We
may be unable to collect balances due on our leases from any tenants in bankruptcy, which could adversely affect our cash flow and the
amount of cash available for distribution to our stockholders.
The
bankruptcy or insolvency of one or more of our tenants may adversely affect the income produced by our properties. We cannot assure
you that any tenant that files for bankruptcy protection will continue to pay us rent. If a tenant files for bankruptcy, any or all the
tenant’s or a guarantor of a tenant’s lease obligations could be subject to a bankruptcy proceeding pursuant to Chapter 11
or Chapter 7 of the U.S. Bankruptcy Code. Such a bankruptcy filing would impose an automatic stay barring all efforts by us to collect pre-bankruptcy rents
from these entities or their properties, unless we receive an order from the bankruptcy court lifting the automatic stay to permit us
to pursue collections. A tenant or lease guarantor bankruptcy could delay our efforts to collect past due balances under the relevant
leases and could ultimately preclude collection of these sums. If a lease is rejected by a tenant in bankruptcy, we would only have a
general unsecured claim for damages. This claim could be paid only in the event funds were available and then only in the same percentage
as that realized on other unsecured claims. Our claim would be capped at the rent reserved under the lease, without acceleration, for
the greater of one year or 15% of the remaining term of the lease, but not greater than three years, plus rent already due
but unpaid. Therefore, if a lease is rejected, it is possible that we would not receive payment from the tenant or that we would receive
substantially less than the full value of any unsecured claims we hold, which would result in a reduction in our rental income, cash
flow and the amount of cash available for distribution to our stockholders.
We
may face additional risks and costs associated with owning properties occupied by government tenants, which could negatively impact our
cash flows and results of operations.
We
may put some of our residential properties into government approved/sponsored affordable housing schemes. Some of our leases with government
tenants may be subject to statutory or contractual rights of termination by the tenants, which will allow them to vacate the leased premises
before the stated terms of the leases expire with little or no liability. For fiscal policy reasons, security concerns or other reasons,
some or all our government tenants may decide to vacate our properties. If a significant number of such vacancies occur, our rental income
may materially decline, our cash flow and results of operations could be adversely affected and our ability to pay regular distributions
to you may be jeopardized.
Our
government tenants may also be subject to discretionary funding from the federal government. Federal government programs are subject
to annual congressional budget authorization and appropriation processes. For many programs, Congress appropriates funds on a fiscal
year basis even though the program performance period may extend over several years. Laws and plans adopted by the federal government
relating to, along with pressures on and uncertainty surrounding the federal budget, potential changes in priorities and spending levels,
sequestration, the appropriations process, use of continuing resolutions (with restrictions, e.g., on new starts) and the permissible
federal debt limit, could adversely affect the funding for our government tenants. The budget environment and uncertainty surrounding
the appropriations processes remain significant long-term risks as budget cuts could adversely affect the viability of our government
tenants.
Compliance
with the Americans with Disabilities Act and similar laws may require us to make significant unanticipated expenditures.
All
of our properties and any future properties that we acquire are and will be required to comply with the ADA. The ADA requires that all
public accommodations must meet federal requirements related to access and use by disabled persons. For those projects receiving federal
funds, the Rehabilitation Act of 1973 (the “RA”) also has requirements regarding disabled access. Although we believe that
our properties are substantially in compliance with the present requirements, we may incur unanticipated expenses to comply with the
ADA, the RA and other applicable legislation in connection with the ongoing operation or redevelopment of our properties. These and other
federal, state and local laws may require modifications to our properties or affect renovations of our properties. Non-compliance with
these laws could result in the imposition of fines or an award of damages to private litigants and could result in an order to correct
any non-complying feature, which could result in substantial capital expenditure.
Our
property taxes could increase due to property tax rate changes or reassessment, which may adversely impact our cash flows.
We
will be required to pay some state and local taxes on our properties. The real property taxes on our properties may increase as property
tax rates change or as our properties are assessed or reassessed by taxing authorities. Therefore, the amount of property taxes that
we pay in the future may increase substantially. In addition, the real property taxes on Cherry Creek are reduced due to having a government
user as its largest tenant and loss of such tenant would increase the amount of property taxes. If the property taxes that we pay increase,
our cash flow could be impacted, and our ability to pay expected distributions to our stockholders may be adversely affected.
Risks
Relating to Our Securities
These securities
are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination
that these securities are exempt If a market for our common stock does not develop, shareholders may be unable to sell their shares.
Our common stock
is quoted under the symbol “AWAW” on the OTC PINK Market operated by OTC Markets Group, Inc., an electronic inter-dealer
quotation medium for equity securities. We do not currently have an active trading market. There can be no assurance that an active and
liquid trading market will develop or, if developed, that it will be sustained.
Our securities are very
thinly traded. Accordingly, it may be difficult to sell shares of our common stock without significantly depressing the value of the
stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could continue to result in
major fluctuations in the price of the stock.
Because
we are subject to the “Penny Stock” rules, the level of trading activity in our stock may be reduced.
The Securities and Exchange
Commission has adopted regulations which generally define "penny stock" to be any listed, trading equity security that has
a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. The penny
stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized
risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must
also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson
in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account.
In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker- dealer makes a special
written determination that the penny stock is a suitable investment for the purchaser and receives the purchaser’s written agreement
to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market
for a stock that becomes subject to the penny stock rules which may increase the difficulty Purchasers may experience in attempting to
liquidate such securities.
Effect of Amended Rule
15c2-11 on the Company’s securities.
The SEC released and published
a Final Rulemaking on Publication or Submission of Quotations without Specified Information amending Rule 15c2-11 under the Exchange
Act ("Rule 15c2-11,” the "Amended Rule 15c2-11"). To be eligible for public quotations on an ongoing basis, Amended
Rule 15c2-11's modified the "piggyback exemption" that required that (i) the specified current information about the company
is publicly available, and (ii) the security is subject to a one-sided (i.e. a bid or offer) priced quotation, with no more than four
business days in succession without a quotation. Under Amended Rule 15c2-11, shell companies like the Company (and formerly suspended
securities) may only rely on the piggyback exemption in certain limited circumstances. Amended Rule 15c2-11 will require, among other
requirements, that a broker-dealer has a reasonable basis for believing that information about the issuer of securities is accurate.
Our security holders may find it more difficult to deposit common stock with a broker-dealer,
and if deposited, more difficult to trade the securities on the Pink Sheets. The Company intends to provide the specified current information
under the Exchange Act but there is no assurance that a broker-dealer will accept our common stock or if accepted, that the broker-dealer
will rely on our disclosure of the specified current information.
We
do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
We do not anticipate
paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on earnings,
financial condition and other business and economic factors affecting it at such time as the board of directors may consider relevant.
If we do not pay dividends, our common stock may be less valuable because a return on your investment will occur only if our stock price
appreciates.
Management
has broad discretion as to the use of proceeds.
The net proceeds from
this Securities Offering will be used for the purposes described under “USE OF PROCEEDS.” The Company reserves the right
to use the funds obtained from this Offering for other similar purposes not presently contemplated, which it deems to be in the best
interests of the Company to address changed circumstances or opportunities. This poses a risk to an investor should they be relying on
current use of proceeds forecasts for the investment as business conditions may require a change of the use of these funds.
We have used an arbitrary
offering price. The offering price per unit was arbitrarily determined by the Company and is unrelated to specific investment criteria,
such as the assets or past results of the Company’s operations. In determining the offering price, the Company considered such
factors as the prospects, if any, of similar companies, the previous experience of management, the Company’s anticipated results
of operations, and the likelihood of acceptance of this offering. Please review any financial or other information contained in this
offering with qualified people to determine its suitability as an investment before purchasing any shares in this offering.
If we make
mistakes or have unforeseen things happen to us, our suppliers, partners, vendors, etc., or the world, we can make little or no profit
and can be driven out of business.
THE
BOTTOM LINE:
Investment
in the securities of smaller companies can involve greater risk than is generally associated with investment in larger, more established
companies. All investments can result in significant or total loss of your loan and/or investment. If we do well, the stock should do
well also, yet life offers no guarantees, and neither can we. If we make mistakes or have unforeseen things happen to us, our suppliers
or the world, we can make little or no profit and can be driven out of business. We cannot guarantee success, return on investment, or
repayment of loans.
Please
only invest what you can afford to lose.
IN ADDITION TO THE RISKS LISTED ABOVE,
BUSINESSES ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY THE MANAGEMENT. IT IS NOT POSSIBLE TO FORESEE ALL THE RISKS
THAT MAY AFFECT THE COMPANY. MOREOVER, THE COMPANY CANNOT PREDICT WHETHER THE COMPANY WILL SUCCESSFULLY EFFECTUATE THE COMPANY’S
CURRENT BUSINESS PLAN. EACH PROSPECTIVE PURCHASER IS ENCOURAGED TO CAREFULLY ANALYZE THE RISKS AND MERITS OF AN INVESTMENT IN THE SECURITIES
AND SHOULD TAKE INTO CONSIDERATION WHEN MAKING SUCH ANALYSIS, AMONG OTHER FACTORS, THE RISK FACTORS DISCUSSED ABOVE.
THIS CHOICE OF LAW PROVISION DOES NOT
APPLY TO ACTIONS ARISING UNDER THE SECURITIES ACT OR EXCHANGE ACT.
DETERMINATION OF
OFFERING PRICE
The Offering Price
will be determined after qualification pursuant to Rule 253(b). The Offering Price will be arbitrarily determined and is not meant to
reflect a valuation of the Company.
DILUTION
The term ‘dilution’ refers
to the reduction (as a percentage of the aggregate Shares outstanding) that occurs for any given share of stock when additional Shares
are issued. If all the Shares in this Offering are fully subscribed to and sold, the Shares offered herein will constitute approximately
97.50% of the total Shares of common stock of the Company. The Company anticipates that, after this Offering, the Company may require
additional capital and such capital may take the form of Common Stock, other stock or securities or debt convertible into stock. Such
future capital raising, or conversion of existing convertible debt or Preferred Stock will further dilute the percentage ownership of
the Shares sold herein by the Company.
If you purchase shares in this Offering,
your ownership interest in our Common Stock will be diluted immediately, to the extent of the difference between the price to the public
charged for each share in this Offering and the net tangible book value per share of our Common Stock after this Offering.
Our historical net tangible book value
as of June 30, 2023, was $(28,457). Historical net tangible book value per share equals the amount of our total tangible assets, less
total liabilities, divided by the total number of shares of our Common Stock outstanding, all as of the date specified. Net tangible
book value per share is an estimate based on the net tangible book value as of June 30, 2023, and 51,251,321 shares of common stock outstanding
as of the date of this Offering Circular.
The following table illustrates the per
share dilution to new investors discussed above, assuming the sale of, respectively, 100%, 75%, 50% and 25% of the Shares offered for
sale in this Offering (before deducting our estimated offering expenses of 10% of the raise) at the maximum offering price of $0.005
per share:
Funding Level |
100% |
|
75% |
|
50% |
|
25% |
|
Gross
Proceeds |
$ |
10,000,000 |
|
$ |
7,500,000 |
|
$ |
5,000,000 |
|
$ |
2,500,000 |
|
Offering
Price |
$ |
0.0050 |
|
$ |
0.0050 |
|
$ |
0.0050 |
|
$ |
0.0050 |
|
Net
Tangible Book Value per Share of Common Stock before this Offering |
|
(0.00056) |
|
$ |
(0.00056) |
|
$ |
(0.00056) |
|
$ |
(0.00056) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase
in Net Tangible Book Value per Share Attributable to New Investors in this Offering |
|
0.0050
|
|
|
0.0050
|
|
|
0.0050
|
|
|
0.0050
|
|
Net
Tangible Book Value per Share of Common Stock after this Offering |
$ |
0.0049
|
|
$ |
0.0048
|
|
$ |
0.0048
|
|
$ |
0.0045
|
|
Dilution
per share to Investors in the Offering |
|
0.00012
|
|
|
0.00017
|
|
|
0.00024
|
|
|
0.00046
|
|
Shares
Outstanding before pre-offering |
|
51,251,321 |
|
|
51,251,321 |
|
|
51,251,321 |
|
|
51,251,321 |
|
Shares
Outstanding before post-offering |
|
2,051,251,321 |
|
|
1,551,251,321 |
|
|
1,051,251,321 |
|
|
551,251,321 |
|
The Company used the upper end of
the $0.001 to $0.005 price range to estimate the aggregate offering price.
There is no material disparity between
the price of the Shares in this Offering and the effective cash cost to officers, directors, promoters, and affiliated persons for shares
acquired by them in a transaction during the past year, or that they have a right to acquire.
PLAN OF DISTRIBUTION
We are offering a Maximum Offering of
up to $10,000,000 in Shares of Common Stock. The Offering is being conducted on a best-efforts basis without any minimum number of shares
or amount of proceeds required to be sold. There is no minimum subscription amount required (other than a per investor minimum purchase)
to distribute funds to the Company. The Company will not initially sell the Shares through commissioned broker-dealers but may do so
after the commencement of the offering. Any such arrangement will add to our expenses in connection with the offering. If we engage one
or more commissioned sales agents or underwriters, we will supplement this Form 1-A to describe the arrangement. Subscribers have no
right to a return of their funds. The Company may terminate the offering at any time for any reason at its sole discretion and may extend
the Offering past the termination date of 365 days from the date of qualification by the Commission in the absolute discretion of the
Company and in accordance with the rules and provisions of Regulation A of the JOBS Act. None of the Shares being sold in this Offering
are being sold by existing securities holders.
After the Offering Statement has been
qualified by the Securities and Exchange Commission (the “SEC”), the Company will accept tenders of funds to purchase the
Shares. No escrow agent is involved, and the Company will receive the proceeds directly from any subscription. You will be required to
complete a subscription agreement to invest.
All subscription agreements and checks
received by the Company for the purchase of shares are irrevocable until accepted or rejected by the Company and should be delivered
to the Company as provided in the subscription agreement. A subscription agreement executed by a subscriber is not binding on the Company
until it is accepted on our behalf by the Company’s Chief Executive Officer or by the specific resolution of our board of directors.
Any subscription not accepted within 30 days will be automatically deemed rejected. Once accepted, the Company will deliver a stock certificate
to a purchaser within five days from request by the purchaser; otherwise, purchasers’ shares will be noted and held on the book
records of the Company.
The Company, by determination of the Board
of Directors, in its sole discretion, may issue the Securities under this Offering for cash, promissory notes, services, and/or other
consideration without notice to subscribers.
At this time no broker-dealer registered
with the SEC and a member of the Financial Industry Regulatory Authority (“FINRA”), is being engaged as an underwriter or
for any other purpose in connection with this Offering. This Offering will commence on the qualification of this Offering Circular, as
determined by the Securities and Exchange Commission and continue for a period of 365 days. The Company may extend the Offering for an
additional time unless the Offering is completed or otherwise terminated by us, or unless we are required to terminate by application
of Regulation A of the JOBS Act. Funds received from investors will be counted towards the Offering only if the form of payment, such
as a check or wire transfer, clears the banking system and represents immediately available funds held by us prior to the termination
of the subscription period, or prior to the termination of the extended subscription period if extended by the Company.
This is an offering made under “Tier
1” of Regulation A, and the shares will not be listed on a registered national securities exchange upon qualification. Therefore,
the shares will be sold only to a person if the aggregate purchase price paid by such person is no more than 10% of the greater of such
person’s annual income or net worth, not including the value of his primary residence, as calculated under Rule 501 of Regulation
D promulgated under Section 4(a)(2) of the Securities Act of 1933, as amended. In the case of sales to fiduciary accounts (Keogh Plans,
Individual Retirement Accounts (IRAs) and Qualified Pension/Profit Sharing Plans or Trusts), the above suitability standards must be
met by the fiduciary account, the beneficiary of the fiduciary account, or by the donor who directly or indirectly supplies the funds
for the purchase of the shares. Investor suitability standards in certain states may be higher than those described in this Form 1-A
and/or Offering Circular. These standards represent minimum suitability requirements for prospective investors, and the satisfaction
of such standards does not necessarily mean that an investment in the Company is suitable for such people. Different rules apply to accredited
investors.
Each investor must represent in writing
that he/she/it meets the applicable requirements set forth above and in the Subscription Agreement, including, among other things, that
(i) he/she/it is purchasing the shares for his/her/its own account and (ii) he/she/it has such knowledge and experience in financial
and business matters that he/she/it is capable of evaluating without outside assistance the merits and risks of investing in the shares,
or he/she/it and his/her/its purchaser representative together have such knowledge and experience that they are capable of evaluating
the merits and risks of investing in the shares. Broker dealers and other people participating in the offering must make a reasonable
inquiry to verify an investor’s suitability for an investment in the Company. Transferees of the shares will be required to meet
the above suitability standards.
The shares may not be offered, sold, transferred,
or delivered, directly or indirectly, to any person who (i) is named on the list of “specially designated nationals” or “blocked
persons” maintained by the U.S. Office of Foreign Assets Control (“OFAC”) at www.ustreas.gov/offices/enforcement/ofac/sdn
or as otherwise published from time to time, (ii) an agency of the government of a Sanctioned Country, (iii) an organization controlled
by a Sanctioned Country, or (iv) is a person residing in a Sanctioned Country, to the extent subject to a sanctions program administered
by OFAC. A “Sanctioned Country” means a country subject to a sanctions program identified on the list maintained by OFAC
and available at www.ustreas.gov/offices/enforcement/ofac/sdn or as otherwise published from time to time. Furthermore, the shares may
not be offered, sold, transferred, or delivered, directly or indirectly, to any person who (i) has more than fifteen percent (15%) of
its assets in Sanctioned Countries or (ii) derives more than fifteen percent (15%) of its operating income from investments in, or transactions
with, sanctioned persons or Sanctioned Countries.
OTC Markets Considerations
The OTC Markets are separate and distinct
from the New York Stock Exchange and Nasdaq stock market or other national exchanges. Neither the New York Stock Exchange nor Nasdaq
has a business relationship with issuers of securities quoted on the OTC Markets. The SEC’s order handling rules, which apply to
New York Stock Exchange and Nasdaq-listed securities, do not apply to securities quoted on the OTC Markets.
Although other national stock markets
have rigorous listing standards to ensure the high quality of their issuers and can delist issuers for not meeting those standards; the
OTC Markets has no listing standards. Rather, it is the market maker who chooses to quote a security on the system, files the application,
and is obligated to comply with keeping information about the issuer in its files.
Investors may have greater difficulty
in getting orders filled than if we were on Nasdaq or other exchanges. Trading activity in general is not conducted as efficiently and
effectively on OTC Markets as with exchange-listed securities. Also, because OTC Markets stocks are usually not followed by analysts,
there may be lower trading volume than New York Stock Exchange and Nasdaq-listed securities.
USE OF PROCEEDS
TO ISSUER
The Use of Proceeds is an estimate based
on the Company’s current business plan. We may find it necessary or advisable to reallocate portions of the net proceeds reserved
for one category to another, or to add additional categories, and we will have broad discretion in doing so.
The maximum gross proceeds from the sale
of the Shares in this Offering are $10,000,000. The net proceeds from the offering, assuming it is fully subscribed, are expected to
be approximately $9,000,000 after the payment of offering costs estimated in the range of $1,000,000 (or 10% of the total proceeds) for
items such as printing, mailing, marketing, legal and accounting costs, and other compliance and professional fees that may be incurred.
The estimate of the budget for offering costs is an estimate only and the actual offering costs may differ from those expected by management.
The Company plans to utilize all the proceeds
to create a portfolio of residential and commercial properties with EV-charge-points across Los Angeles County and other counties in
the states of California, Nevada and Maryland. The company will achieve its goal by acquiring existing properties and retrofitting them
with EV-Charge-Points that will be available and open to all EV-drivers allowing them to recharge at affordable fees.
The management of the Company has wide
latitude and discretion in the use of proceeds from this Offering. Ultimately, the management of the Company intends to use substantially
all the net proceeds for general working capital and acquisitions. At present, management’s best estimate of the use of proceeds,
at various funding milestones, is set out in the chart below. However, potential investors should note that this chart contains only
the best estimates of the Company’s management based upon information available to them at the present time, and that the actual
use of proceeds is likely to vary from this chart based upon circumstances as they exist in the future, various needs of the Company
at different times in the future, and the discretion of the Company’s management always.
A portion of the proceeds from this Offering
may be used to compensate or otherwise make payments to officers or directors of the issuer. The officers and directors of the Company
may be paid salaries and receive benefits that are commensurate with similar companies, and a portion of the proceeds may be used to
pay these ongoing business expenses.
Assuming
$0.005 Offering Price (Max) |
|
25% |
|
50% |
|
75% |
|
100% |
RE Property
Acquisition |
|
$ |
2,050,000 |
|
$ |
4,100,000 |
|
$ |
6,150,000 |
|
$ |
8,200,000 |
EV Retrofit and
Rehab |
|
|
200,000 |
|
|
400,000 |
|
|
600,000 |
|
|
800,000 |
Offering
Expenses |
|
$ |
250,000 |
|
$ |
500,000 |
|
$ |
750,000 |
|
$ |
1,000,000 |
Total |
|
$ |
2,500,000 |
|
$ |
5,000,000 |
|
$ |
7,500,000 |
|
$ |
10,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assuming
$0.002 Offering Price (Mid) |
|
25% |
|
50% |
|
75% |
|
100% |
RE Property Acquisition |
|
$ |
820,000 |
|
$ |
1,640,000 |
|
$ |
2,460,000 |
|
$ |
3,280,000 |
EV Retrofit and
Rehab |
|
|
80,000 |
|
|
160,000 |
|
|
240,000 |
|
|
320,000 |
Offering
Expenses |
|
$ |
100,000 |
|
$ |
200,000 |
|
$ |
300,000 |
|
$ |
400,000 |
Total |
|
$ |
1,000,000 |
|
$ |
2,000,000 |
|
$ |
3,000,000 |
|
$ |
4,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assuming
$0.001 Offering Price (Min) |
|
25% |
|
50% |
|
75% |
|
100% |
RE Property Acquisition |
|
$ |
410,000 |
|
$ |
820,000 |
|
$ |
1,230,000 |
|
$ |
1,640,000 |
EV Retrofit and
Rehab |
|
|
40,000 |
|
|
80,000 |
|
|
120,000 |
|
|
160,000 |
Offering
Expenses |
|
$ |
50,000 |
|
$ |
100,000 |
|
$ |
150,000 |
|
$ |
200,000 |
Total |
|
$ |
500,000 |
|
$ |
1,000,000 |
|
$ |
1,500,000 |
|
$ |
2,000,000 |
The expected use of net proceeds from
this Offering represents our intentions based upon our current plans and business conditions, which could change in the future as our
plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working
capital, may vary significantly depending on numerous factors. The precise amounts that we will devote to each of the foregoing items,
and the timing of expenditures, will vary depending on numerous factors. As a result, our management will retain broad discretion over
the allocation of the net proceeds from this Offering.
In the event we do not sell all the shares
being offered, we may seek additional financing from other sources to support the intended use of the proceeds indicated above. If we
secure additional equity funding, investors in this Offering would be diluted. In all events, there can be no assurance that additional
financing would be available to us when wanted or needed and, if available, on terms acceptable to us.
The allocation of the use of proceeds
among the categories of anticipated expenditures represents management’s best estimates based on the status of the Company’s
proposed operations, plans, investment objectives, capital requirements, and financial conditions. No assurances can be provided that
any milestone represented herein will be achieved. Future events, including changes in the economic or competitive conditions of our
business plan or the completion of less than the total Offering amount, may cause the Company to modify the above-described allocation
of proceeds. The Company’s use of proceeds may vary significantly in the event any of the Company’s assumptions prove inaccurate.
We reserve the right to change the allocation of net proceeds from the Offering as unanticipated events or opportunities arise. Additionally,
the Company may from time to time need to raise more capital to address future needs.
The Company reserves the right to change
the use of proceeds set out herein based on the needs of the ongoing business of the Company and the discretion of the Company’s
management. The Company may reallocate the estimated use of proceeds among the various categories or for other uses if management deems
such a reallocation to be appropriate.
DESCRIPTION OF
BUSINESS
Organization and History
Sino Bioenergy Corp.
was incorporated in the State of Nevada on August 18, 1999. The Company was originally incorporated as Pacific Rim Solutions Inc. to
market and distribute an oxygen enriched water product called biocatalyst in the province of British Columbia. That business purpose
collapsed because of a dispute with the original license holder, which led to the discontinuance of all operations relating to biocatalyst.
The Company then acquired the rights to several domain names, all related to the supplements industry including: VitaminSales.us VitaminsPrime.com,
VitaminChoices.com, HerbsPrime.com, SupplementsPrime.com and NewHealthReview.com, which would be the corporate online newsletter. Initially
the Company worked as an online affiliated distributor of existing Internet-based vitamin and other supplement sales companies. Management
was not able to sustain this business and discontinued operations in December 2005. On January 30, 2006, the Company changed its name
to Sino Fibre Communication, Inc. and later on January 3, 2011, the Company again changed its name to its current name, Sino Bioenergy
Corp.
With the last name change, the Company
had planned to operate an optical fiber network in China that would provide domestic and international backbone transmission and data
network services such as synchronous digital hierarchy, internet protocol wholesale, managed bandwidth and leased lines to other network
operators, wholesale carriers and web-centric service providers. However, sometime after September 30, 2018, the Company abandoned its
business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting
requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2018 to
2022 which resulted in its Nevada charter being permanently revoked.
The company incurred operating losses
in from inception through 2018 resulting in accumulated deficit of $8,173,571 as at September 30, 2018. After their September 30, 2018
reports filed November 4, 2018, the Company stopped all forms of making public report of its operation and financial results.
On April 5, 2022, Alpharidge Capital,
LLC, a shareholder of the Company, served a demand to the Company, at last address of record, to comply with the Nevada Secretary of
State statues N.R.S. 78.710 and N.R.S. 78.150. On May 13, 2022, a petition was filed against the Company in the District Court of Clark
County, Nevada, entitled “In the Matter of SINO BIOENERGY CORP., a Nevada corporation” under case number A-22-852552-P by
Alpharidge Capital, LLC, along with an Application for Appointment of Custodian, after several attempts to get prior management to revive
the Company’s Nevada charter, which had been dissolved.
On June 10, 2022, the District Court of
Clark County, Nevada entered an Order Granting Application for Appointment of Alpharidge Capital, LLC (the “Order”), as Custodian
of the Company. Pursuant to the Order, the Alpharidge Capital, LLC (the “Custodian”) has the authority to take any actions
on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including, but not limited to, issuing shares
of stock and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant
to the Order, is required to meet the requirements under the Nevada charter.
On June 10, 2022, pursuant to a Securities
Purchase Agreement (SPA) the Custodian granted to Alpharidge LLC. (Alpharidge), 5 Series A preferred shares (convertible at 1 into 200,000,000
common shares, and the converted shares have 1/1 voting rights similar to all common stock) in exchange for $7,500 which the Company
used to fund the settlement of the Stock Transfer Agent’s balance. Alpharidge also undertook to reinstate the Company’s Charter
with the State of Nevada, and make all reasonable efforts to provide adequate current public information to meet the requirements under
the Securities Act of 1933.
On June 10, 2022, the Custodian appointed
Frank I Igwealor, who is associated to Alpharidge Capital, LLC., as the Company’s sole officer, secretary, treasurer and director.
The purchaser of the 5 Series A preferred
shares has control of the Company through super voting rights over all classes of stock and the 5 Series A preferred shares are convertible
into 1,000,000,000 (5 Series A preferred shares multiplied by 200,000,000) shares of the Company’s common stock. However, the court
appointed control remains with the Custodian until the Custodian files a petition with the District Court of Clark County, Nevada to
relinquish custodianship and control of the Company.
On June 24, 2022, the Company filed a
Certificate of Reinstatement with the Secretary of State of Nevada, which reinstated the Company’s charter and appointed a new
Resident Agent in Nevada.
The company is currently engaged with
a forensic assets recovery consultant to help recover the assets of the company from previous management to make shareholders whole again.
The Company intends to go after the Toxic lenders and predatory lenders that have been milking the corporation and depriving the shareholders
of stability because of the nonstop dilutions they had subjected the company to these past years.
The Company recently wrote down all its
assets to zero following a change of management because new management had doubts about the value of each asset and their availability
for the Company’s utilization. Following the management change, the Company has funded its operation with advances from the new
management. The company hopes to continue with this arrangement until it can raise sufficient capital to stand on its own feet. The company
has also engaged with forensic accountants and assets recovery consultants to help recover the assets of the company from previous management
and predatory lenders to make shareholders whole again.
On April 1, 2023, the Company completed
its new business plan and started implementation. Based on its new business plan, Sino Bioenergy Corp. seeks to create a portfolio of
residential and commercial properties with EV-charge-points across Los Angeles County. The company plans to achieve its goal by acquiring
existing properties and retrofitting them with EV-Charge-Points that will be available and open to all EV-drivers allowing them to recharge
at affordable fees.
Since April 1, 2023, in accordance with
its business plan, the Company has devoted significant energy, time and resources researching residential and commercial real estate
properties, reviewing and rewriting agreements with partners, customers, vendors, and manufacturers, reviewing licenses and sublicense
agreements with potential licensors, interviewing, and engaging consultants, and conducting research and due diligence on potential EV-ChargePoint
partners, Joint-ventures, and acquisitions in the target industry. We are actively seeking residential and commercial properties which
we would retrofit with EV-Charge points accessible to EV-drivers in host communities as time and resources permits.
We have narrowed
our targeted acquisition to the list of ten available for sale properties listed below:
RE
Id. |
Property
Description |
Cost/Price |
Units |
Price/Unit |
Lot
Size |
Target
#1 |
1625
W 162nd St, Gardena, CA 90247 |
1,499,000 |
4 |
$374,750 |
10,454
sq.ft. |
Target
#2 |
3722
W 132nd St, Hawthorne, CA 90250 |
1,595,000 |
5 |
$319,000 |
12,197
sq.ft. |
Target
#3 |
11700
S Normandie Ave, Los Angeles, CA 90044 |
1,550,000 |
6 |
$258,333 |
8,276
sq.ft. |
Target
#4 |
1883
W 20th St, Los Angeles, CA 90007 |
1,450,000 |
8 |
$181,250 |
4,491
sq.ft |
Target
#5 |
1114
Eubank Ave, Los Angeles, CA 90744 |
1,351,000 |
8 |
$168,875 |
7,878
sq.ft |
Target
#6 |
2627
S Victoria Ave, Los Angeles, CA 90016 |
1,595,000 |
7 |
$227,857 |
6,289
sq.ft |
Target
#7 |
6902
Milwood Ave, Los Angeles, CA 91303 |
1,595,000 |
8 |
$199,375 |
5,438
sq.ft |
Target
#8 |
6636
Wilkinson Ave, Los Angeles, CA 91606 |
1,225,000 |
5 |
$245,000 |
6,707
sq.ft |
Target
#9 |
707
Crenshaw Blvd, Los Angeles, CA 90005 |
3,395,000 |
11 |
$308,636 |
7,499
sq.ft. |
Total
projected Real Estate acquisition targeted |
$
15,255,000 |
62 |
|
|
We do not presently
have any contract or agreement with the sellers of any of these properties listed above. Although we believe the above listed properties
would still be available by the time we have raised the money to make the acquisition, there is no guarantee that the seller would still
be interested in selling at the stated price. While we hope we could find similar properties in Los Angeles County, our hope is just
that, hope, and there is no guarantee that our hope would materialize when we are ready.
Leveraged at 2:1, the Company will use
the proceed from this offering to acquire all or some of the real estate properties listed above, and then retrofit them with EV-Charge
points which would be available and accessible to the residents and EV-driving members of the host communities at a reasonable fee.
Sino Bioenergy Corp. intends to be both
a landlord and a provider of charging solutions, incorporating into its portfolio of residential and commercial properties, the infrastructures
and tools needed to expedite the mass adoption of electric vehicles for individual drivers, rideshare and commercial fleets, and businesses.
Sino Bioenergy Corp. wants to become a crucial player in the clean transportation future and its portfolio of residential and commercial
properties would be retrofitted and designed to be powered by mostly renewable energy. Sino Bioenergy Corp. plans to start with a charging
network of approximately 150 fast charging points over 10 metropolitan areas and 4 states, starting with Los Angeles, California.
Furthermore, Sino Bioenergy Corp. also
plans to accelerate transportation electrification through partnerships with other landlords, automakers, fleet and rideshare operators,
retail hosts such as grocery stores, shopping centers, and gas stations, policy leaders, and other organizations. With a fast-charge
network, good software products and unique service offerings for drivers and partners, Sino Bioenergy Corp. hopes to enable a world-class
charging experience where EV-drivers live, work, travel and play.
Needs Analysis.
Los Angeles has a goal for 25% zero-emission
vehicle stock by 2025 and 80% by 2035. Home charging remains a critical component in the infrastructure network. Most electric vehicle
charging is likely to continue at home, where it is less expensive and more convenient than public options. Los Angeles will need approximately
536,000 home chargers by 2030 to accommodate roughly 1.3 million electric vehicles. These home chargers will make up 90% of the total
charger needs and account for 60% of the total electric vehicle energy demand. Los Angeles plans provide more access to home charging
for its residents by continuing and expanding current programs. Stronger EV-ready building codes, incentives for home and multi-unit
dwelling chargers, and strategic and targeted deployment of curbside and streetlight chargers in residential areas can facilitate adequate
and equitable home charging access.
One of Los Angeles county's biggest challenges
is ensuring chargers are accessible in multifamily communities. Sino Bioenergy Corp. is keying into this strategic plan of the County
and City to achieve 25% zero-emission vehicle stock by 2025 and 80% by 2035. The company intends to focus on deploying EV-Charging infrastructure
at these properties is crucial for easing drivers' charging anxiety and meeting California's electrification goals.
Sino Bioenergy Corp. is assured of demand
for our services because studies showed that these day across Los Angeles and other neighboring Counties, landlords of apartments, hotels,
office buildings and other commercial properties are rushing to avoid similar trouble. And owners of convenience stores, fast food chains,
movie theaters and big box retailers are hoping to cash in on EV chargers to lure customers with time to kill as they fill up.
Subsidiaries
None
Current Operations
Our current operations consist of devoting
significant energy, time and resources researching residential and commercial real estate properties, reviewing and rewriting agreements
with partners, customers, vendors, and manufacturers, reviewing licenses and sublicense agreements with potential licensors, interviewing,
and engaging consultants, and conducting research and due diligence on potential EV-ChargePoint partners, Joint-ventures, and acquisitions
in the target industry.
We plan to generate revenue through acquisition
of a portfolio of residential and commercial properties which would be retrofitted with EV-Charge points and made available to both renters
and other EV users that find it convenient at reasonable fees. Sino Bioenergy Corp. intends to be
both a landlord and a provider of charging solutions, incorporating into its portfolio of residential and commercial properties,
the infrastructures and tools needed to expedite the mass adoption of electric vehicles for individual
drivers, rideshare and commercial fleets, and businesses. Sino Bioenergy Corp. wants to become a crucial player in the clean transportation
future and its portfolio of residential and commercial properties would be retrofit and designed
to be powered by mostly renewable energy. Sino Bioenergy Corp. plans to start with a charging network of approximately 150 fast charging
points over 10 metropolitan areas and 4 states, starting with Los Angeles, California
Management Team
Sino Bioenergy Corp’s has 2 employees
in California. These employees are focused on implementing the Company’s business plan, creating and entering into agreements with
partners and customers; executing license or sublicense agreements with respect to the company’s goals of making acquisition and
growing its assets base; entering into product development agreements or similar agreements for the development of targeted mineral-rich
properties; hiring consultants, contractors, employees and vendors; and conducting research and development for the Company.
Employees
As of the date of this Offering Circular,
the Company has 2 are full-time in the United States. There is no collective agreement between the Company and its employees. The employment
relationship between employees and the Company is individual and standard for the industry. The success of this Offering will help the
Company to staff up its operations as needed.
Our targeted properties are primarily
located in Los Angeles County. In addition, the Company also plans on expanding into other counties in the states of California, Nevada
and Maryland. Many of these properties would be acquired with on-site property managers. Thus, the Company anticipates employing an additional
1-2 employees per property acquired.
Property
We maintain an administrative head office
at:
1. 370 Amapola Ave.
Ste 200A, Torrance, CA 90501
This facility and office space are sufficient
for our current needs.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking
Statements
Certain statements, other than purely
historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating
results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements
generally are identified by the words believes, project, expects, anticipates, estimates, intends, strategy, plan, may, will, would,
will be, will continue, will likely result, and similar expressions. Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of the future or strategies is inherently uncertain. Factors which could
have a material adverse effect on our operations and prospects on a consolidated basis include but are not limited to changes in economic
conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed
on such statements.
Sino Bioenergy Corp. was incorporated
in the State of Nevada on August 18, 1999, originally as Pacific Rim Solutions Inc., to market and distribute an oxygen enriched water
product called biocatalyst in the province of British Columbia. That business purpose collapsed because of a dispute with the original
license holder, which led to the discontinuance of all operations relating to biocatalyst. The Company then tried to operate as an online
affiliated distributor of existing Internet-based vitamin and other supplement sales companies without recording tangible success. The
company also acquired the rights to several domain names, all related to the supplements industry including: VitaminSales.us VitaminsPrime.com,
VitaminChoices.com, HerbsPrime.com, SupplementsPrime.com and NewHealthReview.com, which would be the corporate online newsletter. Management
was not able to sustain this business and discontinued operations in December 2005. On January 30, 2006, the Company changed its name
to Sino Fibre Communication, Inc. and later on January 3, 2011, the Company again changed its name to its current name, Sino Bioenergy
Corp. With the last name change, the Company had planned to operate an optical fiber network in China that would provide domestic and
international backbone transmission and data network services such as synchronous digital hierarchy, internet protocol wholesale, managed
bandwidth and leased lines to other network operators, wholesale carriers and web-centric service providers. However, sometime after
September 30, 2018, the Company abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It
had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders
and pay its annual franchise tax from 2018 to 2022 which resulted in its Nevada charter being permanently revoked.
On April 5, 2022, Alpharidge Capital,
LLC, a shareholder of the Company, petitioned the District Court of Clark County, Nevada and was appointed custodian of the Company on
June 10, 2022. The custodian subsequently revived the Company’s charter with the State of Nevada, cleared the Transfer Agent’s
outstanding balance, organized shareholders meeting to elect new board for the company.
By April 1, 2023, the new management of
the Company has completed its new business plan that seeks to create a portfolio of residential and commercial properties with EV-charge-points
across Los Angeles County. The company will achieve its goal by acquiring existing properties and retrofitting them with EV-Charge-Points
that will be available and open to all EV-drivers allowing them to recharge at affordable fees.
Sino Bioenergy Corp. intends to be both
a landlord and a provider of charging solutions, incorporating into its portfolio of residential and commercial properties, the infrastructures
and tools needed to expedite the mass adoption of electric vehicles for individual drivers, rideshare and commercial fleets, and businesses.
Sino Bioenergy Corp. wants to become a crucial player in the clean transportation future and its portfolio of residential and commercial
properties would be retrofitted and designed to be powered by mostly renewable energy. Sino Bioenergy Corp. plans to start with a charging
network of approximately 150 fast charging points over 10 metropolitan areas and 4 states, starting with Los Angeles, California.
Furthermore, Sino Bioenergy Corp. also
plans to accelerate transportation electrification through partnerships with other landlords, automakers, fleet and rideshare operators,
retail hosts such as grocery stores, shopping centers, and gas stations, policy leaders, and other organizations. With it fast-charge
network, good software products and unique service offerings for drivers and partners, Sino Bioenergy Corp. hopes to enables a world-class
charging experience where drivers live, work, travel and play.
Results of Operations
The years ended December 31, 2022,
and 2021.
For the years ended December 31, 2022,
and 2021, the Company generated revenues of $0 and $0, respectively.
Cost of goods sold for the years ended
December 31, 2022, and 2021 was $0 and $0, respectively.
Operating expenses for the years ended
December 31, 2022, and 2021 were $24,163 and $0, respectively.
Accrued Interest for the years ended December
31, 2022, and 2021 was $0 and $0, respectively.
Net Loss for the years ended December
31, 2022, and 2021 was $24,163 and $0, respectively.
The Period ended June 30, 2023 and
2022.
For the period ended June 30, 2023 and
2022, the Company generated revenues of $0 and $0, respectively.
Cost of goods sold for the period ended
June 30, 2023 and 2022 was $0 and $0, respectively.
Operating expenses for the period ended
June 30, 2023 and 2022 were $4,294 and $0, respectively.
Accrued Interest for the period ended
June 30, 2023 and 2022 was $0 and $0, respectively.
Net Loss for the period ended June 30,
2023 and 2022 was $4,294 and $0, respectively.
Liquidity and Capital Resources
Net cash provided by operating activities
for the years ended December 31, 2022, and 2021 was $0 and $0, respectively. Net cash used in operating activities for the years ended
December 31, 2022, and 2021 was $24,163 and $0, respectively.
Net cash provided by or used in investing
activities for the years ended December 31, 2022, and 2021 was $0 and $0, respectively.
Net cash provided by financing activities
for the years ended December 31, 2022, and 2021 was $26,000 and $0, respectively.
As of December 31, 2022, we had $1,837
in cash to fund our operations.
Going Concern
The financial statements attached to this
Offering Circular have been prepared assuming that the company will continue as a going concern which contemplates, among other things,
the realization of assets and the satisfaction of liabilities in the normal course of business. For the 6 months ended June 30, 2023,
the Company has incurred a net loss of $4,294 from operations. We had an accumulated deficit of $8,202,028 as of June 30, 2023. It is
the management’s opinion that these matters raise substantial doubt about the Company’s ability to continue as a going concern
for a period of twelve months from the issuance date of this report. The ability of the Company to continue as a going concern is dependent
upon management’s ability to further implement its business plan and raise additional capital as needed from the sales of stock
or issuance of debt. The Company will begin to raise capital through private placements of common stock and is planning an offering of
common stock under Regulation A. Additionally the Company has been implementing cost-cutting measures and restructuring or setting up
payment plans with vendors and service providers and has restructured some obligations. The accompanying financial statements do not
include any adjustments that might be required should the Company be unable to continue as a going concern.
Critical Accounting Policies
The discussion and analysis of the Company’s
financial condition and results of operations are based upon the Company’s condensed financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. In consultation
with the Company’s Board of Directors, management has identified in the accompanying financial statements the accounting policies
that it believes are key to an understanding of its financial statements. These are important accounting policies that require management’s
most difficult, subjective judgments.
Recently Issued Accounting Pronouncements
The Company does not believe that any
other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect
on the accompanying financial statements.
Off-Balance Sheet Arrangements
As of the date of this Offering Circular,
there were no off-balance sheet arrangements.
Subsequent Material Events
None.
Impact
of Inflation
In 2022, we experienced
increases in product and labor costs due in part to higher rates of inflation, particularly to the global supply chain as well as our
own internal supply chain. In 2022, higher rates of inflation affected the costs of labor and mining equipment and maintenance.
Financial
Risk Management
We do not have
financial derivatives or contracts that may impact our operations.
Interest
Rate Risk
We do not have
a debt or payable with a variable interest rate. Hence, we currently do not have an interest rate risk that would directly impact on
our operations.
Twelve Months Plan of Operation
The Company seeks
to create a portfolio of residential and commercial properties with EV-charge-points across Los Angeles County. With about $1,837 in
cash on hand, during the first stages of our business plan execution (until we raise $1 million or more), our officers and directors
without pay, will provide all the labor required to execute our business plan at our current location. Our officers will be devoting
at least 15 hours per week to our operations. Depending on how many funds we would be able to secure, we also plan to start. Once we
reach this threshold (raising $1 million), our officers have agreed to commit more time as required, plus additional staff could be hired
to execute our business plan.
We intend to carry out a systematic acquisition
of properties that would be retrofitted and placed into use immediately to bring in revenue in the form of rents and EV-charging fees
from renters and customers. Although we have identified and evaluated 9 properties as ready for immediate acquisition, we intend to acquire
the properties one-at-a-time, treating each individual acquisition on its individual merits. Starting with Los Angeles County, then progressing
to other counties in California, Nevada, and Maryland, we plan to target only properties that are ready for immediate acquisition, which
could close within two months.
We have identified nine such properties
that could start our acquisition from, as shown below:
RE
Id. |
Property
Description |
Cost/Price |
Units |
Price/Unit |
Lot
Size |
Target
#1 |
1625
W 162nd St, Gardena, CA 90247 |
1,499,000 |
4 |
$374,750 |
10,454
sq.ft. |
Target
#2 |
3722
W 132nd St, Hawthorne, CA 90250 |
1,595,000 |
5 |
$319,000 |
12,197
sq.ft. |
Target
#3 |
11700
S Normandie Ave, Los Angeles, CA 90044 |
1,550,000 |
6 |
$258,333 |
8,276
sq.ft. |
Target
#4 |
1883
W 20th St, Los Angeles, CA 90007 |
1,450,000 |
8 |
$181,250 |
4,491
sq.ft |
Target
#5 |
1114
Eubank Ave, Los Angeles, CA 90744 |
1,351,000 |
8 |
$168,875 |
7,878
sq.ft |
Target
#6 |
2627
S Victoria Ave, Los Angeles, CA 90016 |
1,595,000 |
7 |
$227,857 |
6,289
sq.ft |
Target
#7 |
6902
Milwood Ave, Los Angeles, CA 91303 |
1,595,000 |
8 |
$199,375 |
5,438
sq.ft |
Target
#8 |
6636
Wilkinson Ave, Los Angeles, CA 91606 |
1,225,000 |
5 |
$245,000 |
6,707
sq.ft |
Target
#9 |
707
Crenshaw Blvd, Los Angeles, CA 90005 |
3,395,000 |
11 |
$308,636 |
7,499
sq.ft. |
Total
projected Real Estate acquisition targeted |
$
15,255,000 |
62 |
|
|
We do not presently
have any contract or agreement with the sellers of any of these properties listed above. Although we believe the above listed properties
would still be available by the time we have raised the money to make the acquisition, there is no guarantee that the seller would still
be interested in selling at the stated price. While we hope we could find similar properties in Los Angeles County, our hope is just
that, hope, and there is no guarantee that our hope would materialize when we are ready.
Within the next twelve
months, we intend to use the first $1-$2 million we could raise to commence acquisition, acquiring one property at a time.
We intend to implement the following
tasks within the next twelve months:
- Month 1-3: Phase
1 (1-3 months in duration; $1-$2 million in estimated fund receipt)
- Acquire 1 or more
of the properties identified above.
- Retrofit acquired
properties, conduct rehabs and put properties into operation.
- Conduct research
for additional properties to line-up for due diligence and possible acquisition.
- Month 3-6 Phase
2 (1-3 months in duration; quality control, process establishment, admin & mngt.).
- Acquire 1 or more
of the properties identified above.
- Establish accounting
and finance systems, synchronization of their operating systems, and HR functions.
- Sell an additional
$1-$2 million of offering and use the proceeds to effectuate our business plan.
- Complete and file
semi-annual reports and other required filings for the reporting period.
- Month 6-9: Phase
3 (1-3 months in duration; $1-$2 million in estimated fund receipt)
- Acquire 1 or more
of the properties identified above.
- Find more properties
for acquisition.
- Engage stakeholders
in the EV industry for potential partnerships and collaborations.
- Month 9-12: Phase
4 (1-3 months duration; $4 million in estimated fund receipt)
- Continue making
acquisitions and putting acquired and rehabilitated/retrofitted residential and commercial properties into use, generating revenue, giving
employees a conducive and friendly workplace and add value to investors and shareholders by identifying and executing growth strategies.
- Operating expenses
during the twelve months would be as follows:
- For the six months through July 31, 2024,
we anticipate incurring general and other operating expenses of $180,000, not including operating expenses that would come with the acquisitions.
- For the six months through January 31,
2025, we anticipate incurring additional general and other operating expenses of $180,000, not including operating expenses that would
come with the acquisitions.
- Once we have completed acquisitions and
putting acquired and rehabilitated/retrofitted residential and commercial properties into use, we plan to fund ongoing operating expenses
using cashflow from the rental and EV-charging revenues generated by acquired properties in California, Nevada, and Maryland.
As noted above, the
execution of our current plan of operations requires us to raise significant additional capital immediately. If we are successful in
raising capital through the sale of shares offered for sale in this Offering Circular, we believe that the Company will have sufficient
cash resources to fund its plan of operations for the next twelve months. If we are unable to do so, our ability to continue as a going
concern will be in jeopardy, likely causing us to curtail and possibly cease operations.
We continually evaluate
our plan of operations discussed above to determine the way we can most effectively utilize our limited cash resources. The timing of
completion of any aspect of our plan of operations is highly dependent upon the availability of cash to implement that aspect of the
plan and other factors beyond our control. There is no assurance that we will successfully obtain the required capital or revenues, or,
if obtained, that the amounts will be sufficient to fund our ongoing operations. The inability to secure additional capital would have
a material adverse effect on us, including the possibility that we would have to sell or forego a portion or all of our assets or cease
operations. If we discontinue our operations, we will not have sufficient funds to pay any amounts to our stockholders.
Because our working
capital requirements depend upon numerous factors there can be no assurance that our current cash resources will be sufficient to fund
our operations. At present, we have no committed external sources of capital, and do not expect any significant service revenues for
the foreseeable future. Thus, we will require immediate additional financing to fund future operations. There can be no assurance, however,
that we will be able to obtain funds on acceptable terms, if at all.
The Company evaluated subsequent events
that have occurred after the balance sheet date of December 31, 2022, and up through the date of this Offering Circular. There are two
types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the
date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized,
or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to
that date. The Company has determined that there are no additional events that would require adjustment to or disclosure in the attached
financial statements.
Credit Facilities
and Accounts Payable
We do not have any
credit facilities or other access to bank credit. We do not have any trade account that could allow us to purchase supplies and equipment
on credit as at January 30, 2024.
Capital Expenditures
We do not have any
contractual obligations for ongoing capital expenditure currently. We may, however, purchase lands, real properties, equipment and software
necessary to conduct our mining and extraction operations on an as needed basis.
Contractual
Obligations, Commitments and Contingencies
As of the date of
this Offering Circular, we do not have any contractual obligations, commitments or contingencies.
Off-Balance
Sheet Arrangements
We did not have during
the periods presented, and we do not currently have, any off-balance sheet arrangements.
Quantitative
and Qualitative Disclosures about Market Risk
As a company that
intends to continue operating as a junior miner of select mineral resources, we may typically be exposed to market risk of the sort that
may arise from changes in interest rates. However, since we have not started any major mining operation, we are not exposed to market
risk of the sort that may arise from changes in interest rates or foreign currency exchange rates, or that may otherwise arise from transactions
in derivatives.
Contingencies
Certain conditions
may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. The Company's management, in consultation with its legal counsel as appropriate,
assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies
related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company,
in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived
merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that
a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in
the Company's financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably
possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range
of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed
unless they involve guarantees, in which case the guarantees would be disclosed.
Relaxed Ongoing
Reporting Requirements
Upon the completion
of this Offering, we may elect to become a public reporting company under the Exchange Act. If we elect to do so, we will be required
to publicly report on an ongoing basis as an “emerging growth company” (as defined in the Jumpstart Our Business Startups
Act of 2012, which we refer to as the “JOBS Act”) under the reporting rules set forth under the Exchange Act. As defined
in the JOBS Act, an emerging growth company is defined as a company with less than $1.0 Billion in revenue during its last fiscal year.
An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally
to public companies.
For so long as we
remain an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements
that are applicable to other Exchange Act reporting companies that are not “emerging growth companies,” including
but not limited to:
|
|
not being required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; |
|
|
taking advantage
of extensions of time to comply with certain new or revised financial accounting standards; |
|
|
being permitted
to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and |
|
|
being exempt
from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. |
If we are required
to publicly report under the Exchange Act as an “emerging growth company”, we expect to take advantage of these reporting
exemptions until we are no longer an emerging growth company. We would remain an “emerging growth company” for up
to five years, though if the market value of our Common Stock that is held by non-affiliates exceeds $700 million, we would cease to
be an “emerging growth company”.
If we elect not to
become a public reporting company under the Exchange Act, we will be required to publicly report on an ongoing basis under the reporting
rules set forth in Regulation A for Tier 2 issuers. The ongoing reporting requirements under Regulation A are more relaxed than for “emerging
growth companies” under the Exchange Act. The differences include, but are not limited to, being required to file only annual
and semi-annual reports, rather than annual and quarterly reports. Annual reports are due within one hundred twenty (120) calendar days
after the end of the issuer's fiscal year, and semi-annual reports are due within ninety (90) calendar days after the end of the first
six (6) months of the issuer's fiscal year.
DIRECTORS, EXECUTIVE
OFFICERS AND SIGNIFICANT EMPLOYEES
Directors and Executive Officers
The following table sets forth regarding
our executive officers, directors and significant employees, including their ages as of the date of this Offering Circular:
Name |
|
Position |
|
|
Age |
|
Director
or Officer Since |
Frank
I Igwealor (1) |
|
Chairman,
President CEO, Director |
|
|
52 |
|
May
2022 |
Ambrose
Egbuonu(1) |
|
Director |
|
|
53 |
|
May
2022 |
(1)
The address of each of the individuals listed above is: 370 Amapola Ave., Suite 200A,
Torrance, CA 90501
Frank Igwealor, President/CEO/Director
Frank Igwealor,
CPA, CMA, JD, MBA, MSRM, Esq. is a California based Attorney and Financial Manager with broad technical and management experience
in accounting, finance, and business advisory as a principal partner at Goldstein Franklin, Inc. since November 2011. Mr. Igwealor is
a Certified Financial Manager, Certified Management Accountant, and Certified Public Accountant. Before Goldstein Franklin, Mr. Igwealor
was the Sr. Vice President and CFO of Los Angeles Neighborhood Housing between May 2007 and October 2011.
During the sixteen
years prior to his joining Los Angeles Neighborhood Housing as the chief financial officer, Mr. Igwealor worked in various financial
management, accounting, strategic planning, risk management, restructuring, recapitalization and turnaround capacities for various big
and small businesses where he helped save or preserve about 252 American jobs that would have otherwise been lost through liquidations.
Mr. Igwealor’s
business and professional experience include:
| (a) | 7/2007
to 10/2011 - SVP & CFO at Los Angeles Neighborhood Housing, Inc., one of Los Angeles
largest affordable housing nonprofit agency. |
| (b) | 11/2004
to 2015 – President and CEO of Igwealth Franklin, Inc., a Los Angeles private equity
firm |
| (c) | 03/2008
to present – Director at Poverty Solutions, Inc., a Los Angeles based nonprofit that
designs and deploys programs that help low-income families divest poverty through education,
employment, and entrepreneurship. |
| (d) | 11/2006
to 04/2007 – Assistant Controller at SDI Media Group, a Culver City, CA based translation
and dubbing company. |
| (e) | 03/2006
to 09/2006 – SEC Financial reporting analyst at OSI Systems, Inc., a Hawthorne CA based
manufacturer. |
| (f) | 11/2003
to 11/2004 – Financial Advisor at Morgan Stanley |
| (g) | 10/2019
to Present - President and CEO, Video River Network, Inc. |
| (h) | 08/2019
to Present - Managing Member, Alpharidge Capital LLC (Alpharidge operates an entrepreneurship
development project that controls about 62 private and public companies) |
Over the past 28
years in accounting and finance, Mr. Igwealor has always operated on the premise that a country’s most asset is her human capital
– and that job creation is the essential element to a true and sustainable economy and prosperity.
During the past five
years, Mr. Igwealor held the following directorships:
- Igwealth Franklin,
Inc. – November 2004 to 2015.
- Los Angeles Community
Capital – April 2012 to Present.
- American Community
Capital, LP. – August 2013 to Present.
- Goldstein Franklin,
Inc. – April 2012 to Present.
| 5. | Kid
Castle Educational Corporation since October 2019 |
| 6. | GiveMePower
Corporation since December 2019 |
| 7. | Video
River Network, Inc. since October 2019 |
Mr. Igwealor’s
professional education includes (1) BA in Accounting from Union Institute & University; (2) BA in Economics from Union Institute
& University; (3) MBA finance from California State University, Dominguez Hills; (4) Masters in Risk Management at New York University
(in progress); and (5) Juris Doctor from Southwestern School of Law.
The company believes
that someone with finance and accounting expertise as Mr. Igwealor would be invaluable to the company’s need of identifying the
right acquisition candidates as well as performing due diligence on those targets.
Ambrose O Egbuonu, Director
Ambrose O Egbuonu has been a member
of the Company’s Board of Director of our company since July 7, 2021. Mr. Egbuonu is a US Navy Veteran. For the past 10 years,
Mr. Egbuonu has been a self-employed business owner residing in Los Angeles County, California. From January 1, 2021, to present, Mr.
Egbuonu has sat on board or on the management team of the following company all of which has limited operations: Diguang International
Development Company Ltd., Wiremedia, Inc., Embarr Downs, Inc., FluoroPharma Medical, Inc., RBC Life Sciences, Inc., Red Truck Entertainment,
Inc., Trio Resources, Inc., Zenovia Digital Exchange Corporation, Zonzia Media, Inc., and Santaro Interactive Entertainment Co.
Board of Directors
Our board of directors currently
consists of two directors. None of which is considered “independent” as defined in Rule 4200 of FINRA’s listing standards.
We may appoint additional independent directors to our board of directors in the future, particularly to serve on committees should they
be established.
We have no formal policy regarding board
diversity. In selecting board candidates, we seek individuals who will further the interests of our stockholders through an established
record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and
understanding of our prospective markets.
Committees of the Board of Directors
We may establish an audit committee, compensation
committee, a nominating and governance committee and other committees to our Board of Directors in the future but have not done so as
of the date of this Offering Circular. Until such committees are established, matters that would otherwise be addressed by such committees
will be acted upon by the Board of Directors.
Compensation of Directors and Executive
Officers
Executive and Director Compensation
We have no standard arrangement to compensate
our directors for their services in their capacity. Directors are not paid for meetings to attend. However, we intend to review and consider
future proposals regarding board and executive compensation. All travel and lodging expenses associated with corporate matters are reimbursed
by us, when incurred.
None of our Officers and Directors is
currently receiving compensation.
Summary Compensation Table
The following table represents information
regarding the total compensation of our officers and directors for the year ended December 31, 2022 and the six months ended June 30,
2023.
Name |
|
Position |
|
Cash
Compensation |
|
|
Other
Compensation |
|
|
Total
Compensation |
|
Ambrose
Egbuonu |
|
Director |
|
$
- |
|
|
- |
|
|
$
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frank
I Igwealor |
|
Board
Chairman, President and CEO. |
|
$
- |
|
|
- |
|
|
$
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There are no other employment agreements
between the Company and its executive officers or directors. Our executive officers and directors have the responsibility of determining
the timing of remuneration programs for key personnel based upon such factors as positive cash flow, shares sales, product sales, estimated
cash expenditures, accounts receivable, accounts payable, notes payable, and cash balances. At this time, management cannot accurately
estimate when sufficient revenues will occur to implement this compensation, or the exact amount of compensation.
Stock Incentive Plan; Options;
Equity Awards
We have not adopted any long-term incentive
plan that provides compensation intended to serve as an incentive for performance. None of our executive officers or directors received,
nor do we have any arrangements to pay out, any bonus, stock awards, option awards, non-equity incentive plan compensation, or non-qualified
deferred compensation.
Limitation of Liability and Indemnification
of Officers and Directors
Our Bylaws limit the liability of directors
and officers of the Company to the maximum extent permitted by Nevada law. The Bylaws state that the Company shall indemnify and hold
harmless each person who was or is a party or is threatened to be made a party to, or is otherwise involved in any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person
is or was a director or an officer of the Company or such director or officer is or was serving at the request of the Company as a director,
officer, partner, member, manager, trustee, employee or agent of another company or of a partnership, limited liability company, joint
venture, trust or other enterprise.
The Company believes that indemnification
under our Bylaws covers at least negligence and gross negligence on the part of indemnified parties. The Company also may secure insurance
on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their
services to us, regardless of whether our Bylaws permit such indemnification.
The Company may also enter into separate
indemnification agreements with its directors and officers, in addition to the indemnification provided for in our Bylaws. These agreements,
among other things, may provide that we will indemnify our directors and officers for certain expenses (including attorneys’ fees),
judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of such person’s
services as one of our directors or officers, or rendering services at our request, to any of its subsidiaries or any other company or
enterprise. We believe that these provisions and agreements are necessary to attract and retain qualified people as directors and officers.
There is no pending litigation or proceeding
involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened
litigation or proceeding that may result in a claim for indemnification.
For additional information on indemnification
and limitations on the liability of our directors and officers, please review the Company’s Bylaws, which are attached to this
Offering Circular.
SECURITY OWNERSHIP
OF MANAGEMENT AND CERTAIN SECURITYHOLDERS
The following table sets forth information
regarding beneficial ownership of our Stock as of the date of this Offering Circular.
Beneficial ownership and percentage ownership
are determined in accordance with the rules of the Securities and Exchange Commission and include voting or investment power with respect
to Shares of stock. This information does not necessarily indicate beneficial ownership for any other purpose.
Unless otherwise indicated and subject
to applicable community property laws, to our knowledge, each Shareholder named in the following table possesses sole voting and investment
power over their Shares of Stock. The percentage of beneficial ownership before the offering is based on 51,251,321 Shares of Common
Stock and Five (5) Shares of Preferred Stock outstanding as of the date of this Offering Circular. Percentage of beneficial ownership
after the Offering assumes the sale of the Maximum Offering Amount.
Name
and Position |
Class |
Shares
Beneficially Owned Prior to Offering |
|
Shares
Beneficially Owned After Offering |
|
|
|
|
|
Number |
Percent
of Class |
|
Percent
of Total Votes |
|
Number |
Percent
of Class |
|
Percent
of Total Votes |
|
Frank
I Igwealor, President |
Series
A Preferred |
5 |
100 |
% |
60 |
% |
5 |
100 |
% |
60 |
% |
Frank
Igwealor, Beneficial Owner |
Common
Shares |
100,000 |
0.20
|
% |
0.08 |
% |
100,000 |
0.005
|
% |
0.002 |
% |
Ambrose
O Egbuonu, Director |
Common
Shares |
0 |
0 |
% |
|
% |
|
0 |
% |
|
% |
INTEREST OF MANAGEMENT
AND OTHERS IN CERTAIN TRANSACTIONS
The company has entered into the following
transactions in which the management or related persons have interest in outside of the ordinary course of our operations:
On April 5, 2022,
Alpharidge Capital, LLC, a shareholder of the Company, served a demand to the Company, at last address of record, to comply with the
Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. On May 13, 2022, a petition was filed against the Company in the District
Court of Clark County, Nevada, entitled “In the Matter of SINO BIOENERGY CORP., a Nevada corporation” under case number A-22-852552-P
by Alpharidge Capital, LLC, along with an Application for Appointment of Custodian, after several attempts to get prior management to
revive the Company’s Nevada charter, which had been dissolved.
On June
10, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of Alpharidge Capital,
LLC (the “Order”), as Custodian of the Company. Pursuant to the Order, the Alpharidge Capital, LLC (the “Custodian”)
has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including,
but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering in contracts on behalf of the Company.
In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.
On June
10, 2022, pursuant to a Securities Purchase Agreement (SPA) the Custodian granted to Alpharidge Capital, LLC. (Alpharidge), 5
Series A preferred shares (convertible at 1 into 200,000,000 common shares, and the converted shares have 1/1 voting rights similar to
all common stock) in exchange for $7,500 which the Company used to fund the settlement of the Stock Transfer Agent’s outstanding
balance. Alpharidge also undertook to reinstate the Company’s Charter with the State of Nevada, and make all reasonable efforts
to provide adequate current public information to meet the requirements under the Securities Act of 1933.
Our President and
CEO is the sole control person of Alpharidge Capital, LLC.
DESCRIPTION OF
SECURITIES
Common Stock
The holders of our common stock are entitled
to one vote per share on all matters submitted to a vote of our stockholders. The holders of the common stock have the right to vote,
except as otherwise provided by law, by our articles of incorporation, or in a statement by our board of directors on all matters requiring
shareholders’ vote.
In addition, such holders are entitled
to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds,
subject to the payment of preferential dividends or other restrictions on dividends contained in any Preferred Stock Designation, including,
without limitation, the Preferred Stock Designation establishing a series of preferred stock. In the event of the dissolution, liquidation
or winding up of Sino Bioenergy Corp., the holders of our common stock are entitled to share ratably in all assets remaining after payment
of all our liabilities, subject to the preferential distribution rights granted to the holders of any series of our preferred stock in
any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of our preferred
stock described above.
The holders of the common stock do not
have cumulative voting rights or preemptive rights to acquire or subscribe for additional, unissued or treasury shares in accordance
with the laws of the State of Nevada. Accordingly, excluding any voting rights granted to any series of our preferred stock, the holders
of more than 50 percent of the issued and outstanding shares of the common stock voting for the election of directors can elect all of
the directors if they choose to do so, and in such event, the holders of the remaining shares of the common stock voting for the election
of the directors will be unable to elect any person or persons to the board of directors. All outstanding shares of the common stock
are fully paid and nonassessable.
The laws of the State of Nevada provide
that the affirmative vote of most of the majority shareholders of the outstanding shares of our common stock and any series of our preferred
stock entitled to vote thereon is required to authorize any amendment to our articles of incorporation, any merger or consolidation of
Sino Bioenergy Corp. with any corporation, or any liquidation or disposition of any substantial assets of Sino Bioenergy Corp.
Preferred Stock
The Company is authorized to issue 5 shares
of Preferred Stock at a value of $0.001 per share. Total issued Preferred Stock is five (5) shares.
Series A
The Series A Preferred shares (a) rank
senior, with respect to liquidation, winding up or dissolution to all other classes of stock; (b) rank senior to any future designation
of preferred stock; and (c) maintain at least 60% of the voting interest of the Company.
SECURITIES BEING
OFFERED
The Company is offering Shares of its
Common Stock. Except as otherwise required by law, in the Company’s Articles of Incorporation or Bylaws, each Shareholder shall
be entitled to one vote for each Share held by such Shareholder on the record date of any vote of Shareholders of the Company. The Shares
of Common Stock, when issued, will be fully paid and non-assessable.
The Company does not expect to create
any additional classes of Common Stock during the next 12 months, but the Company is not limited from creating additional classes which
may have preferred dividend, voting and/or liquidation rights or other benefits not available to holders of its common stock.
The Company does not expect to declare
dividends for holders of Common Stock in the foreseeable future. Dividends will be declared, if at all (and subject to the rights of
holders of additional classes of securities, if any), at the discretion of the Company’s Board of Directors. Dividends, if ever
declared, may be paid in cash, in property, or in shares of the capital stock of the Company, subject to the provisions of law, the Company’s
Bylaws and the Certificate of Incorporation. Before payment of any dividend, there may be set aside out of any funds of the Company available
for dividends such sums as the Board of Directors, in its absolute discretion, deems proper as a reserve for working capital, to meet
contingencies, for equalizing dividends, for repairing or maintaining any property of the Company, or for such other purposes as the
Board of Directors shall deem in the best interests of the Company.
Because this is a best-efforts offering,
there is no minimum number of Shares that need to be sold in order for funds to be released to the Company and for this Offering to hold
its first closing.
The minimum subscription that will be
accepted from an investor is $1,000 (the ‘Minimum Subscription’).
A subscription for $1,000 or more in the
Shares may be made only by tendering to the Company the executed Subscription Agreement (electronically or in writing) delivered with
the subscription price in a form acceptable to the Company, via check, wire, credit or debit card, or ACH. The execution and tender of
the documents required, as detailed in the materials, constitutes a binding offer to purchase the number of Shares stipulated therein
and an agreement to hold the offer open until the Expiration Date or until the offer is accepted or rejected by the Company, whichever
occurs first.
The Company reserves the unqualified discretionary
right to reject any subscription for Shares, in whole or in part. The Company reserves the unqualified discretionary right to accept
any subscription for Shares, in an amount less than the Minimum Subscription. If the Company rejects any offer to subscribe for the Shares,
it will return the subscription payment, without interest or reduction. The Company’s acceptance of your subscription will be effective
when an authorized representative of the Company issues you written or electronic notification that the subscription was accepted.
There are no liquidation rights, preemptive
rights, conversion rights, redemption provisions, sinking fund provisions, impacts on classification of the Board of Directors where
cumulative voting is permitted or required related to the Common Stock, provisions discriminating against any existing or prospective
holder of the Common Stock as a result of such Shareholder owning a substantial amount of securities, or rights of Shareholders that
may be modified otherwise than by a vote of a majority or more of the shares outstanding, voting as a class defined in any corporate
document as of the date of filing. The Common Stock will not be subject to further calls or assessment by the Company. There are no restrictions
on alienability of the Common Stock in the corporate documents other than those disclosed in this Offering Circular. The Company has
engaged Pacific Stock Transfer Co. to serve as the transfer agent and registrant for the Shares. For additional information regarding
the Shares, please review the Company’s Bylaws, which are attached to this Offering Circular.
Excepting matters arising under federal
securities laws, any disputes between the Company and shareholders shall be governed in reliance on the laws of the state of Nevada.
Furthermore, the Subscription Agreement for this Regulation A offering appoints the state and federal courts located in the state of
Nevada as having jurisdiction over any disputes related to this Regulation A offering between the Company and shareholders.
Transfer Agent
Our transfer agent is Transfer Online,
Inc., 512 SE Salmon Street, Portland, OR 97214. The transfer agent is registered under the Exchange Act and operates under the regulatory
authority of the SEC and FINRA.
DISQUALIFYING EVENTS
DISCLOSURE
Recent changes to Regulation A promulgated
under the Securities Act prohibit an issuer from claiming an exemption from registration of its securities under such rule if the issuer,
any of its predecessors, any affiliated issuer, any director, executive officer, other officer participating in the offering of the interests,
general partner or managing member of the issuer, any beneficial owner of 20% or more of the voting power of the issuer’s outstanding
voting equity securities, any promoter connected with the issuer in any capacity as of the date hereof, any investment manager of the
issuer, any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with
such sale of the issuer’s interests, any general partner or managing member of any such investment manager or solicitor, or any
director, executive officer or other officer participating in the offering of any such investment manager or solicitor or general partner
or managing member of such investment manager or solicitor has been subject to certain “Disqualifying Events” described in
Rule 506(d)(1) of Regulation D subsequent to September 23, 2013, subject to certain limited exceptions. The Company is required to exercise
reasonable care in conducting an inquiry to determine whether any such persons have been subject to such Disqualifying Events and is
required to disclose any Disqualifying Events that occurred prior to September 23, 2013, to investors in the Company. The Company believes
that it has exercised reasonable care in conducting an inquiry into Disqualifying Events by the foregoing persons and is aware of the
no such Disqualifying Events.
It is possible that (a) Disqualifying
Events may exist of which the Company is not aware and (b) the SEC, a court or other finder of fact may determine that the steps that
the Company has taken to conduct its inquiry were inadequate and did not constitute reasonable care. If such a finding were made, the
Company may lose its ability to rely upon exemptions under Regulation A, and, depending on the circumstances, may be required to register
the Offering of the Company’s Common Stock with the SEC and under applicable state securities laws or to conduct a rescission offer
with respect to the securities sold in the Offering.
ERISA CONSIDERATIONS
Trustees and other fiduciaries of qualified
retirement plans or IRAs that are set up as part of a plan sponsored and maintained by an employer, as well as trustees and fiduciaries
of Keogh Plans under which employees, in addition to self-employed individuals, are participants (together, “ERISA Plans”),
are governed by the fiduciary responsibility provisions of Title 1 of the Employee Retirement Income Security Act of 1974 (“ERISA”).
An investment in the Shares by an ERISA Plan must be made in accordance with the general obligation of fiduciaries under ERISA to discharge
their duties (i) for the exclusive purpose of providing benefits to participants and their beneficiaries; (ii) with the same standard
of care that would be exercised by a prudent man familiar with such matters acting under similar circumstances; (iii) in such a manner
as to diversify the investments of the plan, unless it is clearly prudent not do so; and (iv) in accordance with the documents establishing
the plan. Fiduciaries considering an investment in the Shares should accordingly consult their own legal advisors if they have any concern
as to whether the investment would be inconsistent with any of these criteria.
Fiduciaries of certain ERISA Plans which
provide for individual accounts (for example, those which qualify under Section 401(k) of the Code, Keogh Plans and IRAs) and which permit
a beneficiary to exercise independent control over the assets in his individual account, will not be liable for any investment loss or
for any breach of the prudence or diversification obligations which results from the exercise of such control by the beneficiary, nor
will the beneficiary be deemed to be a fiduciary subject to the general fiduciary obligations merely by virtue of his exercise of such
control. On October 13, 1992, the Department of Labor issued regulations establishing criteria for determining whether the extent of
a beneficiary’s independent control over the assets in his account is adequate to relieve the ERISA Plan’s fiduciaries of
their obligations with respect to an investment directed by the beneficiary. Under the regulations, the beneficiary must not only exercise
actual, independent control in directing the particular investment transaction, but also the ERISA Plan must give the participant or
beneficiary a reasonable opportunity to exercise such control and must permit him to choose among a broad range of investment alternatives.
Trustees and other fiduciaries making
the investment decision for any qualified retirement plan, IRA or Keogh Plan (or beneficiaries exercising control over their individual
accounts) should also consider the application of the prohibited transactions provisions of ERISA and the Code in making their investment
decision. Sales and certain other transactions between a qualified retirement plan, IRA or Keogh Plan and certain persons related to
it (e.g., a plan sponsor, fiduciary, or service provider) are prohibited transactions. The particular facts concerning the
sponsorship, operations and other investments of a qualified retirement plan, IRA or Keogh Plan may cause a wide range of persons to
be treated as parties in interest or disqualified persons with respect to it. Any fiduciary, participant or beneficiary considering an
investment in Shares by a qualified retirement plan IRA or Keogh Plan should examine the individual circumstances of that plan to determine
that the investment will not be a prohibited transaction. Fiduciaries, participants or beneficiaries considering an investment in the
Shares should consult their own legal advisors if they have any concern as to whether the investment would be a prohibited transaction.
Regulations issued on November 13, 1986,
by the Department of Labor (the “Final Plan Assets Regulations”) provide that when an ERISA Plan or any other plan covered
by Code Section 4975 (e.g., an IRA or a Keogh Plan which covers only self-employed persons) makes an investment in an equity interest
of an entity that is neither a “publicly offered security” nor a security issued by an investment company registered under
the Investment Company Act of 1940, the underlying assets of the entity in which the investment is made could be treated as assets of
the investing plan (referred to in ERISA as “plan assets”). Programs which are deemed to be operating companies or which
do not issue more than 25% of their equity interests to ERISA Plans are exempt from being designated as holding “plan assets.”
Management anticipates that we would clearly be characterized as “operating” for the purposes of the regulations, and that
it would therefore not be deemed to be holding “plan assets.”
Classification of our assets as “plan
assets” could adversely affect both the plan fiduciary and management. The term “fiduciary” is defined generally to
include any person who exercises any authority or control over the management or disposition of plan assets. Thus, classification of
our assets as plan assets could make the management a “fiduciary” of an investing plan. If our assets are deemed to be plan
assets of investor plans, transactions which may occur during its operations may constitute violations by the management of fiduciary
duties under ERISA. Violation of fiduciary duties by management could result in liability not only for management but also for the trustee
or other fiduciary of an investing ERISA Plan. In addition, if our assets are classified as “plan assets,” certain transactions
that we might enter in the ordinary course of our business might constitute “prohibited transactions” under ERISA and the
Code.
Under Code Section 408(i), as amended
by the Tax Reform Act of 1986, IRA trustees must report the fair market value of investments to IRA holders by January 31 of each year.
The Service has not yet promulgated regulations defining appropriate methods for the determination of fair market value for this purpose.
In addition, the assets of an ERISA Plan or Keogh Plan must be valued at their “current value” as of the close of the plan’s
fiscal year to comply with certain reporting obligations under ERISA and the Code. For purposes of such requirements, “current
value” means fair market value where available. Otherwise, current value means the fair value as determined in good faith under
the terms of the plan by a trustee or other named fiduciary, assuming an orderly liquidation at the time of the determination. We do
not have an obligation under ERISA or the Code with respect to such reports or valuation although management will use good faith efforts
to assist fiduciaries with their valuation reports. There can be no assurance, however, that any value so established (i) could or will
be realized by the IRA, ERISA Plan or Keogh Plan upon sale of the Shares or upon liquidation of us, or (ii) will comply with the ERISA
or Code requirements.
The income earned by a qualified pension,
profit sharing or stock bonus plan (collectively, “Qualified Plan”) and by an individual retirement account (“IRA”)
is generally exempt from taxation. However, if a Qualified Plan or IRA earns “unrelated business taxable income” (“UBTI”),
this income will be subject to tax to the extent it exceeds $1,000 during any fiscal year. The amount of unrelated business taxable income
in excess of $1,000 in any fiscal year will be taxed at rates up to 36%. In addition, such unrelated business taxable income may result
in a tax preference, which may be subject to the alternative minimum tax. It is anticipated that income and gain from an investment in
Shares will not be taxed as UBTI to tax exempt shareholders, because they are participating only as passive financing sources.
DIVIDEND POLICY
Subject to preferences that may be applicable
to any then-outstanding shares of Preferred Stock, if any, and any other restrictions, holders of Common Stock are entitled to receive
ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. We and
our predecessors have not declared any dividends in the past. Further, we do not presently contemplate that there will be any future
payment of any dividends on Common Stock.
SHARES ELIGIBLE
FOR FUTURE SALE
Prior to this Offering, there has been
a limited market for our Common Stock on the OTC Markets. Future sales of substantial amounts of our Common Stock, or securities or instruments
convertible into our Common Stock, in the public market, or the perception that such sales may occur, could adversely affect the market
price of our Common Stock prevailing from time to time. Furthermore, because there will be limits on the number of shares available for
resale shortly after this Offering due to contractual and legal restrictions described below, there may be resales of substantial amounts
of our Common Stock in the public market after those restrictions lapse. This could adversely affect the market price of our Common Stock
prevailing at that time.
Upon completion of this Offering, assuming
the maximum number of shares of Common Stock offered in this Offering are sold, there will be 2,051,251,321 shares of our Common Stock
outstanding.
Rule 144
In general, a person who has beneficially
owned restricted shares of our Common Stock for at least twelve months, in the event we are a reporting company under Regulation A, or
at least six months, in the event we have been a reporting company under the Exchange Act for at least 90 days before the sale, would
be entitled to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have
been an affiliate of ours at any time during the 90 days preceding the sale. A person who is an affiliate of ours at such time would
be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of
shares that does not exceed the greater of the following:
|
● |
1%
of the number of shares of our Common Stock then outstanding; or |
|
● |
the
average weekly trading volume of our Common Stock during the four calendar weeks preceding the filing by such person of a notice
on Form 144 with respect to the sale; |
provided that, in each case, we are subject
to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply with
the manner of sale, notice and other provisions of Rule 144, to the extent applicable.
INVESTOR ELIGIBILITY
STANDARDS & ADDITIONAL INFORMATION ABOUT THE OFFERING
Investment Limitations
Generally, no sale may be made to you
in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please see
below on how to calculate your net worth). Different rules apply to accredited investors and non-natural persons. Before making any representation
that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A+. For general
information on investing, we encourage you to refer to www.investor.gov.
Because this is a Tier 1, Regulation A+
offering, most investors must comply with the 10% limitation on investment in the Offering. The only investor in this Offering exempt
from this limitation is an “accredited investor” as defined under Rule 501 of Regulation D under the Securities Act.
If you meet one of the following tests you should qualify as an accredited investor:
|
(i) |
You
are a natural person who has had individual income more than $200,000 in each of the two most recent years, or joint income with
your spouse more than $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the
current year; |
|
|
|
|
(ii) |
You
are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase
Shares (please see below on how to calculate your net worth); |
|
|
|
|
(iii) |
You
are an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer; |
|
|
|
|
(iv) |
You are
an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the
Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific
purpose of acquiring the Shares, with total assets more than $5,000,000.
|
|
(v) |
You
are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered
pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered
under the Investment Company Act of 1940 (Investment Company Act), or a business development company as defined in that act, any
Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company
as defined in the Investment Advisers Act of 1940; |
|
(vi) |
You
are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor; |
|
(vii) |
You
are a trust with total assets in excess of $5,000,000, your purchase of Shares is directed by a person who either alone or with his
purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in
financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were
not formed for the specific purpose of investing in the Shares; or |
|
(viii)
|
You
are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
political subdivisions, for the benefit of its employees, if such plan has assets more than $5,000,000. |
Offering Period and Expiration Date
This Offering will start on the date on
which the SEC initially qualifies this Offering Statement (the Qualification Date) and will terminate on the Termination Date.
Procedures for Subscribing
If you decide to subscribe for our Common
Stock shares in this Offering, you should:
1. |
Electronically
receive, review, execute and deliver to us a Subscription Agreement; and |
2. |
Deliver
funds directly to the Company’s designated bank account via bank wire transfer (pursuant to the wire transfer instructions
set forth in our Subscription Agreement) or electronic funds transfer via wire transfer. |
Any potential investor will have ample
time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only deliver
such a subscription agreement upon request after a potential investor has had ample opportunity to review this Offering Circular.
Right to Reject Subscriptions.
After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred
to our designated account, we have the right to review and accept or reject your subscription in whole or in part, for any reason or
for no reason. We will return all monies from rejected subscriptions immediately to you, without interest or deduction.
Acceptance of Subscriptions. Upon
our acceptance of a subscription agreement, we will countersign the subscription agreement and issue the shares subscribed at closing.
Once you submit the subscription agreement, you may not revoke or change your subscription or request your subscription funds. All submitted
subscription agreements are irrevocable.
Under Rule 251 of Regulation A+, non-accredited,
non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the
purchaser’s revenue or net assets (as of the purchaser’s most recent fiscal year end). A non-accredited, natural person may
only invest funds which do not exceed 10% of the greater of the purchaser’s annual income or net worth (please see below on how
to calculate your net worth).
NOTE: For the purpose of calculating
your net worth, it is defined as the difference between total assets and total liabilities. This calculation must exclude the value of
your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value of your
primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied by the beneficiary
of the account or by the fiduciary, if the fiduciary directly or indirectly provides funds for the purchase of the Shares.
In order to purchase our Common Stock
shares and prior to the acceptance of any funds from an investor, an investor will be required to represent, to the Company’s satisfaction,
that such investor is either an accredited investor or is in compliance with the 10% of net worth or annual income limitation on investment
in this Offering.
LEGAL MATTERS
Certain legal matters with respect to
the shares of common stock offered hereby will be passed upon by Udo Ekekeulu, Esq., Alpha Advocate Law Group PC.
REPORTS
Following this Tier 1, Regulation A offering,
we will be required to comply with certain ongoing disclosure requirements under Rule 257 of Regulation A, in addition to our reporting
requirements under the OTC Pink Basic Disclosure Guidelines.
WHERE YOU CAN FIND
MORE INFORMATION
We have filed with the SEC a Regulation
A Offering Statement on Form 1-A under the Securities Act with respect to the shares of common stock offered hereby. This Offering Circular,
which constitutes a part of the Offering Statement, does not contain all of the information set forth in the Offering Statement or the
exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the Offering
Statement and the exhibits and schedules filed therewith. Statements contained in this Offering Circular regarding the contents of any
contract or other document that is filed as an exhibit to the Offering Statement are not necessarily complete, and each such statement
is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the Offering Statement.
Upon the completion of this Offering, we will be required to file periodic reports, proxy statements, and other information with the
SEC pursuant to the Securities Exchange Act of 1934. You may read and copy this information at the SEC’s Public Reference Room,
100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling
the SEC on 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy statements and other information about
issuers, including us, that file electronically with the SEC. The address of this site is www.sec.gov.
SIGNATURES
Pursuant to the requirements of Regulation
A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has
duly caused this Offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, on January 30, 2024.
Sino
Bioenergy Corp. |
|
|
|
By: |
/s/
Frank I Igwealor |
|
|
Frank
I Igwealor |
|
|
President
& CEO, Principal Executive Officer, Principal Financial Officer, and Director |
|
|
January
30, 2024
|
|
This Offering statement has been
signed by the following persons in the capacities and on the dates indicated.
By: |
/s/ Frank
I Igwealor |
|
|
Frank
I Igwealor |
|
|
President
& CEO, Principal Executive Officer, Principal Financial Officer, and Director |
|
|
January
30, 2024 |
|
ACKNOWLEDGEMENT
ADOPTING TYPED SIGNATURES
The undersigned hereby authenticate, acknowledge,
and otherwise adopt the typed signatures above and as otherwise appear in this filing and offering.
By: |
/s/
Frank I Igwealor |
|
|
Frank
I Igwealor |
|
|
President
& CEO, Principal Executive Officer, Principal Financial Officer, and Director |
|
|
January
30, 2024 |
|
PART III: EXHIBITS
Index to Exhibits
PART F/S: FINANCIAL
STATEMENTS
TABLE OF CONTENTS
Financial Statements
of Sino Bioenergy Corp. for the Twelve Months Ended December 31, 2022
and Twelve Months
Ended December 31, 2021
Sino
Bioenergy Corp. |
INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS |
|
Page |
Condensed
Consolidated Balance Sheets |
F-3 |
Condensed
Consolidated Statements of Operations |
F-4 |
Condensed
Consolidated Statement of Stockholders’ Deficit |
F-5 |
Condensed
Consolidated Statements of Cash Flows |
F-6 |
Notes
to Condensed Consolidated Financial Statements |
F-7 |
Unaudited Financial
Statements of Sino Bioenergy Corp. for the Six Months Ended June 30, 2023
Sino
Bioenergy Corp. |
INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS |
|
Page |
Condensed
Consolidated Balance Sheets |
F-1 |
Condensed
Consolidated Statements of Operations |
F-2 |
Condensed
Consolidated Statement of Stockholders’ Deficit |
F-3 |
Condensed
Consolidated Statements of Cash Flows |
F-4 |
Notes
to Condensed Consolidated Financial Statements |
F-5 |
Exhibit
2.1
AMENDED
AND RESTATED
ARTICLES
OF INCORPORATION
OF
Sino
Bioenergy Corp.
Pursuant
to NRS Chapter 78
ARTICLE
FIRST
NAME:
The name of the corporation is Sino Bioenergy Corp.
ARTICLE
SECOND
REGISTERED
AGENT FOR SERVICE: The registered agent for services of process is Nevada Registered Agent LLC. The address of the registered agent
is 401 Ryland St. Ste 200A, Reno, NV, 89502, USA.
ARTICLE
THIRD
AUTHORIZED
STOCK: The total number· of shares of capital stock which the corporation shall have authority to issue is two billion five
hundred and ten million (2,510,000,000) shares, of which (i) two billion five hundred million (2,500,000,000) shares are designated as
common stock with a par value of $0.000I per share ("Common Stock"), and (ii) ten million (10,000,000) shares are designated
as preferred stock, with a par value of $0.001 per share ("Preferred Stock").
ARTICLE
FOUR
[Intentionally
Omitted]
ARTICLE
FIFTH
PURPOSE:
The purpose of the corporation shall be to engage in any lawful act or activity for which corporations may be organized in Nevada.
ARTICLE
SIXTH
[Intentionally
Omitted]
ARTICLE
SEVENTH
[Intentionally
Omitted]
ARTICLE
EIGHTH
DURATION:
This corporation shall exist perpetually unless sooner dissolved by law.
ARTICLE
NINETH
STOCK:
The total number of shares of all classes which the corporation is authorized to have outstanding is two billion five hundred and
ten million (2,510,000,000) shares, of which (i) two billion five hundred million (2,500,000,000) shares are designated as common stock
with a par value of $0.000I per share ("Common Stock"), and (ii) ten million (10,000,000) shares are designated as preferred
stock, with a par value of $0.001 per share ("Preferred Stock")..
The
Board of Directors is authorized, subject to limitations prescribed by law, to provide for the issuance of the authorized shares of preferred
stock in series, and by filing a certificate pursuant to the applicable law of the State of Nevada, to establish from time to time the
number of shares to be included in each such series and the qualifications, limitations or restrictions thereof. The authority of the
board with respect to .each series includes, but is not limited to, determination of the following:
(1)
The number of shares constituting that series and the distinctive designation of that series;
(2)
The dividend rate on the shares of that series, whether dividends shall be cumulative, and, if so, from which date or dates, and the
relative rights of priority, if any, of payment of dividends on shares of that series;
(3)
Whether that series shall have voting rights, in addition to the voting rights provided by law, and, if so, the terms of such voting
rights;
(4)
Whether that series shall have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for
adjustment of the conversion rate in such events as the Board of Directors shall determine;
(5)
Whether or not the shares of that series shall be redeemable, and, if so, the terms and conditions of such redemption, including the
date or date upon or after which they shall be redeemable, and the amount per share payable in case of redemption, which amount may vary
under different conditions, and at different redemption rates;
(6)
Whether that series shall have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount
of such sinking fund;
(7)
The rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation,
and the relative rights of priority, if any, of payment of shares of that series; and
(8)
Any other relative rights, preferences and limitations of that series, unless otherwise provided by the certificate of determination.
ARTICLE
TENTH
PRE-EMPTIVE
RIGHTS: The stockholders shall have no pre-emptive rights to acquire additional shares of the corporation.
ARTICLE
ELEVENTH
MANAGEMENT
OF THE CORPORATION'S AFFAIRS.
(a) The
business and affairs of the corporation shall be managed under the direction of the Board of Directors. The number of directors constituting
the entire Board of Directors shall be not less than one nor more than nine as fixed from time to ti.me by vote of a majority of the
entire board or directors, provided, however; that the number of directors shall not be reduced so as to shorten the term of any director
at the time in office, and provided further, that the number of directors constituting the entire Board of Directors shall be one until
otherwise fixed by a majority of the entire board or directors.
(b) Notwithstanding
any other provisions in these Articles of Incorporation or the Bylaws of the corporation (and notwithstanding the fact that some lesser
percenta.ge may be specified by law, in these Articles of Incorporation or the Bylaws of the corporation), any director or the entire
Board of Directors of the corporation may be removed at any time, but only for cause and only by the affirmative vote of the holders
of 75% or more of the outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors
(considered for this purpose as one class) cast at a meeting of the stockholders called for that purpose.
ARTICLE
TWELFTH
AMENDMENT:
Except as otherwise provided in these Articles of Incorporation, the provisions of these Articles of Incorporation may be amended
by the affirmative vote of a majority of the shares entitled to vote on each such amendment In furtherance and not in limitation of the
powers conferred by the laws of the State of Nevada the Board of Directors of the corporation is expressly authorized to make, alter
and repeal the Bylaws of the corporation, subject to the power of the stockholders of the corporation to alter or repeal any Bylaw whether
adopted by them or otherwise.
ARTICLE
THIRTEENTH
LIMITATION
OF DIRECTORS' LlABILITY: To the fullest extent permitted by the Jaws of the State of Nevada now or hereafter in force, no director
of this corporation shall be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty
as a director. Any repeal or modification of the foregoing provisions of this Article THIRTEENTH shall not adversely affect any right
or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification. The
provisions of this Article THIRTEENTH shall not be deemed to limit or preclude indemnification
of a director by the corporation for any liability of a director which has not been eliminated by the provisions of this Article THIRTEENTH.
ARTICLE
FOURTEENTH
INDEMNIFICATION:
The corporation may indemnify an individual against liability incurred in a proceeding where the individual was made a party to a
proceeding because the person is or was a director or officer and if: (1) the individual's conduct was in good faith; (2) the individual
reasonably believed that the conduct was in, or not opposed to, the corporation's best interests; and (3) in the case of any criminal
proceeding, the individual had no reasonable cause to believe the individual's conduct was unlawful.
The
corporation will indemnify a director or officer who was successful, on the merits or otherwise, in defense of any proceeding, or in
defense of any claim, issue, or matter in the proceeding, to which the individual was a party because the person is or was a director
or officer of the corporation, against reasonable expenses incurred by the individual in connection with the proceeding or claim with
respect to which the individual has been successful.
The
corporation may not indemnify a director or officer in connection with: (l) acts or omissions which involve intentional misconduct, fraud,
or a knowing violation of law; or (2) the payment of distributions in violation of NRS 78.300.
ARTICLE
FIFTEENTH
CUMULATIVE
VOTING: There shall be no cumulative voting.
CONSENT
The
number of shares of the corporation outstanding and entitled to vote on these Amended and Restated Articles of Incorporation is 51,251,321
shares of common stock which is entitle to 1 share / 1 vote with 40% total vote of the Company’s total votes of all classes, and
5 shares of preferred stock (representing having 60% total vote of the Company’s total votes of all classes), and these Amended
and Restated Articles of Incorporation have been consented to and approved by stockholders holding at least a majority of such total
votes of all classes.
IN
WITNESS WHEREOF, the Corporation has caused the undersigned, the President of the Sino Bioenergy Corp., to execute, file and record these
Amended and Restated Articles of Incorporation.
//
Frank I Igwealor________
Frank
I Igwealor 01/30/2024
Exhibit
2.2
AMENDED
AND RESTATED BYLAWS
OF
Sino
Bioenergy Corp.
ARTICLE
I.
OFFICES
Section
1.01 Principal Office. Sino Bioenergy Corp. (the “Corporation”)
will maintain its principal office within or without the State of Nevada as the Board of Directors (the “Board”) may
determine from time to time.
Section
1.02 Registered Office and Other Offices. The registered office of the Corporation
in Nevada shall be that of its registered agent most recently appointed in the Articles (as defined in Section 1.03), or as evidenced
by a certificate of acceptance executed by a registered agent and filed with the Secretary of State of Nevada in the manner prescribed
by the Nevada Revised Statutes (“NRS”). The Corporation may also maintain offices at such other place or places, either
within or without the State of Nevada, as may be designated from time to time by the Board, where the business of the Corporation may
be transacted with the same effect as though done at the principal office.
Section
1.03 Records. The Corporation will keep and maintain at its registered office a
certified copy of its articles of incorporation and all amendments thereto (the “Articles”) and a certified copy of
these bylaws and all amendments hereto (the “Bylaws”). The Corporation will also keep at its registered office a stock
ledger or duplicate stock ledger, revised annually, containing the names, alphabetically arranged, of all stockholders of the Corporation,
showing their places of residence, if known, and the number of shares held by them respectively, or a statement setting out the name
of the custodian of the stock ledger or duplicate stock ledger, and the present and complete postal address, including street and number,
if any, where such stock ledger or duplicate ledger is kept.
ARTICLE
II.
STOCKHOLDERS
Section
2.01 Stockholders’ Meetings. All meetings of stockholders will be held at
such places as may be fixed from time to time by the Board, or in the absence of direction by the Board, by the President or Secretary,
either within or without the State of Nevada, as will be stated in the notice of the meeting or in a duly executed waiver of notice thereof.
If authorized by the Board, in its sole discretion and subject to such guidelines and procedures as the Board may adopt, stockholders
may participate in a meeting of stockholders, whether annual or special, through electronic communications, videoconferencing, teleconferencing,
or other available technology which allows the stockholders to communicate simultaneously or sequentially. Such participation in a meeting
will constitute presence in person at the meeting.
Section
2.02 Annual Meetings. Annual meetings of stockholders will be held each year on
a date and at a time to be designated by the Board. Stockholders will, at the annual meeting, elect the directors to serve on the Board
and transact such other business as properly may be brought before the meeting.
Section
2.03 Special Meetings of Stockholders. Special meetings of the stockholders, for
any purpose or purposes, unless otherwise prescribed by statute or by the Articles, may be called by the President and will be called
by the President or Secretary at the request in writing of a majority of the Board. Such request will state the purpose or purposes of
the proposed meeting.
Section
2.04 List of Stockholders. The Transfer Agent (as defined in Section 6.04)
or, if a Transfer Agent has not been appointed, the Secretary, will prepare, and make, at least ten (10) days before every meeting
of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the
address of each stockholder and the number of shares registered in the name of each stockholder. Such list is not required to include
stockholders’ electronic email addresses or facsimile numbers. Such list will be open to the examination of any stockholder, for
any purpose germane to the meeting, during ordinary business hours, for a period
of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place will
be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list will also
be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is
present.
Section
2.05 Notice of Meetings.
(a) Written
notice stating the time and place of any meeting of the stockholders will be delivered to each stockholder of record entitled to vote
at such meeting not less than ten (10) nor more than sixty (60) days before the date of the meeting.
(b) In
the case of an annual meeting, the notice of meeting need not specifically state the purpose or purposes for which the meeting is called.
In the case of a special meeting, the notice of meeting shall specifically state the purpose or purposes for which the meeting is called.
(c) If
a meeting is adjourned for sixty (60) days or more after the date fixed for the original meeting, notice of the adjourned meeting
will be given as in the case of an original meeting. When a meeting is adjourned for a period of less than sixty (60) days in any
one adjournment, it is not necessary to give any notice of the date, time, or place of the adjourned meeting other than by announcement
at the meeting at which the adjournment is taken, unless a new record date is set for the meeting.
(d) If
mailed, such notice shall be deemed to be delivered when deposited in the United States mail, addressed to the stockholder at his, her,
or its address as it appears on the record of stockholders of the Corporation, with postage prepaid.
(e) Without
limiting the manner by which notice otherwise may be given to stockholders, any notice to a stockholder may be given by a form of electronic
transmission consented to by the stockholder to whom the notice is given and in the manner prescribed in NRS Section 78.370, as
amended. Any such consent may be revoked by the stockholder by written or electronic notice to the Corporation. Any such consent will
be deemed revoked if: (i) the Corporation is unable to deliver two (2) consecutive electronic transmissions given by the Corporation
in accordance with such consent; and (ii) such inability becomes known to the Secretary or the Transfer Agent or other person responsible
for giving of notice or other communications; provided, however, that the inadvertent failure to treat such inability
as a revocation shall not invalidate any meeting or other action. For purposes of this Section 2.05(e), “electronic transmission”
means facsimile transmission, electronic mail, posting on an electronic network, or any form of communication, not directly involving
the physical transmission of paper or other tangible medium, which is suitable for the retention, retrieval, and reproduction of information
by the recipient, and which is retrievable and reproducible in paper form by the recipient through an automated process used in conventional
commercial practice. An affidavit of the Secretary or the Transfer Agent or any other agent of the Corporation that the notice has been
given, whether by a form of electronic transmission or otherwise, shall, in the absence of fraud, be prima facie evidence
of the facts stated therein.
Section
2.06 Waiver of Notice. Attendance of a stockholder at a meeting, in person or by
proxy, will constitute waiver of notice of such meeting, except when the stockholder attends the meeting for the express purpose of objecting
to the transaction of any business because the meeting is not lawfully called or convened and so objects at the beginning of the meeting.
Any stockholder may waive notice of any annual or special meeting of stockholders by executing a written waiver of notice either before
or after the time of the meeting.
Section
2.07 Fixing of Record Date.
(a) For
the purpose of determining the stockholders entitled to notice of and to vote at any meeting of stockholders or any adjournment thereof,
or entitled to receive payment of any distribution or the allotment of any rights, or entitled to exercise any rights in respect of any
change, conversion, or exchange of stock or for the purpose of any other lawful action, the directors may fix, in advance, a record date,
which shall not be more than sixty (60) days nor less than ten (10) days before the date of such meeting, if applicable. When
a determination of stockholders entitled to vote at any meeting of stockholders
has been made as provided in this Section 2.07, such determination will, unless otherwise provided by the Board, also apply to any
adjournment thereof.
(b) If
no record date is fixed, the record date for determining stockholders: (i) entitled to notice of and to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held; and (ii) for any other purpose shall be at the close of
business on the day on which the Board adopts the resolution relating thereto. A determination of stockholders of record entitled to
notice of or to vote at any meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board may fix a new record date for the adjourned meeting and must fix a new record date if the meeting is adjourned to a date
more than sixty (60) days later than the date set for the original meeting.
Section
2.08 Quorum and Adjournment. The holders of at least one-third (1/3) of the
voting power of all classes and series of stock entitled to vote at the meeting, present in person or by proxy, regardless of whether
the proxy has authority to vote on all matters, will constitute a quorum at all meetings of the stockholders for the transaction of business
except as otherwise provided by the NRS or by the Articles. Once a quorum is established at any meeting of the stockholders, the voluntary
withdrawal of any stockholder from the meeting shall not affect the authority of the remaining stockholders to conduct any business which
properly comes before the meeting. If, however, such quorum is not present or represented at any meeting of the stockholders, the stockholders
entitled to vote at the meeting, present in person or represented by proxy, will have the power to adjourn the meeting from time to time,
without notice other than announcement at the meeting, until a quorum is present or represented by proxy. At such adjourned meeting at
which a quorum is present or represented by proxy any business may be transacted which might have been transacted at the meeting as originally
notified. If the adjournment is for more than sixty (60) days, or if after the adjournment a new record date is fixed for the adjourned
meeting, a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the meeting.
Section
2.09 Nominations for Director.
(a) Only
persons who are nominated in accordance with the procedures set forth in this Section 2.09 will be eligible for election to the
Board. Nominations of persons for election to the Board at a meeting of the stockholders at which directors are being elected may be
made (i) by or at the direction of the Board or (ii) by any stockholder of the Corporation entitled to vote for the election
of directors at such meeting who complies with the procedures set forth in this Section 2.09. Such nominations by any stockholder
must be made pursuant to timely notice in proper written form to the Secretary.
(b) To
be timely, a stockholder’s notice must be delivered to or mailed to and received by the Secretary at the principal office of the
Corporation not less than ninety (90) days nor more than one hundred twenty (120) days in advance of the first anniversary
of the preceding year’s annual meeting; provided, however, that in the event that (i) no annual meeting
was held in the previous year or (ii) the date of the annual meeting has been changed by more than thirty (30) days from the
date of the previous year’s meeting, or in the event of a special meeting of stockholders called for the purpose of electing directors,
not later than the close of business on the 10th day following the day on which notice of the date of the meeting was
mailed or public disclosure of the date of the meeting was made, whichever occurs first. In no event will the public disclosure of an
adjournment or postponement of a stockholders meeting commence a new time period for the giving of a stockholders notice as described
above.
(c) To
be in proper written form, a stockholder’s notice to the Secretary must set forth in writing: (i) as to each person whom such
stockholder proposes to nominate for election or re-election as a director, all information relating to such person that is required
to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation
14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, such
person’s written consent to being named in the proxy statement as a nominee and to serving as director if elected as well as (A) such
person’s name, age, business address and residence address, (B) his or her principal occupation or employment, (C) the
class and number of shares of the Corporation that are beneficially owned by such person, and (D) a description of all arrangements
or understandings between the stockholder
and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by
the stockholder; and (ii) as to such stockholder (A) the name and address, as they appear on the Corporation’s books,
of such stockholder and the beneficial owner, if any, on whose behalf the nomination is made, and (B) the class and number of shares
of the Corporation which are beneficially owned by such stockholder and the beneficial owner, if any, on whose behalf the nomination
is made, and any material interest of such stockholder and owner. At the request of the Board, any person nominated by the Board for
election as a director will furnish to the Secretary the information required to be set forth in a stockholder’s notice of nomination
which pertains to the nominee.
(d) No
person will be eligible for election by the stockholders as a director unless nominated in accordance with the procedures set forth in
this Section 2.09. The chairman of the meeting will, if the facts warrant, determine and declare at the meeting that a nomination
was not made in accordance with the procedures prescribed in this Section 2.09, and if he or she so determines, he or she will so
declare at the meeting that the defective nomination will be disregarded.
Section
2.10 Stockholder Proposals.
(a) At
any special meeting of the stockholders, only such business will be conducted as has been brought
before
the meeting by or at the direction of the Board.
(b) At
any annual meeting of the stockholders, only such business will be conducted as has been brought before the meeting (i) specified
in the notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) otherwise properly brought
before the meeting by or at the direction of the Board, or (iii) by any stockholder who complies with the procedures set forth in
this Section 2.10.
(c) For
business to be properly brought before an annual meeting by a stockholder, the stockholder must give timely notice thereof in proper
written form to the Secretary and such business must otherwise be a proper matter for stockholder action.
(d) To
be timely, a stockholder’s notice must be delivered to or mailed to and received by the Secretary at the principal office of the
Corporation not less than ninety (90) days nor more than one hundred twenty (120) days in advance of the first anniversary
of the preceding year’s annual meeting; provided, however, that in the event that (i) no annual meeting
was held in the previous year or (ii) the date of the annual meeting has been changed by more than thirty (30) days before
or after the date of the previous year’s meeting, not later than the close of business on the 10th day following
the day on which notice of the date of the meeting was mailed or public disclosure of the date of the meeting was made, whichever occurs
first. In no event will the public disclosure of an adjournment or postponement of a stockholders meeting commence a new time period
for the giving of a stockholders notice as described above.
(e) To
be in proper written form, a stockholder’s notice to the Secretary must set forth in writing as to each matter such
stockholder proposes to bring before the annual meeting: (i) a brief description of the business desired to be brought before
the meeting; (ii) the name and address, as they appear on the Corporation’s books, of the stockholder proposing such
business, and the beneficial owner, if any, on whose behalf the proposal is made; (iii) the text of the proposal or business
(including the text of any resolutions proposed for consideration) and the reasons for conducting such business at the meeting;
(iv) the class and number of shares of the Corporation which are owned beneficially by such stockholder and the beneficial
owner, if any, on whose behalf the proposal is made; (v) any material interest in such business of the stockholder or the
beneficial owner, if any, on whose behalf the proposal is made; (vi) any other information that is required to be provided by
the stockholder pursuant to Regulation 14A under the Exchange Act in such stockholder’s capacity as a proponent of a
stockholder proposal; (vii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to
vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business; and (viii) a
representation whether the stockholder or the beneficial owner, if any, intends or is part of a group which intends (A) to
deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s
outstanding capital stock required to approve or adopt the proposal or (B) otherwise to solicit proxies from stockholders in support
of such proposal. The foregoing notice requirements will be deemed satisfied by a stockholder if the stockholder has notified the Corporation
of his, her, or its intention to present a proposal at an annual meeting in compliance with Rule 14a-8 (or any successor thereof) promulgated
under the Exchange Act and such stockholder’s proposal has been included in a proxy statement that has been prepared by the Corporation
to solicit proxies for such annual meeting.
(f) No
business will be conducted at an annual meeting except in accordance with the procedures set forth in this Section 2.10. The chairman
of an annual meeting will, if the facts warrant, determine and declare at the meeting that business was not properly brought before the
meeting in accordance with the provisions of this Section 2.10, and, if he or she should so determine, he or she shall so declare
at the meeting that any such business not properly brought before the meeting will not be transacted.
Section
2.11 Public Disclosure; Conduct of Nominations, and Proposals by Stockholders.
(a) For
purposes of Sections 2.09 and 2.10, “public disclosure” means disclosure in a press release reported by the Dow Jones News
Service, Associated Press, Reuters or any comparable national news service or in a document publicly filed or furnished by the Corporation
with the Securities and Exchange Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act.
(b) Notwithstanding
Sections 2.09 and 2.10, if the stockholder (or a representative of the stockholder) does not appear at the annual meeting to present
a nomination or proposal, such nomination and proposal will be disregarded, notwithstanding that proxies in respect of such vote may
have been received by the Corporation.
(c) Without
limiting Sections 2.09 and 2.10, a stockholder will also comply with all applicable requirements of the Exchange Act and the rules and
regulations thereunder with respect to the matters set forth in Sections 2.09 and 2.10. Nothing in Sections 2.09 or 2.10 will affect
any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under
the Exchange Act.
Section
2.12 Conduct of Meetings. The President, or any person so designated by the President,
or if the President is absent, did not so designate, or otherwise is unable to so serve, any Vice President, will chair all meetings
of the stockholders. The Secretary or, in his or her absence, such other person as the chairman of the meeting may designate, will serve
as secretary of the meeting. The chairman of the meeting will conduct all meetings of the stockholders in accordance with the best interests
of the Corporation and will have the authority and discretion to establish reasonable procedural rules for the conduct of such meetings,
including such regulation of the manner of voting and the conduct of discussion as he or she deems appropriate.
Section
2.13 Voting; Proxies.
(a) Each
stockholder entitled to vote at any meeting may vote either in person or by proxy. Unless otherwise specified in the Articles or in resolutions
of the Board providing for the issuance of different classes or series of shares, each stockholder entitled to vote will be entitled
to one (1) vote for each share of capital stock registered in his, her, or its name on the transfer books or records of the Corporation.
(b) Except
as otherwise provided herein, all votes with respect to shares standing in the name of an individual at the close of business on the
record date (including pledged shares) shall be cast only by that individual or such individual’s duly authorized proxy. With
respect to shares held by a representative of the estate of a deceased stockholder, or a guardian, conservator, custodian or
trustee, even though the shares do not stand in the name of such holder, votes may be cast by such holder upon proof of such
representative capacity. In the case of shares under the control of a receiver, the receiver may cast votes carried by such shares
even though the shares do not stand of record in the name of the receiver; provided, that the order of a court of competent
jurisdiction which appoints the receiver contains the authority to cast votes carried by such shares. If shares stand of record in
the name of a minor, votes may be cast by the duly appointed guardian
of the estate of such minor only if such guardian has provided the Corporation with written proof of such appointment.
(c) With
respect to shares standing of record in the name of another corporation, partnership, limited liability company or other legal entity
on the record date, votes may be cast: (i) in the case of a corporation, by such individual as the bylaws of such other corporation
prescribe, by such individual as may be appointed by resolution of the Board of Directors of such other corporation or by such individual
(including, without limitation, the officer making the authorization) authorized in writing to do so by the chairman of the board, if
any, president, chief executive officer, if any, or any vice president of such corporation; and (ii) in the case of a partnership,
limited liability company or other legal entity, by an individual representing such stockholder upon presentation to the Corporation
of satisfactory evidence of his or her authority to do so.
(d) Notwithstanding
anything to the contrary contained herein and except for the Corporation’s shares held in a fiduciary capacity, the Corporation
shall not vote, directly or indirectly, shares of its own stock owned by it; and such shares shall not be counted in determining the
total number of outstanding shares entitled to vote.
(e) Any
holder of shares entitled to vote on any matter may cast a portion of the votes in favor of such matter and refrain from casting the
remaining votes or cast the same against the proposal, except in the case of elections of directors. If such holder entitled to vote
does vote any of such stockholder’s shares affirmatively and fails to specify the number of affirmative votes, it will be conclusively
presumed that the holder is casting affirmative votes with respect to all shares held.
(f) With
respect to shares standing of record in the name of two (2) or more persons, whether fiduciaries, members of a partnership, joint
tenants, tenants in common, husband and wife as community property, tenants by the entirety, voting trustees or otherwise and shares
held by two (2) or more persons (including proxy holders) having the same fiduciary relationship in respect to the same shares,
votes may be cast in the following manner: (i) if only one (1) person votes, the vote of such person binds all; (ii) if
more than one (1) person casts votes, the act of the majority so voting binds all; and (iii) if more than one (1) person
casts votes, but the vote is evenly split on a particular matter, the votes shall be deemed cast proportionately, as split.
(g) Each
stockholder entitled to vote may authorize another person or persons to act for his, her, or it by proxy. All proxies must be in writing,
signed by the stockholder or by his, her, or its duly authorized attorney-in-fact, and will be filed with the Secretary before being
voted; provided, that no proxy will be valid after six (6) months from the date of its execution unless the person executing
it specifies in it the length of time for which it is to continue in force, which in no event will exceed seven (7) years. A duly
executed proxy is not revoked and will continue in full force and effect until another instrument or transmission revoking it or a properly
created proxy bearing a later date is filed with or transmitted to the Secretary. The mere attendance at a meeting by a stockholder who
has previously given a proxy applicable to such meeting will not constitute a revocation of such proxy.
(h) Except
for the election of directors or as otherwise provided by applicable law, the Articles, or these Bylaws, at all meetings of stockholders,
action by the stockholders on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast
in opposition to the action.
(i) Except
as otherwise required by applicable law, the Articles, or these Bylaws, directors will be elected to the Board by a plurality of the
votes cast by each of the holders of the shares of capital stock present and entitled to vote at the meeting. Cumulative voting for directors
will not be required or permitted.
Section
2.14 Inspectors of Election. In advance of any meeting of stockholders, the Board
will appoint one (1) or more persons, other than officers, directors, or nominees for office, as inspectors of election to act at
such meeting or any adjournment thereof. Such appointment will not be altered at the meeting. If inspectors of election are not so appointed,
the chairman of the meeting will make such appointment at the meeting. If any person appointed
as inspector fails to appear or fails or refuses to act at the meeting, the vacancy so created may be filled by appointment by the Board
in advance of the meeting or at the meeting by the chairman of the meeting. The duties of the inspectors of election will include determining
the number of shares outstanding and the voting power of each; determining the shares represented at the meeting; determining the existence
of a quorum; determining the validity and effect of proxies; receiving votes, ballots, or consents; hearing and deciding all challenges
and questions arising in connection with the right to vote; counting and tabulating all votes, ballots, or consents; determining the
results of any election, vote, or other determination; and doing such acts as are proper to the conduct of the election or the vote with
fairness to all stockholders. Any report or certificate made by them will be prima facie evidence of the facts stated
and of the vote as certified by them. Each inspector will be entitled to a reasonable compensation for his or her services, to be paid
by the Corporation.
Section
2.15 Action Without Meeting. Any action required or permitted to be taken at any
meeting of stockholders may be taken without a meeting, without prior notice, and without a vote, if a consent in writing, setting forth
the action so taken, is signed by the holders of a majority of the voting power of all classes and series of stock entitled to vote with
respect to the subject matter of the action, except that if any greater proportion of voting power is required for such an action at
a meeting, then the greater proportion of written consents is required. Such written consents will be delivered to the Secretary. Every
written consent must bear the date of signature of each stockholder who signs the consent. No written consent will be effective unless
it is delivered, with signatures of stockholders holding sufficient shares to authorize or take such action, to the Secretary within
sixty (60) days after the earliest dated signature on such consent. In no instance where action is authorized by written consent
need a meeting of stockholders be called or notice given.
ARTICLE
III.
BOARD OF DIRECTORS
Section
3.01 General Powers. The business and affairs of the Corporation shall be managed
under the direction of the Board except as otherwise provided by the Articles or by applicable law.
Section
3.02 Number, Term, and Qualification. The number of directors on the Board will
be determined from time to time by resolution adopted by the Board. In the absence of such resolution, the number of directors elected
at the meeting shall constitute the number of directors of the Corporation until the next annual meeting of stockholders, unless the
number is changed prior to such meeting by action of the Board. Unless otherwise required or permitted by applicable law, a majority
of the members of the Board must be Independent Directors (as defined in Section 4.04). Each director’s term shall expire
at the annual meeting next following the director’s election as a director; provided, that, notwithstanding the expiration
of the term of the director, the director shall continue to hold office until a successor is elected and qualifies or until his death,
resignation, retirement, removal, or disqualification or until there is a decrease in the number of directors. Directors need not be
residents of the State of Nevada or stockholders of the Corporation. No decrease in the number of directors constituting the Board shall
shorten the term of any incumbent directors.
Section
3.03 Removal. Directors may be removed from office with or without cause, at an
annual or special meeting of the stockholders upon a vote of stockholders holding at least two-thirds (2/3) of the voting power
of all classes and series of stock entitled to vote at such meeting. The notice of the stockholders’ meeting at which such action
is to be taken must state that a purpose of the meeting is removal of the director.
Section
3.04 Vacancies. A vacancy occurring on the Board, including, without limitation,
a vacancy resulting from death, resignation, retirement, removal, disqualification, an increase in the number of directors, or from the
failure by the stockholders to elect the full authorized number of directors, may be filled by a majority vote of the remaining directors
or by the sole director remaining in office, in either case though less than a quorum.
Section
3.05 Compensation. The Corporation may compensate directors for their service on
the Board as such and may provide for the payment of expenses incurred by the directors in connection with such services. Any director
may serve the Corporation in any other capacity and receive compensation therefor.
Section
3.06 Chairman and Vice Chairman of the Board. The chairman of the Board (the “Chairman
of the Board”) and vice chairman of the Board (the “Vice Chairman of the Board”) will be elected by the
Board, the
Chairman of the Board, or if the Chairman of the Board is unable to attend the meeting or if the Chairman of the Board is not then an
Independent Director and a meeting on the Independent Directors is called, the Vice Chairman of the Board, will preside at meetings of
the Board, and each shall have such other authority and perform such other duties as the Board may designate.
Section
3.07 Place of Meetings; Meetings by Telephone. The Board may hold meetings, both
regular and special, either within or outside the State of Nevada. Members of the Board or any committee designated by the Board may
participate in a meeting of the Board or committee through electronic communications, videoconferencing, teleconferencing or other available
technology which allows the stockholders to communicate simultaneously or sequentially. Such participation in a meeting will constitute
presence in person at the meeting.
Section
3.08 Regular Meetings. Regular meetings of the Board may be held without notice
at such date, time, and place as the Board will determine from time to time.
Section
3.09 Special Meetings; Notice. Special meetings of the Board may be called at any
time by the Chairman of the Board, the President, or any two (2) directors. Notice of the date, time, and place of special meetings
of the Board will be delivered personally, by first class mail, overnight courier, telephone, facsimile, or electronic mail to each director
at that director’s address as shown on the records of the Corporation.
Section
3.10 Waiver of Notice. Notice of the date, time, place, and purpose of any meeting
of directors may be waived in writing, signed by the person entitled to notice, either before or after such meeting, and a director’s
attendance at a meeting waives objection to lack of notice or defective notice of the meeting, unless the director at the beginning of
the meeting objects to holding the meeting or transacting business at the meeting because the meeting is not lawfully called or convened.
Neither of the business to be transacted at, nor the purpose of, any regular or special meeting of the directors, or members of a committee
of directors, need to be specified in a written waiver of notice.
Section
3.11 Quorum; Vote. Except as otherwise provided by applicable law, at all meetings
of the Board, a majority of the authorized number of directors will constitute a quorum for the transaction of business and the vote
of a majority of the directors present at any meeting at which there is a quorum will be the act of the Board. If a quorum is present
at the call of a meeting, the directors may continue to transact business until adjournment notwithstanding the withdrawal of enough
directors to leave less than a quorum. In the event of a tie vote of the Board and one (1) or more directors is absent from the
meeting, the matter will be deferred until the next meeting of the Board. In the event of a tie vote and all directors have participated
in the meeting and have voted or abstained from voting, the Chairman of the Board will cast an additional vote and the matter will be
approved or disapproved based upon such vote. In the event the Chairman of the Board has abstained from voting on the issue, the matter
will be deemed disapproved due to the matter failing to obtain a majority of affirmative votes.
Section
3.12 Adjourned Meeting; Notice. If a quorum is not present at any meeting of the
Board, then the directors present at the meeting may adjourn the meeting from time to time without notice other than announcement at
the meeting, until a quorum is present, but may not transact business.
Section
3.13 Conduct of Business. Meetings of the Board will be presided over by the Chairman
of the Board, if any, or in his or her absence by the President, or in his or her absence by a chairman chosen at the meeting. The Secretary
will act as secretary of the meeting, but in his or her absence the chairman of the meeting may appoint any person to act as secretary
of the meeting. The chairman of the meeting will determine the order of business and the procedures at the meeting.
Section
3.14 Action by Written Consent. Any action required or permitted to be taken at
any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the
case may be, consent thereto in writing and the writing or writings are filed with the minutes of proceedings of the Board or committee.
ARTICLE
IV.
COMMITTEES
Section
4.01 Audit Committee. The Board by resolution will designate an audit committee
(the “Audit Committee”) consisting of at least three (3) members. All of the members of the Audit Committee must
be Independent Directors. The Audit Committee will review the internal financial controls of the Corporation, and the integrity of its
financial reporting, and have such other powers and duties as the Board determines. The Board will adopt a charter, which may be amended
from time to time, setting forth the powers and duties of the Audit Committee. The Board will designate by resolution a member of the
Audit Committee as a “financial expert” within the meaning of Item 401 of Regulation S-K under the Exchange Act.
Section
4.02 Compensation Committee. The Board by resolution will designate a compensation
committee (the “Compensation Committee”) consisting of at least two (2) members. All members of the Compensation
Committee must be Independent Directors. The Compensation Committee will administer the Corporation’s compensation plans and have
such other powers and duties as the Board determines. The Board will adopt a charter, which may be amended from time to time, setting
forth the powers and duties of the Compensation Committee.
Section
4.03 Nominating and Corporate Governance Committee. The Board by resolution will
designate a nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”) consisting
of at least two (2) members. All members of the Nominating and Corporate Governance Committee must be Independent Directors. The
Nominating and Corporate Governance Committee will nominate candidates for election to the Board, formulate corporate governance principles,
and have such other powers and duties as the Board determines. The Board will adopt a charter, which may be amended from time to time,
setting forth the powers and duties of the Nominating and Corporate Governance Committee.
Section
4.04 Independent Directors. For purposes of this Article 4, “Independent
Director” means a director who is not an officer or employee of the Corporation or its affiliates and who does not have any
other relationship with the Corporation which, in the opinion of the Board, would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. Without limiting the foregoing, all Independent Directors must satisfy the requirements
set forth in the applicable rule concerning director independence of the national securities exchange on which the Corporation’s
common stock or other equity security is then listed, and if not listed then the requirements set forth in Rule 5605(a)(2) of the NASDAQ
Listing Rules.
Section
4.05 Other Committees. The Board, by resolution adopted by a majority of the entire
Board, may designate other committees of directors of one (1) or more directors, which shall serve at the Board’s pleasure
and have such powers and duties as the Board determines.
Section
4.06 Meetings and Action of Committees.
(a) The
members of all committees will serve at the pleasure of the Board. The Board may designate one (1) or more directors as alternate
members of any committee, who may replace any absent or disqualified member at any meeting of the committee; provided, that
such alternate members of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee must be Independent
Directors. Each committee will keep regular minutes of its meetings and report the same to the Board at its next meeting. Each committee
may adopt rules of procedure and shall meet as provided by those rules or by resolutions of the Board. Subject to the provisions requiring
Independent Directors, any director may serve simultaneously on multiple committees.
(b) Except
as otherwise provided in resolutions or charters adopted by the Board, all meetings and actions of committees will be governed by, and
held and taken in accordance with, the provisions of Sections 3.07 through 3.14, with such changes in the context of those Bylaws as
are necessary to substitute the committee and its members for the Board and its members; provided, however, that
(i) the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;
(ii) special meetings of committees may also be called by resolution of the Board; (iii) notice of special meetings of committees
will also be given to all alternate members, who will have the right to attend
all meetings of the committee; (iv) a majority of the members of a committee will constitute a quorum for the transaction of business
at any meeting; and (v) the affirmative vote of a majority of the members of a committee will be required to take action in respect
of any matter presented to or requiring the approval of the committee.
ARTICLE
V.
OFFICERS
Section
5.01 Designation. The officers of the Corporation will be chosen by the Board and
will be a President, a Secretary, and a Treasurer. The Board may also choose one (1) or more vice presidents, assistant secretaries,
and assistant treasurers, and such other officers as may be deemed necessary. Any person may hold two (2) or more offices.
Section
5.02 Appointment of Officers. The Board at its first meeting after each annual
meeting of stockholders will choose a President, a Secretary, a Treasurer, and a Chief Financial Officer and may choose a Chairman of
the Board, each of whom will serve at the pleasure of the Board. The Board at any time may appoint such other officers as it deems necessary
who will hold their offices at the pleasure of the Board and who will exercise such powers and perform such duties as will be determined
from time to time by the Board.
Section
5.03 Compensation. The compensation of the officers will be fixed from time to
time by the Board, upon recommendation from the Compensation Committee, and no officer will be prevented from receiving such compensation
by reason of the fact that he or she is also a director of the Corporation. The compensation of the officers or the method by which compensation
is set will be set forth in the minutes of the meetings of the Board.
Section
5.04 Vacancies. A vacancy in any office because of death, resignation, removal,
disqualification, or otherwise may be filled by the Board at any time.
Section
5.05 Resignation and Removal. Any officer may resign at any time by giving written
notice to the President. Any resignation will take effect on the date the President receives such notice or at any later time specified
in such notice; and, unless otherwise specified in such notice, acceptance of the resignation will not be necessary to make it effective.
Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party, or
of the Board to remove an officer at any time as provided in this Section 5.05. Subject to the rights, if any, of an officer under
any contract of employment, the Board may remove any officer, either with or without cause, at any regular or special meeting of the
Board.
Section
5.06 Chairman of the Board. The Chairman of the Board, if one is appointed and
serving, or if the Chairman of the Board is unable to attend the meeting or the Chairman of the Board is not then an Independent Director
and a meeting of the Independent Directors is called, the Vice Chairman of the Board, will preside at all meetings of the Board and will
perform such other duties as may be from time to time assigned to him or her by the Board.
Section
5.07 President. The President will serve as the chief executive officer (the “Chief
Executive Officer”) of the Corporation may be designated as the Chief Executive Officer if determined by the Board, and will,
subject to the control of the Board, be responsible for the general supervision, direction, and control of the business and affairs and
supervision of the other officers of the Corporation. The President will have the general powers and duties of management usually vested
in the president or chief executive officer of a corporation and will have such other powers and duties as may be from time to time prescribed
by the Board.
Section
5.08 Vice Presidents. There will be as many vice presidents (each a “Vice
President”) as may be determined from time to time and they will perform such duties as may be from time to time assigned to
them by the Board or the President. Any one of the vice presidents, as authorized by the Board, will have all the powers and perform
all the duties of the President in case of the President’s temporary absence or inability to act. In case of the President’s
permanent absence or inability to act, the office will be declared vacant by the Board and a successor chosen by the Board.
Section
5.09 Secretary. The secretary (the “Secretary”) will see that
the minutes of all meetings of the Board and of any standing committees are kept. The Secretary will be the custodian of the corporate
seal, if any, and will affix it to all proper instruments when deemed advisable. The Secretary will give or cause to be given required
notices of all meetings of the Board. The Secretary will have charge of all the books and records of the Corporation except the books
of account and in general will perform all the duties incident to the office of secretary of a corporation and such other duties as may
be assigned to him or her by the Board or the President.
Section
5.10 Treasurer. The treasurer (the “Treasurer”) will have general
custody of all of the funds and securities of the Corporation except such as may be required by applicable law to be deposited with any
state official. The Treasurer will see to the deposit of the funds of the Corporation in such bank or banks as the Board may designate.
If required by the Board, the Treasurer will give the Corporation such fidelity bond as may be required, and the premium therefor will
be paid by the Corporation as an operating expense.
Section
5.11 Chief Financial Officer. The chief financial officer (the “Chief
Financial Officer”) shall keep or cause to be kept the books of account of the Corporation in a thorough and proper manner
and shall render statements of the financial affairs of the Corporation in such form and as often as required by the Board or the President.
The Chief Financial Officer shall perform other duties commonly incident to the office and shall perform such other duties and have such
others powers as the Board or the President may from time to time delegate.
Section
5.12 Assistant Secretaries. There may be such number of assistant secretaries (each
an “Assistant Secretary”) as the Board may from time to time determine, and such persons will perform such functions
as may be from time to time assigned to them.
Section
5.13 Assistant Treasurers. There may be such number of assistant treasurers (each
an “Assistant Treasurer”) as the Board may from time to time determine, and such persons will perform such functions
as may be from time to time assigned to them.
ARTICLE
VI.
CAPITAL STOCK
Section
6.01 Issuance. Shares of the Corporation’s authorized stock shall, subject
to any provisions or limitations of the laws of the State of Nevada, the Articles, or any contracts or agreements to which the Corporation
may be a party, be issued in such manner, at such times, upon such conditions and for such consideration as shall be prescribed by the
Board.
Section
6.02 Stock Certificates and Uncertificated Shares.
(a) Every
holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by two (2) officers
or agents so authorized by the Board, certifying the number of shares of stock owned by him, her, or it in the Corporation; provided, however,
that the Board may authorize the issuance of uncertificated shares of some or all of the Corporation’s stock. Any such issuance
of uncertificated shares shall have no effect on existing certificates for shares until such certificates are surrendered to the Corporation,
or on the respective rights and obligations of the stockholders. Whenever such certificate is countersigned or otherwise authenticated
by a Transfer Agent, or a transfer clerk and by a registrar (other than the Corporation), then a facsimile of the signatures of any corporate
officers or agents, the Transfer Agent, transfer clerk, or the registrar of the Corporation may be printed or lithographed upon the certificate
in lieu of the actual signatures. In the event that any officer or officers who have signed, or whose facsimile signatures have been
used on any certificate or certificates for stock cease to be an officer or officers because of death, resignation, or other reason,
before the certificate or certificates for stock have been delivered by the Corporation, the certificate or certificates may nevertheless
be adopted by the Corporation and be issued and delivered as though the person or persons who signed the certificate or certificates,
or whose facsimile signature or signatures have been used thereon, had not ceased to be an officer or officers of the Corporation.
(b) Within
a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner thereof
a written statement certifying the number of shares owned by him,
her, or it in the Corporation and, at least annually thereafter, the Corporation shall provide to such stockholders of record holding
uncertificated shares, a written statement confirming the information contained in such written statement previously sent. Except as
otherwise expressly provided by applicable law, the rights and obligations of the stockholders shall be identical whether or not their
shares of stock are represented by certificates.
(c) Certificates
of stock shall be in such form consistent with applicable law and the Articles as shall be prescribed by the Board. All certificates
evidencing shares of the Corporation’s stock or other securities issued by the Corporation shall contain such legend or legends
as may from time to time be required by the Board, the NRS, or such other federal, state, or local laws or regulations then in effect.
Section
6.03 Transfer of Shares. Shares shall be transferable in the manner prescribed
by applicable law, the Articles, and in these Bylaws. Transfers of Shares shall be made on the books of the Corporation only by the person
named in the certificate or by his, her, or its attorney lawfully constituted in writing and, if such Shares are certificated, upon the
surrender of the certificate therefore properly endorsed, and payment of all necessary transfer taxes, which certificate shall be canceled
before a new certificate shall be issued; or, in the case of uncertificated Shares, upon receipt of proper transfer instructions from
the registered holder of the Shares or by such person’s attorney lawfully constituted in writing, and upon payment of all necessary
transfer taxes and compliance with appropriate procedures for transferring Shares in uncertificated form. Any transfer shall be accompanied
by proper evidence of succession, assignment, or authority and, upon receipt of such evidence and compliance with the other applicable
provisions of these Bylaws and applicable law; it shall be the duty of the Corporation to record the transaction in its books. The Corporation
may treat, as the absolute owner of Shares, the person or persons in whose name or names the Shares are registered on the books of the
Corporation.
Section
6.04 Transfer Agent. The Board may appoint one (1) or more transfer agents
(each a “Transfer Agent”) for the transfer and registration of certificates of stock of any class and may require
that stock certificates be countersigned and registered by one (1) or more of such Transfer Agents. The Transfer Agent will keep
the stock transfer records of the Corporation, which will reflect the name and address of each stockholder of record, the number and
class or series of shares issued to each stockholder of record and the date of issue of each such share.
Section
6.05 Lost, Stolen, or Destroyed Certificates. The Board may authorize the issuance
of a new certificate in place of a certificate alleged to have been lost, stolen, or destroyed, upon receipt of: (a) an affidavit
from the person explaining the loss, theft, or destruction; and (b) a bond or other security from the owner or legal representative
of the owner in a sum as the Corporation may reasonably direct to indemnify the Corporation against any claim with respect to the certificate
claimed to have been lost, stolen, or destroyed. The Board may, in its discretion, waive the affidavit and bond or other security and
authorize the issuance of a new certificate in place of a certificate claimed to have been lost, stolen, or destroyed.
ARTICLE
VII.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section
7.01 Indemnification of Directors and Officers.
(a) For
purposes of this Article, (A) “Indemnitee” shall mean each director or officer who was or is a party to, or is
threatened to be made a party to, or is otherwise involved in, any Proceeding (as hereinafter defined), by reason of the fact that he
or she is or was a director or officer of the Corporation or member, manager, or managing member of a predecessor limited liability company
or affiliate of such limited liability company, or is or was serving in any capacity at the request of the Corporation as a director,
officer, employee, agent, partner, member, manager, or fiduciary of, or in any other capacity for, another corporation or any partnership,
joint venture, limited liability company, trust, or other enterprise or affiliate; (B) “Proceeding” shall mean
any threatened, pending, or completed action, suit, or proceeding (including, without limitation, an action, suit, or proceeding by or
in the right of the Corporation), whether civil, criminal, administrative, or investigative; and (C) “Liabilities”
shall mean any and all expenses, liabilities, and losses (including, without limitation, attorneys’ fees, judgments, fines, taxes,
penalties, and amounts paid or to be paid in settlement).
(b) Each
Indemnitee shall be indemnified and held harmless by the Corporation to the fullest extent permitted by Nevada law, against Liabilities
actually and reasonably incurred or suffered by the Indemnitee in connection with any Proceeding; provided, that such Indemnitee
either is not liable pursuant to NRS 78.138 or acted in good faith and in a manner such Indemnitee reasonably believed to be in or not
opposed to the best interests of the Corporation and, with respect to any Proceeding that is criminal in nature, had no reasonable cause
to believe that his or her conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon
a plea of nolo contendere or its equivalent, does not, of itself, create a presumption that the Indemnitee is liable
pursuant to NRS 78.138 or did not act in good faith and in a manner in which he or she reasonably believed to be in or not opposed to
the best interests of the Corporation, or that, with respect to any criminal Proceeding he or she had reasonable cause to believe that
his or her conduct was unlawful.
(c) With
regard solely to a Proceeding that is an action or suit by or in the right of the Corporation to procure a judgment in the Corporation’s
favor, the Corporation shall not indemnify an Indemnitee against Liabilities for any claim, issue, or matter as to which the Indemnitee
has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Corporation or
for any amounts paid in settlement to the Corporation, unless and only to the extent that the court in which the Proceeding was brought
or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the Indemnitee
is fairly and reasonably entitled to indemnity for such amounts as the court deems proper.
(d) Except
as so ordered by a court and for advancement of expenses pursuant to this Article 7, indemnification may not be made to or on behalf
of an Indemnitee if a final adjudication establishes that his or her acts or omissions involved intentional misconduct, fraud, or a knowing
violation of law and was material to the cause of action.
(e) The
expenses of Indemnitees must be paid by the Corporation or through insurance purchased and maintained by the Corporation or through other
financial arrangements made by the Corporation, as they are incurred and in advance of the final disposition of the Proceeding, upon
receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately adjudged by a court of competent
jurisdiction, after exhaustion of all appeals therefrom, that he or she is not entitled to be indemnified by the Corporation.
(f) Notwithstanding
anything to the contrary herein, to the extent that a director or officer of the Corporation is successful on the merits or otherwise
in defense of any Proceeding, including in the defense of any claim, issue, or matter arising out of an action or suit by or in the right
of the Corporation to procure a judgment in the Corporation’s favor, the Corporation shall indemnify him or her against Liabilities
actually and reasonably incurred by him or her in connection with the defense.
Section
7.02 Enforcement. Without the necessity of entering into an express contract, all
rights to indemnification and advances to persons under this Article 7 will be deemed to be contractual rights and be effective to the
same extent and as if provided for in a contract between the Corporation and the Indemnitee. an Indemnitee may enforce any right to indemnification
or advances under this Article 7 in any court of competent jurisdiction if: (a) the Corporation denies the claim for indemnification
or advances, in whole or in part; or (b) the Corporation does not dispose of such claim within ninety (90) days of request
therefor. The claimant in such enforcement action, if successful in whole or in part, will be entitled to be paid also the expense of
prosecuting his claim. The burden of proof is on the claimant to substantiate that he is entitled to be indemnified under this Article
7. The Corporation will be entitled to raise as a defense to any such action that the claimant has not met the standard of conduct that
makes it permissible under NRS Section 78.7502 for the Corporation to indemnify the claimant for the amount claimed. Neither the
failure of the Corporation (including the Board, independent legal counsel, or the stockholders) to have, prior to the commencement of
such action, made a determination that indemnification of the claimant is proper in the circumstances because the claimant has met the
applicable standard of conduct set forth in NRS Section 78.7502, nor an actual determination by the Corporation (including the Board,
independent legal counsel, or the stockholders) that the claimant has not met such applicable standard of conduct, will be a defense
to the action or create a presumption that claimant has not met the applicable standard of conduct.
Section
7.03 Non Exclusivity of Rights. The rights conferred on any person by this Article
7 will not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Articles,
Bylaws, agreement, vote of stockholders, or disinterested directors or otherwise, both as to action in the person’s official capacity
and as to action in another capacity while serving the Corporation. The Corporation is specifically authorized to enter into individual
contracts with any or all of its directors, officers, employees, or agents respecting indemnification and advances, to the fullest extent
not prohibited by applicable law.
Section
7.04 Survival of Rights. Indemnification pursuant to this Section shall continue
as to an Indemnitee who has ceased to be a director or officer of the Corporation or member, manager, or managing member of a predecessor
limited liability company or affiliate of such limited liability company, or a director, officer, employee, agent, partner, member, manager,
or fiduciary of, or to serve in any other capacity for, another corporation or any partnership, joint venture, limited liability company,
trust, or other enterprise or affiliate and shall inure to the benefit of his or her heirs, executors, and administrators.
Section
7.05 Insurance; Other Financial Arrangements.
(a) To
the fullest extent permitted by NRS Section 78.752, the Corporation, upon approval by the Board, may purchase and maintain insurance
or make other financial arrangements on behalf of any person required or permitted to be indemnified pursuant to this Article 7 for any
liability asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer,
employee, member, manager, managing member, or agent, or arising out of his or her status as such, whether or not the Corporation has
the authority to indemnify him or her against such liability and expenses.
(b) The
other financial arrangements which may be made by the Corporation may include the following (i) the creation of a trust fund; (ii) the
establishment of a program of self-insurance; (iii) the securing of its obligation of indemnification by granting a security interest
or other lien on any assets of the Corporation; and/or (iv) the establishment of a letter of credit, guarantee or surety. No financial
arrangement made pursuant to this subsection may provide protection for a person adjudged by a court of competent jurisdiction, after
exhaustion of all appeals therefrom, to be liable for intentional misconduct, fraud, or a knowing violation of law, except with respect
to advancement of expenses or indemnification ordered by a court.
(c) Any
insurance or other financial arrangement made on behalf of a person pursuant to this Article 7 may be provided by the Corporation or
any other person approved by the Board, even if all or part of the other person’s stock or other securities is owned by the Corporation.
In the absence of fraud (i) the decision of the Board as to the propriety of the terms and conditions of any insurance or other
financial arrangement made pursuant to this Article 7 and the choice of the person to provide the insurance or other financial arrangement
is conclusive; and (ii) the insurance or other financial arrangement is not void or voidable and does not subject any director approving
it to personal liability for his action; even if a director approving the insurance or other financial arrangement is a beneficiary of
the insurance or other financial arrangement.
Section
7.06 Indemnification of Employees and Other Persons. The Corporation may, by action
of its Board and to the extent provided in such action, indemnify employees and other persons as though they were Indemnitees.
Section
7.07 Amendment. The provisions of this Article 7 relating to indemnification shall
constitute a contract between the Corporation and each of its directors and officers which may be modified as to any director or officer
only with that person’s consent or as specifically provided in this Section 7.07. Notwithstanding any other provision of these
Bylaws relating to their amendment generally, any repeal or amendment of this Article 7 which is adverse to any director or officer shall
apply to such director or officer only on a prospective basis, and shall not limit, eliminate, or impair the rights of an Indemnitee
to indemnification with respect to any action or failure to act occurring prior to the time of such repeal or amendment. Notwithstanding
any other provision of these Bylaws (including, without limitation, Section 8.08 below), no repeal or amendment of these Bylaws
shall affect any or all of this Article 7 so as to limit or reduce the indemnification in any manner unless adopted by the unanimous
vote of the
directors of the Corporation then serving; provided, that no such amendment shall have a retroactive effect inconsistent
with the preceding sentence.
ARTICLE
VIII.
MISCELLANEOUS
Section
8.01 Corporate Seal. The Board may, but is not require to, adopt a corporate seal,
which shall be in the form of a circle and shall bear the Corporation’s name and the year and state in which it was incorporated.
Section
8.02 Fiscal Year. The Board may by resolution determine the Corporation’s
fiscal year. Until changed by the Board, the Corporation’s fiscal year shall be the calendar year.
Section
8.03 Voting of Shares in Other Corporations. Unless another person is designated
by the Board, shares in other corporations which are held by the Corporation may be represented and voted by the President or a Vice
President of the Corporation or by proxy or proxies appointed by one of them.
Section
8.04 Checks; Drafts; Evidences of Indebtedness. From time to time, the Board will
determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes, or
other evidences of indebtedness that are issued in the name of or payable to the Corporation, and only the persons so authorized shall
sign or endorse those instruments.
Section
8.05 Corporate Contracts and Instruments; How Executed. The Board may authorize
any officers or agents to enter into any contract or execute any instrument in the name of and on behalf of the Corporation. Such authority
may be general or confined to specific instances.
Section
8.06 Provisions Additional to Provisions of Law. All restrictions, limitations,
requirements, and other provisions of these Bylaws shall be construed, insofar as possible, as supplemental and additional to all provisions
of law applicable to the subject matter thereof and shall be fully complied with in addition to the said provisions of law unless such
compliance shall be illegal.
Section
8.07 Provisions Contrary to Law. Any article, section, subsection, subdivision,
sentence, clause, or phrase of these Bylaws which is contrary to or inconsistent with any applicable provisions of law, shall not apply
so long as said provisions of law shall remain in effect, but such result shall not affect the validity or applicability of any other
portions of these Bylaws.
Section
8.08 Amendments. The Board may make the Bylaws of the Corporation. Unless otherwise
prohibited by applicable law, the Board may adopt, amend, or repeal these Bylaws, or any portion hereof, including any bylaw adopted
by the stockholders. Whenever an amendment or new Bylaws are adopted, the amendment or the new Bylaws will be copied in the Corporation’s
minute book with the original Bylaws.
Section
8.09 Changes in Nevada Law. References in these Bylaws to Nevada law or the NRS
or to any provision thereof shall be to such law as it existed on the date these Bylaws were adopted or as such law thereafter may be
changed; provided, that (a) in the case of any change which expands the liability of directors or officers or limits
the indemnification rights or the rights to advancement of expenses which the Corporation may provide in Article 7 hereof, the rights
to limited liability, to indemnification and to the advancement of expenses provided in the Articles and/or these Bylaws shall continue
as theretofore to the extent permitted by applicable law; and (b) if such change permits the Corporation, without the requirement
of any further action by stockholders or directors, to limit further the liability of directors or limit the liability of officers or
to provide broader indemnification rights or rights to the advancement of expenses than the Corporation was permitted to provide prior
to such change, then liability thereupon shall be so limited and the rights to indemnification and the advancement of expenses shall
be so broadened to the extent permitted by applicable law.
CONSENT
The
undersigned, being the Court appointed custodian of Sino Bioenergy Corp., a Nevada corporation (the "Corporation"), acting
in accordance with Section 78.347 of the Nevada Revised Statutes, hereby consents to these Amended and Restated Articles of Incorporation
and approved them as presented.
WHEREFORE,
this Consent shall have the same force and effect as a majority vote cast at a meeting of the shareholders duly called, noticed, convened
and held in accordance with the law, the Articles of lncorporation, and the Bylaws of the Corporation.
IN
WITNESS WHEREOF, the Corporation has caused the undersigned, the President of the Court-Appointed Custodian for Sino Bioenergy Corp.,
to execute, file and record these Amended and Restated Articles of Incorporation.
//
Frank I Igwealor_______
Frank
Ikechukwu Igwealor Adopted on 06/30/2022
Exhibit 3.1
SINO
BIOENERGY CORP.
RESOLUTION
OF ALPHARIDGE CAPITAL LLC AS COURT
APPOINTED
CUSTODIAN
The
undersigned, being the Court appointed custodian of SINO BIOENERGY CORP., a Nevada corporation (the "Corporation"), acting
in accordance with Section 78.347 of the Nevada Revised Statutes, hereby consents to the adoption of the following resolutions:
Appointment
of Officer
WHEREAS,
in accordance with the Section 78.347 of the Nevada Revised Statutes, Alpharidge Capital LLC a California limited liability
company was appointed Custodian of the Corporation pursuant to an Order of District Court of Clark County, Nevada, case no. A-22-852552-P
on June 10, 2022 (the "Order")(the "Custodian")(See Exhibit A};
WHEREAS,
pursuant to Section 78.347 of the Nevada Revised Statutes Order, the Custodian is authorized to take any actions on behalf of the Corporation
that arc reasonable, prudent, or for the benefit of the Corporation.
WHEREAS,
the Custodian deems it to be in the best interest of the Corporation and its stockholders to adopt the following resolutions;
NOW,
THEREFORE, BE IT
RESOLVED,
that the following persons are elected as officers of the Corporation in the position listed to serve until the next annual meeting and
election of their successors:
Frank
I Igwealor . . . President & CEO
Frank
I Igwealor . . . CFO & Controller
Frank
I Igwealor . . . Secretary & Treasurer
FURTHRE
RESOLVED, that any appointment of any other Officer is hereby terminated, such Officers having abandoned their positions for a period
no less than four (4) years.
WHEREFORE,
this Consent shall have the same force and effect as a majority vote cast at a meeting of the shareholders duly called, noticed, convened
and held in accordance with the law, the Articles of Incorporation, and the Bylaws of the Corporation.
Effective
date: June 10, 2022
ALPHARIDGE
CAPITAL LLC a California limited liability company
As
Court-Appointed Custodian for Sino Bioenergy Corp., Nevada corporation
/s/ Frank I Igwealor
By:
Frank I Igwealor
Its:
Managing Member
SINO
BIOENERGY CORP
RESOLUTION
OF ALPHARIDGE CAPITAL LLC AS COURT
APPOINTED
CUSTODIAN
The
undersigned, being the Court appointed custodian of SINO BIOENERGY CORP., a Nevada corporation (the "Corporation"), acting
in accordance with Section 78.347 of the Nevada Revised Statutes, hereby consents to the adoption of the following resolutions:
Appointment
of Directors and Officers
WHEREAS,
in accordance with the Section 78.347 of the Nevada Revised Statutes, Alpharidge Capital LLC a California limited liability company was
appointed Custodian of the Corporation pursuant to an Order of District Court of Clark County, Nevada, case no. A-22-852552-P on June
10, 2022 (the "Order")(the "Custodian")(See Exhibit A};
WHEREAS,
pursuant to Section 78.347 of the Nevada Revised Statutes Order, the Custodian is authorized to take any actions on behalf of the Corporation
that arc reasonable, prudent, or for the benefit of the Corporation.
WHEREAS,
the Custodian deems it to be in the best interest of the Corporation and its stockholders to adopt the following resolutions;
NOW,
THEREFORE, BE IT
RESOLVED,
that the following persons are elected as directors of the Corporation to serve until the next annual meeting and election of their successors:
Ambrose
O Egbuonu
Frank
I Igwealor
FURTHRE
RESOLVED, that any appointment of any other Director is hereby terminated, such Directors having abandoned their position and otherwise
failed to participate in any meeting of the Corporation's stockholders for a period no less than four (4) years.
WHEREFORE,
this Consent shall have the same force and effect as a majority vote cast at a meeting of the shareholders duly called, noticed, convened
and held in accordance with the law, the Articles of Incorporation, and the Bylaws of the Corporation.
Effective
date: June 10, 2022
ALPHARIDGE
CAPITAL LLC a California limited liability company
As
Court-Appointed Custodian for Sino Bioenergy Corp., Nevada corporation
/s/
Frank I Igwealor
By:
Frank I Igwealor
Its:
Managing Member
Exhibit
4.1
Sino
Bioenergy Corp.
SUBSCRIPTION
AGREEMENT REGULATION A SHARES
THIS
SUBSCRIPTION AGREEMENT made as of the day of , 2024, between Sino Bioenergy Corp.., a corporation organized under
the laws of the State of Nevada, (the “Company”), and the undersigned (the “Subscriber”
and together with each of the other subscribers in the Offering (defined below), the “Subscribers”).
WHEREAS,
the Company desires to sell registered Regulation A shares of Common Stock (collectively, the “Shares”), at
a purchase price of $[*] per Share and per the terms set forth in the Company’s Form 1-A (as amended) which was originally filed
on June 19, 2023, and declared Effective by the SEC on [DATE] (the “Offering”).
NOW,
THEREFORE, for and in consideration of the promises and the mutual covenants hereinafter set forth, the parties hereto do hereby
agree as follows:
|
1.1. |
Subscription for Shares. Subject to the terms and conditions hereinafter set forth, the Subscriber hereby subscribes for and agrees to purchase from the Company such aggregate amount of Shares as is set forth upon the signature page hereof; and the Company agrees to sell such Shares to the Subscriber for said purchase price subject to the Company’s right to sell to the Subscriber such lesser number of Shares as the Company may, in its sole discretion, deem necessary or desirable. The purchase price is payable by wire transfer, or certified or bank checks made payable to “Sino Bioenergy Corp..” and delivered contemporaneously with the execution and delivery of this Subscription Agreement to the Company’s address set forth in the FORM 1- A. |
| 1.2. | Form
1-A Registered Shares. The Subscriber acknowledges that the Shares being purchased herein
are shares of Common
Stock qualified in the Company’s Form 1-A (as amended) which was originally filed on June , 2024. |
| 1.3. | Investment
Purpose. The Subscriber represents that the Shares (the “Securities”)
are being purchased for his or her
or its own account, for investment purposes only and not for distribution or resale to others in contravention of the registration requirements
of the 1933 Act. The Subscriber agrees that it will not sell or otherwise transfer the Securities unless they are registered under the
1933 Act or unless an exemption from such registration is available. |
| 1.4. | Investor
Eligibility. Subscriber represents and warrants that either (i) Subscriber is an “accredited
investor” as such
term is defined in Rule 501 of Regulation D promulgated under the 1933 Act, and that it can bear the economic risk of any investment
in the Shares; or (ii) Subscriber is not an accredited investor and the funds invested through this Agreement do not exceed 10% of the
Subscriber’s annual income or net worth. |
| 1.5. | Domicile.
Subscriber represents and warrants that his, her, or its Domicile matches the address
listed on the signature
page of this Agreement. For individuals, Domicile means actual state of residency. For corporate entities, Domicile means (i) state of
incorporation/organization; or (ii) principal place of business. |
|
1.6 |
RISK OF INVESTMENT. THE SUBSCRIBER RECOGNIZES THAT THE PURCHASE OF THE SHARESINVOLVES A HIGH DEGREE OF RISK INCLUDING, WITHOUT LIMITATION, ANY AND ALL RISKS DISCUSSED IN THIS SUBSCRIPTION AGREEMENT. AN INVESTMENT IN THE COMPANY AND THE SHARES MAY RESULT IN THE LOSS OF A SUBSCRIBER’S ENTIRE INVESTMENT. |
| (a) | Risk
of Loss of Investment. An investment in the Company and the Shares offered hereby involve
a high degree
of risk. An investment in the Shares is suitable only for investors who can bear a loss of their entire investment. |
| (b) | Value
of Shares is Speculative. The terms of this offering have been determined arbitrarily
by the Company.
There is no relationship between such terms and the Company’s assets, earnings, book value and/or any other objective criteria
of value. |
| (c) | Dependence
on Net Proceeds; No Minimum Offering. The Company is dependent upon the net proceeds
of this
Offering to fund its operations, as more specifically described elsewhere in this Subscription Agreement. There is no commitment by any
person to purchase Shares and there is no assurance that any number of Shares will be sold. Additionally, there is no minimum amount
of funds that are required to be raised in order for the Company to accept subscriptions received from investors and the Company’s
may terminate this Offering prior to the expiration of the Offering Period. There is no assurance that the Company will sell a sufficient
number of Shares in this Offering on a timely basis or that the net proceeds after payment of debts and other obligations will be adequate
for the Company’s needs. |
| (d) | Need
for Additional Capital; Additional Private Placement. The net proceeds raised by the
Company from this
Offering will be used immediately to fund the Company’s current operations. The Company will therefore require significant additional
financing shortly after this Offering, regardless of the net proceeds received, in order to satisfy its cash requirements. The Company
may seek to raise additional funds in private placement transactions. However, there is no assurance that it will be able to do so in
a timely manner or on terms that will enable it to enter its proposed business on a reasonable basis. |
| 1.7 | Information.
The Subscriber acknowledges receipt and full and careful review and understanding of
this Subscription
Agreement and of the Form 1-A (as amended) which was originally filed on June , 2024. |
| 1.8 | No
Representations or Warranties. The Subscriber hereby represents that, except as expressly
set forth in the Form
1-A, no representations or warranties have been made to the Subscriber by the Company or any agent, employee, or affiliate of the Company
and in entering into this transaction the Subscriber is not relying on any information other than that contained in the Form 1-A and
the results of independent investigation by the Subscriber. |
| 1.9 | Tax
Consequences. The Subscriber acknowledges that this Offering of the Shares may involve
tax consequences and
that the contents of the Form 1-A does not contain tax advice or information. The Subscriber acknowledges that it must retain its own
professional advisors to evaluate the tax and other consequences of an investment in the Shares. |
| 1.10 | Transfer
or Resale. The Subscriber understands that the Shares purchased herein were qualified
in the Form 1-A under
the Securities Act of 1933 Act, but that Subscriber will be required by the transfer agent or Subscriber’s brokerage firm to obtain
a legal opinion from securities counsel to deposit and sell the Shares. |
| 2.1 | Organization
and Registration. The Company and its “Subsidiaries” (which
for purposes of this Subscription Agreement
means any entity in which the Company, directly or indirectly, owns capital stock and holds a majority or similar interest) are duly
organized and validly existing in good standing under the laws of the jurisdiction in which they were organized, and have the requisite
power and authorization to own their properties and to carry on their business as now being conducted. |
| 2.2 | Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to
enter into and
perform its obligations under this Subscription Agreement and to issue the Securities in accordance with the terms of the Form 1-A. |
| 3.1 | Closing
and Termination of Offering. Provided that the required conditions to closing set forth
herein have been satisfied
or waived, a closing (the “Initial Closing”) shall take place at the offices of the Company as set forth herein
or at such place as may otherwise be agreed to by the Company within 30 days of the receipt of the first cleared subscriber’s funds.
The Company may consummate subsequent closings of the Offering, upon mutual agreement
only, each of which shall be subject to satisfaction or waiver of the conditions to closing set forth herein, and each of which shall
be deemed a “Closing” hereunder. |
| 4.1 | The
obligation of the Company hereunder to issue and sell Shares to the Subscriber at the Closing
is subject to the satisfaction,
at or before the Closing, of each of the following conditions, provided that these conditions are for the Company’s sole benefit
and may be waived by the Company at any time in its sole discretion by providing the Subscriber with prior written notice thereof: |
| 4.2 | Execution
and Delivery. The Subscriber shall have executed this Subscription Agreement and delivered
the same to
the Company. |
| 4.3 | Purchase
Price. The Subscriber shall have paid the purchase price for the Shares being purchased
by the Subscriber
at the Closing in the manner set forth in Section 1.1. |
| 4.4 | Representations
and Warranties. The representations and warranties of the Subscriber shall be true and
correct in all
material respects as of the date when made and as of the Closing as though made at that time, and the Subscriber shall have performed,
satisfied, and complied in all material respects with the covenants, agreements and conditions required by this Subscription Agreement
to be performed, satisfied, or complied with by the Subscriber at or prior to the Closing. |
| 4.5 | Other
Matters. All opinions, certificates and documents and all proceedings related to this
Offering shall be in form
and content reasonably satisfactory to the Company and its legal counsel. |
| 4.6 | Notice.
Any notices, consents, waivers or other communications required or permitted to be given
under the terms of
this Subscription Agreement must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally,
(b) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending party), or (c) one (1) business day after deposit with an overnight courier service, in each case properly addressed
to the party to receive the same. The addresses and facsimile numbers for such communications shall be: |
If
to the Company at the address set forth in the Form 1-A, Attn. Rafael Pinedo CEO.
If
to the Subscriber, to its address and email or facsimile number set forth at the end of this Subscription Agreement, or to such other
address and/or facsimile number and/or to the attention of such other person as specified by written notice given to the Company five
(5) days prior to the effectiveness of such change.
Written
confirmation of receipt (a) given by the recipient of such notice, consent, waiver or other communication, (b) mechanically or electronically
generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page
of such transmission, or (c) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from an overnight courier service in accordance with clauses (a), (b) or (c) above, respectively.
| 4.7 | Entire
Agreement; Amendment. This Subscription Agreement supersedes all other prior oral or
written agreements
between the Subscriber, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein,
and this Subscription Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to
the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Subscriber
makes any representation, warranty, covenant or undertaking with respect to such matters. |
| 4.8 | Severability.
If any provision of this Subscription Agreement shall be invalid or unenforceable in
any jurisdiction, such
invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Subscription Agreement in that
jurisdiction or the validity or enforceability of any provision of this Subscription Agreement in any other jurisdiction. |
|
4.9 |
Governing Law; Jurisdiction. This Agreement shall be governed by and construed solely in accordance with the internal laws of the State of Nevada with respect to contracts executed, delivered and to be fully performed therein, without regard to the conflicts of laws principles thereof. The parties hereto hereby expressly and irrevocably agree that any suit or proceeding arising under this Agreement or the consummation of the transactions contemplated hereby, shall be brought solely in a federal or state court located in the State of Nevada. By its execution hereof, Company and Subscriber hereby expressly and irrevocably submits to the in personam jurisdiction of the federal and state courts located in the State of Nevada and agree that any process in any such action may be served upon him or her personally, or by certified mail or registered mail upon such party or such agent, return receipt requested, with the same full force and effect as if personally served upon such party in Nevada. The parties hereto each waive any claim that any such jurisdiction is not a convenient forum for any such suit or proceeding and any defense or lack of in personam jurisdiction with respect thereto. In the event of any such action or proceeding, the party prevailing therein shall be entitled to payment from the other party hereto of its reasonable counsel fees and disbursements. THIS CHOICE OF LAW PROVISION DOES NOT APPLY TO ACTIONS ARISING UNDER THE SECURITIES ACT OF 1933 OR EXCHANGE ACT OF 1934. |
| 4.10 | Headings.
The headings of this Subscription Agreement are for convenience of reference and shall
not form part of,
or affect the interpretation of, this Subscription Agreement. |
| 4.11 | Successors
and Assigns. This Subscription Agreement shall be binding upon and inure to the benefit
of the parties and
their respective successors and assigns, including any purchasers of the Shares. The Company shall not assign this Subscription Agreement
or any rights or obligations hereunder. Subscriber may assign some or all of its rights hereunder without the consent of the Company,
provided, however, that any such assignment shall not release the Subscriber from its obligations hereunder unless such
obligations are assumed by such assignee and the Company has consented to such assignment and assumption, which consent shall not be
unreasonably withheld. |
| 4.12 | No
Third-Party Beneficiaries. This Subscription Agreement is intended for the benefit of
the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person. |
| 4.13 | Survival.
The representations and warranties of the Company and the Subscriber contained in herein
shall survive the
Closing for a period of twelve (12) months. |
| 4.14 | Legal
Representation. The Subscriber acknowledges that: (a) it has read this Subscription Agreement
and the exhibits
hereto; (b) it understands that the Company has been represented in the preparation, negotiation, and execution of this Subscription
Agreement by counsel to the Company; (c) it has either been represented in the preparation, negotiation, and execution of this Subscription
Agreement by legal counsel of its own choice, or has chosen to forego such representation by legal counsel
after being advised to seek such legal representation; and (d) it understands the terms and consequences of this Subscription Agreement
and is fully aware of its legal and binding effect. |
| 4.15 | Confidentiality.
The Subscriber agrees that it shall keep confidential and not divulge, furnish, or make
accessible to
anyone, the confidential information concerning or relating to the business or financial affairs of the Company contained in the Form
1-A to which it has become privy by reason of this Subscription Agreement. |
| 4.16 | Counterparts.
This Subscription Agreement may be executed in two or more identical counterparts, all
of which shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto
with the same force and effect as if the signature were an original, not a facsimile signature. |
[Signature
Page Follows]
IN
WITNESS WHEREOF, the undersigned Subscriber(s) have executed this Sino Bioenergy Corp.. Subscription Agreement for Regulation A Shares
as of the date first written above. The Company’s acceptance of such subscription is as of the date shown below.
SUBSCRIBER**
Date: ___________
CO-SUBSCRIBER**
Date: ____________
Signature
of Subscriber
Name
of Subscriber [Please Print]
Address
of Subscriber
Signature
of Co-Subscriber
Name
of Co-Subscriber [Please Print]
Address
of Co-Subscriber
SSN
or Tax ID of Subscriber
State
of incorporation/corporate domicile (if different than the address listed above): ______________.
*
Please provide the exact names that you wish to see on the certificates
| (1) | For
individuals, print full name of subscriber. |
| (2) | For
joint, print full name of subscriber and all co-subscribers. |
| (3) | For
corporations, partnerships, LLC, print full name of entity, including “&,”
“Co.,” “Inc.,” “etc.,” “LLC.”,“LP”,
etc. |
| (4) | For
Trusts, print trust name (please contact your trustee for the exact name that should appear
on the certificates.) |
Dollar
Amount of Shares Subscribed For (Number of Shares): $_______________(____________)
-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - -
Dollar
Amount of
Subscription
Accepted_________________
SUBSCRIPTION
ACCEPTED BY THE COMPANY Sino Bioenergy Corp..
Date: ______________ |
By: |
________________________ |
|
|
Rafael Pinedo CEO |
**If
Subscriber is a Registered Representative with an FINRA member firm or an affiliated person of an FINRA member firm, have the acknowledgment
to the right signed by the appropriate party: The undersigned FINRA Member firm acknowledges receipt of the notice required by Rule 3040
of the FINRA Conduct Rules.
Name
of FINRA Member Firm
By:_________________ |
Authorized Officer |
|
ALPHA
ADVOCATE LAW GROUP PC.
11432
South Street Suite 373, Cerritos, CA 90703.
TEL:
562-219-0089. FAX: 562-456-3016.
EMAIL: Alphaadvocatelaw@gmail.com
| ___________________________________________________________________________________ | |
January
22, 2024.
Frank
I Igwealor Chief Executive Officer Sino Bioenergy Corp.
370
Amapola Ave., Suite 200A
Torrance,
CA 90501
Dear
Mr. Igwealor:
I
have acted, at your request, as special counsel to Sino Bioenergy Corp., a Nevada corporation (the “Company”), for the purpose
of rendering an opinion as to the legality of 2,000,000,000 shares of Company common stock, par value $0.0001, offered by the Company
at a price range of $0.001-$0.005 per share of Company common stock to be offered and distributed by Company (the “Shares”),
pursuant to a Tier II Offering Statement filed under Regulation A of the Securities Act of 1933, as amended, by Company with the U.S.
Securities and Exchange Commission (the "SEC") on Form 1-A, for the purpose of registering the offer and sale of the Shares
(“Offering Statement”).
In
rendering this opinion, I have examined copies of (a) statutes of the State of Nevada, to the extent I deem relevant to the matter opined
upon herein; (b) true copies of the Articles of Incorporation of Company and all amendments thereto; (c) the By-Laws of Company; (d)
selected proceedings of the board of directors of Company authorizing the issuance of the Shares; (e) certificates of officers of Company
and of public officials; (f) and such other documents of Company and of public officials as I have deemed necessary and relevant to the
matter opined upon herein. In my examination, I have assumed the legal capacity of all natural persons, the genuineness of all signatures,
the conformity to authentic original documents of the copies of all such documents submitted to me as certified, conformed, and photocopied,
including the quoted, extracted, excerpted, and reprocessed text of such documents.
Based
upon my review described herein, it is my opinion the Shares are duly authorized and when/if issued and delivered by Company against
payment therefore, as described in the offering statement, will be validly issued, fully paid, and non-assessable.
ALPHA
ADVOCATE LAW GROUP PC.
11432
South Street Suite 373, Cerritos, CA 90703.
TEL:
562-219-0089. FAX: 562-456-3016.
EMAIL: Alphaadvocatelaw@gmail.com
| ___________________________________________________________________________________ | |
I
have not been engaged to examine, nor have I examined, the Offering Statement for the purpose of determining the accuracy or completeness
of the information included therein or the compliance and conformity thereof with the rules and regulations of the SEC or the requirements
of Form 1-A, and I express no opinion with respect thereto. The forgoing opinion is strictly limited to matters of Nevada corporation
law; and I do not express an opinion on the federal law of the United States of America or the law of any state or jurisdiction therein
other than Nevada, as specified herein.
I
hereby consent to the filing of this opinion as Exhibit 12.1 to the Offering Statement and to the reference to our firm under the caption
“Legal Matters” in the Offering Circular constituting a part of the Offering Statement. We assume no obligation to update
or supplement any of the opinion set forth herein to reflect any changes of law or fact that may occur following the date hereof.
Alpha
Advocate Law Group PC
Udo
Ekekeulu, Esq.
Exhibit 12.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in the Offering Circular
constituting a part of this Offering Statement on Form 1-A, as it may be amended, of our Independent Auditor’s Report dated
September 18, 2023, relating to the audit of the financial statements for the period ending December 31, 2022 and 2021 of Sino Bioenergy
Corp., and the reference to our firm under the caption “Experts” in the Offering Circular.
/s/ Haroon Imtiaz, CPA
Haroon Imtiaz, CPA
Mountain House, CA 95391
Dated: December 28, 2023
Exhibit 12.3
SINO
BIOENERGY CORP.
FINANCIAL
STATEMENTS
FOR
THE TWELVE MONTHS ENDED DECEMBER 31, 2022 AND 2021
TOGETHER
WITH
INDEPENDENT
ACCOUNTANT AUDIT REPORT
INDEPENDENT
ACCOUNTANTS' AUDIT REPORT
To
the Board of SINO BIOENERGY CORP.:
We
have audited the financial statements of SINO BIOENERGY CORP., which comprise the balance sheets as of December 31, 2022 and 2021, and
the related statements of income, changes in stockholders' equity, and cash flows for the twelve months ended December 31, 2022 and December
2021, and the related notes to the financial statements.
In
our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of SINO BIOENERGY
CORP. as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the twelve months ended December 31,
2022 and December 2021 in accordance with accounting principles generally accepted in the United States of America.
Basis
for Opinion
We
conducted our audits in accordance with auditing standards generally accepted in the United States of America
(GAAS).
Our responsibilities under those standards are further described in the Auditor's Responsibilities for the
Audit
of the Financial Statements section of our report. We are required to be independent of SINO BIOENERGY CORP. and to meet our other ethical
responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we
have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Responsibilities
of Management for the Financial Statements
Management
is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally
accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation
and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the
financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise
substantial doubt about SINO BIOENERGY CORP.'s ability to continue as a going concern within one year after the date that the financial
statements are available to be issued.
Auditor’s
Responsibilities for the Audit of the Financial Statements
Our
objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement,
whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance
but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material
misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting
from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Misstatements
are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment
made by a reasonable user based on the financial statements.
In
performing an audit in accordance with GAAS, we:
| • | Exercise
professional judgment and maintain professional skepticism throughout the audit. |
| • | Identify
and assess the risks of material misstatement of the financial statements, whether due to
fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
include examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. |
| • | Obtain
an understanding of internal control relevant to the audit in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion
on the effectiveness of SINO BIOENERGY CORP.'s internal control. Accordingly, no such opinion
is expressed. |
| • | Evaluate
the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluate the overall presentation of the financial
statements. |
| • | Conclude
whether, in our judgment, there are conditions or events, considered in the aggregate, that
raise substantial doubt about SINO BIOENERGY CORP.'s ability to continue as a going concern
for a reasonable period of time. |
Exhibit
12.3
SINO
BIOENERGY CORP.
Statement
of Assets and Liabilities
As
of December 31, 2022 and 2021
| |
Dec. 31, 2022 | |
Dec. 31, 2021 |
| |
| |
|
ASSETS: | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash and Cash
Equivalents | |
$ | 1,837 | | |
| — | |
Total
Current Assets | |
| 1837 | | |
| — | |
| |
| | | |
| | |
| |
| | | |
| | |
Fixed Assets, net | |
| — | | |
| — | |
Other
Asset | |
| 1837 | | |
| — | |
Total
Assets | |
| 1837 | | |
| — | |
| |
| | | |
| | |
LIABILITIES AND SHARE HOLDERS
EQUITY | |
| | | |
| | |
Current Liabilities | |
| — | | |
| — | |
Accounts
Payable | |
| — | | |
| — | |
Total Current Assets | |
| | | |
| | |
| |
| | | |
| | |
Long Term Liabilities | |
| | | |
| | |
Long
term Liabilities | |
| 26,000 | | |
| — | |
Total Long Term Liabilities | |
| 26,000 | | |
| — | |
| |
| | | |
| | |
| |
| | | |
| | |
Total Liabilities | |
| 26,000 | | |
| — | |
Share Holders Equity | |
| | | |
| | |
Common Stock, $0.0001 par
value, 990,000,000 shares authorized, 51,251,321 and 711,915,750 issued and outstanding as at December 31, 2022 and 2021, respectively. | |
| 5,125 | | |
| 71,192 | |
Additional Paid-in Capital | |
| 8,168,446 | | |
| 8,102,379 | |
Retained
Earnings (Loss) | |
| (8,197,734 | ) | |
| (8,173,571 | ) |
Share Holders Equity | |
| (24,163 | ) | |
| — | |
| |
| | | |
| | |
TOTAL
LIABILITIES AND SHARE HOLDERS EQUITY | |
$ | 202,559 | | |
$ | 273,846 | |
See
accompanying notes and independent accountants' Audit report.
SINO BIOENERGY CORP.
Statement
of Operations
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
| |
For
Twelve Months Ended December 31, 2022 | |
For
Twelve Months Ended December 31, 2021 |
REVENUE,
Net | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
OPERATING
EXPENSES: | |
| | | |
| | |
Automobile
& Travel Expenses | |
| 450 | | |
| — | |
Business
Licenses and Permits: NV SoS | |
| 4,775 | | |
| — | |
Community
Outreach | |
| 185 | | |
| — | |
Computer
and Internet Expenses | |
| 383 | | |
| — | |
Insurance
Expense | |
| 285 | | |
| — | |
Office
Supplies | |
| 825 | | |
| — | |
Legal | |
| 7,500 | | |
| — | |
Stock
Transfer Agents | |
| 7,500 | | |
| — | |
Rent
& Lease Expense | |
| 1,250 | | |
| — | |
Telephone
Expense | |
| 385 | | |
| — | |
Training
and Staff Development | |
| 625 | | |
| — | |
TOTAL OPERATING
EXPENSES: | |
| (24,163 | ) | |
| — | |
| |
| | | |
| | |
OPERATING
INCOME (LOSS) | |
| (24,163 | ) | |
| — | |
| |
| | | |
| | |
Non-operative
gain and losses | |
| | | |
| | |
Other Income | |
| — | | |
| — | |
| |
| | | |
| | |
Net
Income (Loss) before Taxes | |
| (24,163 | ) | |
| — | |
| |
| | | |
| | |
Basic
and Diluted Loss Per Share | |
($ | 0.00047 | ) | |
| 0.0000 | |
| |
| | | |
| | |
WEIGHTED
AVERAGE COMMON SHARES OUTSTANDING: Basic | |
| 51,251,321 | | |
| 711,915,750 | |
See
accompanying notes and independent accountants' Audit report.
SINO
BIOENERGY CORP.
Statement
of Changes in Partners' Capital
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
|
|
Common
Stock |
|
Additional
Paid-in
Capital
|
|
Retained
Earning
(Loss)
|
|
|
|
|
#
of shares |
|
Amount
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2020 |
|
711,915,750
|
|
71,192
|
|
8,102,379
|
|
(8,173,571)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income (Loss) |
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2021 |
|
711,915,750
|
|
71,192
|
|
8,102,379
|
|
(8,173,571)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Share
cancellation and Issuance |
|
(660,664,429)
|
|
(66,067)
|
|
66,067
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income (Loss) |
|
-
|
|
-
|
|
-
|
|
(24,163)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2022 |
|
51,251,321
|
|
5,125
|
|
8,168,446
|
|
(8,197,734)
|
|
(24,163)
|
See
accompanying notes and independent accountants' Audit report.
SINO
BIOENERGY CORP.
Statements
of Cash Flows
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
| |
Dec.
31, 2022 | |
Dec.
31, 2021 |
CASH FLOWS
FROM OPERATING ACTIVITIES | |
| | | |
| | |
Net Income | |
$ | (24,163 | ) | |
| — | |
Adjustments to reconcile Change
in Net Assets to Net cash | |
| | | |
| | |
Provided
By (Used For) operating activities: | |
| | | |
| | |
Total
adjustments | |
| — | | |
| — | |
Net cash provided (used) by
operating activities | |
| (24,163 | ) | |
| — | |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING
ACTIVITIES | |
| | | |
| | |
Net cash
provided (used) by financing activities | |
| — | | |
| — | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING
ACTIVITIES | |
| | | |
| | |
Long term Loans | |
| 26,000 | | |
| — | |
Net Contribution
/ (Distribution) | |
| — | | |
| — | |
Net cash provided (used) by
financing activities | |
| 26,000 | | |
| — | |
| |
| | | |
| | |
Net increase (decrease) in
cash and equivalent | |
| 1,837 | | |
| — | |
| |
| | | |
| | |
CASH
AND CASH EQUIVALENTS: Beginning of Period | |
| — | | |
| — | |
| |
| | | |
| | |
CASH
AND CASH EQUIVALENTS: End of Period | |
$ | 1,837 | | |
| — | |
SINO
BIOENERGY CORP.
Notes
to Financial Statements
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
NOTE
1. GENERAL
Sino
Bioenergy Corp. (the “Company”, “we”, “us” or “our”), a Nevada corporation, is listed
on the OTC Pink Markets under the trading symbol SFBE, was incorporated on August 19, 1999. The Company was originally incorporated as
Pacific Rim Solutions Inc. to market and distribute an oxygen enriched water product called biocatalyst in the province of British Columbia.
That business purpose collapsed because of a dispute with the original license holder, which led to the discontinuance of all operations
relating to biocatalyst.
On
January 30, 2006, the Company changed it name to Sino Fibre Communication, Inc. and later on January 3, 2011, the Company again changed
it name to its current name, Sino Bioenergy Corp. The Company had acquired the rights to several domain names, all related to the supplements
industry including: VitaminSales.us VitaminsPrime.com, VitaminChoices.com, HerbsPrime.com, SupplementsPrime.com and NewHealthReview.com,
which would be the corporate online newsletter. Initially the Company worked as an online affiliated distributor of existing Internet-based
vitamin and other supplement sales companies. Management was not able to sustain this business and discontinued operations in December
2005.
On
January 5, 2006, the two largest stockholders of the Company transferred their shares of the Company (approximately 93% of the then total
outstanding shares of Pacific Rim Solutions, Inc.) to a new stockholder group. Subsequent to the closing of this share transaction, the
new shareholder group appointed a new Board of Directors and changed the company's operating business and name. The new business operated
under the name of Sino Fibre Communications Inc., effective January 30, 2006. The Company planned to operate an optical fiber network
in China that would provide domestic and international backbone transmission and data network services such as synchronous digital hierarchy,
internet protocol wholesale, managed bandwidth and leased lines to other network operators, wholesale carriers and web-centric service
providers.
Sometime
after September 30, 2018, the Company abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets.
It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders
and pay its annual franchise tax from 2018 to 2022 which resulted in its Nevada charter being permanently revoked.
The
Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933,
and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act.
The
company incurred operating losses in from inception through 2018 resulting in accumulated deficit of $8,173,571 as at September 30, 2018.
After their September 30, 2018 reports filed November 14, 2010, the Company stopped all forms of making public report of its operation
and financial results.
On
April 5, 2022, Alpharidge Capital, LLC, a shareholder of the Company, served a demand to the Company, at last address of record, to comply
with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. On May 13, 2022, a petition was filed against the Company
in the District Court of Clark County, Nevada, entitled “In the Matter of SINO BIOENERGY CORP., a Nevada corporation” under
case number
SINO
BIOENERGY CORP.
Notes
to Financial Statements
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
NOTE
1. GENERAL (Continued)
A-22-852552-P
by Alpharidge Capital, LLC, along with an Application for Appointment of Custodian, after several attempts to get prior management to
revive the Company’s Nevada charter, which had been dissolved.
On
June 10, 2022, the District Court of Clark County, Nevada entered an Order Granting
Application for Appointment of Alpharidge Capital, LLC (the “Order”), as Custodian of the Company. Pursuant to the Order,
the Alpharidge Capital, LLC (the “Custodian”) has the authority to take any actions on behalf of the Company, that are reasonable,
prudent or for the benefit of pursuant to, including, but not limited to, issuing shares of stock and issuing new classes of stock, as
well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements
under the Nevada charter.
On
June 10, 2022, pursuant to a Securities Purchase Agreement (SPA) the Custodian
granted to Alpharidge LLC. (Alpharidge), 5 Series A preferred shares (convertible at 1 into 200,000,000 common shares, and the converted
shares have 1/1 voting rights similar to all common stock) in exchange for $7,500 which the Company used to fund the settlement of the
Stock Transfer Agent’s balance. Alpharidge also undertook to reinstate the Company’s Charter with the State of Nevada, and
make all reasonable efforts to provide adequate current public information to meet the requirements under the Securities Act of 1933.
On
June 10, 2022, the Custodian appointed Frank I Igwealor, who is associated to
Alpharidge Capital, LLC., as the Company’s sole officer, secretary, treasurer and director.
The
purchaser of the 5 Series A preferred shares has control of the Company through super voting rights over all classes of stock and the
5 Series A preferred shares are convertible into 1,000,000,000 (5 Series A
preferred
shares multiplied by 200,000,000) shares of the Company’s common stock.
However,
the court appointed control still remains with the Custodian until the Custodian files a petition with the District Court of Clark County,
Nevada to relinquish custodianship and control of the Company.
On
June 24, 2022, the Company filed a Certificate of Reinstatement with the Secretary
State of the State of Nevada, which reinstated the Company’s charter and appointed a new Resident Agent in Nevada.
The
company is currently engaged with forensic an assets recovery consultant to help recover the assets of the company from previous management
to make shareholders whole again.
The
Company intends to go after the Toxic lenders and predatory lenders that have been milking the corporation and depriving the shareholders
of stability because of the nonstop dilutions they had subjected the company to these past years.
The
Company recently wrote down all of its assets to zero following a change of management because
SINO
BIOENERGY CORP.
Notes
to Financial Statements
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
NOTE
1. GENERAL (Continued)
new
management had doubts about the value of each assets and their availability for the Company’s utilization. Following the management
change, the Company has funded its operation with advances from the new management. The company hopes to continue with this arrangement
until it could raise sufficient capital to stand on its own feet. The company has also engaged with forensic accountants and assets recovery
consultants to help recover the assets of the company from previous management and predatory lenders to make shareholders whole again.
On
April 1, 2023, the Company completed its new business plan and started implementation. On April 1, 2023, the Company restarted its business
as an online affiliated distributor of existing Internet-based vitamin and other supplement sales companies. Since April 1, 2023, in
accordance with its business plan, the Company has devoted substantial energy, time and resources reviewing and rewriting agreements
with partners, customers, vendors, and manufacturers, reviewing licenses and sublicense agreements with potential licensors, interviewing
and hiring employees, and conducting research and due diligence on potential partners, Joint-ventures, and acquisitions in the target
industry. We is also actively seeking additional acquisitions Internet-based vitamin and other supplement, food/nutrition/farm and food
technology operations as time and resources permits.
NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Accounting
The
financial statements of the Company are prepared on the accrual basis of accounting and in accordance with accounting principles generally
accepted in the United States of America. Accordingly, revenues are recognized when earned and expenses are recorded when incurred.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of financial statements and the reported amounts of revenues and disbursements during the reporting
period. Actual results could differ from those estimates.
Cash
and cash equivalents
For
purpose of the statement of cash flows, the Company considers all money market funds and highly liquid debt instruments purchased with
a maturity of three months or less when purchased to be cash equivalents.
SINO
BIOENERGY CORP.
Notes
to Financial Statements
Note
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Liabilities
SINO
BIOENERGY CORP.. maintains current liabilities with accounts payable carrying month to month. Further, SINO BIOENERGY CORP.. as of 31
Dec. 2022 maintains no Long term liabilities on its assets.
Revenue
Recognition
All
revenues are recorded in accordance with ASC 606, Revenue from Contracts with Customers, which is recognized when: (i) a contract with
a customer has been identified, (ii) the performance obligation(s) in the contract have been identified, (iii) the transaction price
has been determined, (iv) the transaction price has been allocated to each performance obligation in the contract, and (v) the Organization
has satisfied the applicable performance obligation over time or at a point in time.
Investments
with readily determinable fair values are reported at fair value based upon quoted market prices or published net asset values for alternative
investments with characteristics similar to a mutual fund. Other alternative investments (nontraditional, not readily marketable vehicles),
such as certain hedge funds, private equity, alternative hedged strategies and real assets are reported at net asset value, as a practical
expedient for estimated fair value, as provided by the investment managers of the respective funds. The reported values may differ from
the values that would have been reported had a ready market for these investments existed. All other investments are stated at fair value
based upon quoted market prices in active markets.
Income
Taxes
No
Provision for Federal and State income tax has been calculated. The Company is structured as a corporation. Under this approach, deferred
income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities
and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does
not believe the Company has met the “more likely than not” standard imposed by accounting standards to allow recognition
of such an asset.
As
of December 31, 2022, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards.
Deferred tax assets were offset by a corresponding allowance of 100%. The Company experienced a change in control during the year, and
therefore no more than an insignificant portion of this net operating allowance will ever be used against future taxable income.
SINO
BIOENERGY CORP.
Notes
to Financial Statements
Note
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Advertising
Costs
Advertising
costs associated with marketing the Company’s products and services are generally expensed as costs are incurred.
Property,
Plant and Equipment
Property,
plant and equipment are stated at cost, if purchased or fair value on date of contribution. Depreciation and amortization are computed
on a straight-line basis over the estimated useful life of the asset. Capitalization costs incurred in connection with ongoing capital
projects are recorded as systems and construction in progress. These costs will be reclassified into categories and depreciated once
placed in service. Expenditures for normal maintenance and repairs are charged to expense.
The
estimated useful lives by asset class are as follows:
| |
Years |
Buildings | |
25-50 |
Buildings
Improvements | |
| 10 | |
Vehicles | |
| 5 | |
Furniture
and office equipment | |
| 5 | |
Software
and computer equipment | |
| 3-5
| |
Unpaid
Orders
Cash
deposits received from customers are designated restricted until payment is subsequently made to beneficiaries. The Company is required
by various state departments of financial regulators to maintain these balances in designated bank accounts. As of December, 31, 2022,
the Unpaid Orders were $0.
NOTE
3. LITIGATION, COMMITMENTS AND CONTINGENCIES
From
time to time the SINO BIOENERGY CORP. may be subject to legal proceedings and claims in the ordinary course of its business. However,
in the opinion of management, there are no claims, pending or asserted, that will have a material adverse effect on the SINO BIOENERGY
CORP.'s financial position.
SINO
BIOENERGY CORP.
Notes
to Financial Statements
Note
4. FAIR VALUE MEASUREMENT
The
Organization values its investments in accordance with GAAP and consistent with the FASB’s official pronouncement on Fair Value
Measurements for financial assets and liabilities. The pronouncement defines fair value as the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. GAAP establishes a hierarchy of valuation inputs based
on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent
of the reporting entity. Unobservable inputs reflect the entities own assumptions about how market participants would value an asset
or liability based on the best information available. Valuation techniques used to measure fair value utilize relevant observable inputs
and minimize the use of unobservable inputs.
The
three levels of the fair value hierarchy are as follows:
Level
1 Inputs are quoted prices or published net asset values (unadjusted), in active markets for identical assets or liabilities that
the Organization has the ability to access at the measurement date. Level 2 Inputs are other than quoted prices included in Level
1 that are observable for the asset or liability, either directly or indirectly.
Level
3 Inputs are unobservable inputs for the asset or liability.
A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. In determining fair value, organization utilizes valuation techniques that maximize the use of observable
inputs and minimize the use of unobservable inputs to the extent possible; as well as, considers nonperformance risk in its assessment
of fair value.
Fair
values of assets measured on a recurring basis at December 31, 2022 are as follows:
| |
| |
| |
Quoted Prices
in Active Markets for identical Assets | |
Observables
Inputs | |
Unobservable
Inputs |
| |
| |
FMV | |
(Level
1) | |
(Level
2) | |
(Level
3) |
| Cash | | |
| Dec.
31, 2022 | | |
$ | 1,837 | | |
$ | 1,837 | | |
| — | | |
| — | |
| Cash
| | |
| Dec.
31, 2021 | | |
$ | — | | |
$ | — | | |
| | | |
| | |
SINO
BIOENERGY CORP.
Notes
to Financial Statements
NOTE
5. SUBSEQUENT EVENTS
Management
has evaluated subsequent events through Sep 18, 2023, the date on which the financial statements were available to be issued. Management
has determined that none of the events occurring after the date of the balance sheet through the date of Management’s review substantially
affect the amounts and disclosure of the accompanying financial statements.
NOTE
6. COVID 19 (Continued)
The
outbreak of Novel Coronavirus (COVID 19) continues to progress and evolve. Therefore, it is challenging now, to predict the full extent
and duration of its business and economic impact. The extent and duration of such impacts remain uncertain and dependent on future developments
that cannot be accurately predicted at this time, such as the transmission rate of the coronavirus and the extent and effectiveness of
containment actions taken. Given the ongoing economic uncertainty, a reliable estimate of the impact cannot be made at the date of authorization
of these financial statements. These developments could impact our future financial results, cash flows and financial condition however
the management of the Company was hopeful that it will not significantly impact the business of the Company.
Note
7. CASH AND CASH EQUIVALENTS
Cash
& cash equivalents at December 31, 2022 and 2021 ended consist of the following checking accounts:
| |
December 31,
2022 | |
December 31,
2021 |
| Cash | | |
$ | 1,837 | | |
| — | |
| | | |
| | | |
| | |
| Total | | |
$ | 1,837 | | |
| — | |
NOTE
8. CONCENTRATIONS OF CREDIT AND MARKET RISK
The
SINO BIOENERGY CORP. maintains substantially all of their cash balances in deposit accounts that at times may exceed Federally insured
limits. The SINO BIOENERGY CORP. has not experienced any losses in such accounts. The SINO BIOENERGY CORP. believes they are not exposed
to any significant credit risk related to these deposit accounts.
SINO
BIOENERGY CORP.
Notes
to Financial Statements
For
the Twelve Months Ended Dec 31, 2022, and Ended Dec 31, 2021
Note
9. SICK LEAVE, VACATION AND OTHER COMPENSATED ABSENCES
SINO
BIOENERGY CORP. is in conformity with the state and federal Labor Laws and Regulations, Family Care and Medical Leave and Pregnancy Disability
Leave, and Prohibits Workplace Discrimination.
NOTE
10. NOTES PAYABLE – RELATED
PARTIES
The
following notes payable were from related parties:
Date
of
Note
Issuance
|
Outstanding
Balance ($) |
Principal
Amount
at
Issuance
($) |
Interest
Accrued
($)
|
Maturity
Date |
Conversion
Terms |
Name
of Noteholder. |
Reason
for
Issuance
(e.g.
Loan,
Services, etc.) |
10/1/2022
|
26,000
|
26,000
|
N/A
|
10/2/2024
|
N/A
|
Frank
I Igwealor |
Operating
Capital |
NOTE
11. CONCENTRATIONS OF CREDIT AND MARKET RISK (Continued)
Financial
instruments that potentially expose the Company to concentrations of credit and market risk consist primarily of cash and cash equivalents.
Cash and cash equivalents are maintained at financial institutions and accounts at each institution are insured by the Federal Deposit
Insurance Corporation (FDIC) up to $250,000. At December 31, 2022, and 2021 the SINO BIOENERGY CORP. had $0, of uninsured balances at
these institutions.
Note
12. GOING CONCERN
The
accompanying balance sheet has been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. The entity has not commenced principal operations and realized losses every year since
inception and may continue to generate losses. The Company’s ability to continue as a going concern in the next twelve months following
the date the financial statements were available to be issued is dependent upon its ability to produce revenues and/or obtain financing
sufficient to meet current and future obligations and deploy such to produce profitable operating results. Management has evaluated these
conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. No assurance can be given that the
Company will be successful in these efforts. These factors, among others, raise substantial doubt about the ability of the Company to
continue as a going concern for a reasonable period of time. The financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or the amounts and classification of liabilities.
Exhibit 12.4
Sino
Bioenergy Corp. Statement
of Assets and Liabilities As of June 30, 2023 and December
31, 2022 |
| |
Jun.
30, 2023 | |
Dec.
31, 2022 |
ASSETS: | |
| |
|
Current
Assets | |
| | | |
| | |
Cash
and Cash Equivalents | |
$ | 1,737 | | |
$ | 1,837 | |
Accounts
receivable | |
| — | | |
| — | |
Prepaid
Expenses | |
| — | | |
| — | |
Total
Current Assets | |
$ | 1,737 | | |
$ | 1,837 | |
Fixed
Assets, net | |
| — | | |
| — | |
Total
Assets | |
$ | 1,737 | | |
$ | 1,837 | |
LIABILITIES
AND EQUITY | |
| | | |
| | |
Liabilities | |
| | | |
| | |
Long-term
Liabilities | |
| 30,194 | | |
| 26,000 | |
Total
Liabilities | |
| 30,194 | | |
| 26,000 | |
Share
Holders Equity | |
| | | |
| | |
Preferred
stock, $.001 par value, 5 shares authorized, 10,000,000 issued and outstanding. | |
| 0 | | |
| 0 | |
Common Stock, $0.001
par value, 2,500,000,000 shares authorized, 51,251,321 issued and outstanding as at June 30, 2023 and December 31, 2022. | |
| 5,125 | | |
| 5,125 | |
Additional
Paid-in Capital | |
| 8,168,446 | | |
| 8,168,446 | |
Accumulated
deficit | |
| (8,202,028 | ) | |
| (8,197,734 | ) |
Total
Share Holders Equity | |
| (28,457 | ) | |
| (24,163 | ) |
| |
| | | |
| | |
TOTAL
LIABILITIES AND EQUITY | |
$ | 1,737 | | |
$ | 1,837 | |
Sino
Bioenergy Corp. Statement
of Operations For
the Six Months Ended June
30, 2023 and 2022 |
| |
Twelve
Months | |
Six
Months |
| |
Ended | |
Ended |
| |
June
30, 2023 | |
June
30, 2022 |
REVENUE,
Net | |
$ | — | | |
$ | — | |
Cost
of Sales | |
| — | | |
| — | |
Gross
Profit | |
| — | | |
| — | |
General
and administrative expenses | |
| 4,294 | | |
| — | |
OPERATING
INCOME (LOSS) | |
| (4,294 | ) | |
| — | |
Non-operative
gain and losses | |
| | | |
| | |
Other
Income (Loss) | |
| — | | |
| — | |
Miscellaneous
Expense | |
| — | | |
| — | |
Interest
Expense | |
| — | | |
| — | |
Interest
Income | |
| — | | |
| — | |
Total
Non-Operative Gain (Loss) | |
| — | | |
| — | |
| |
| | | |
| | |
Net
Income (Loss) before Taxes | |
| (4,294 | ) | |
| — | |
NET
COMPREHENSIVE LOSS | |
$ | (4,294 | ) | |
$ | — | |
BASIC
AND DILUTED LOSS PER SHARE: | |
| | | |
| | |
Net
loss per common share - basic and diluted | |
$ | (0.000 | ) | |
$ | — | |
WEIGHTED
AVERAGE COMMON SHARES OUTSTANDING: | |
| | | |
| | |
Basic | |
| 51,251,321 | | |
| 711,915,750 | |
Sino
Bioenergy Corp. Statement
of Changes in Shareholders’ Equity As
of June 30, 2023 and December 31, 2022 |
| |
| |
| |
| |
| |
Additional | |
| |
|
| |
Preferred
Stock | |
Common
Stock | |
Paid-in | |
Accumulated | |
|
| |
#
of Shares | |
Amount | |
#
of Shares | |
Amount | |
Capital | |
Deficit | |
TOTAL |
December
31, 2020 | |
| — | | |
| — | | |
| 711,915,750 | | |
$ | 71,192 | | |
$ | 8,102,379 | | |
$ | (8,173,571 | ) | |
| — | |
New Shares Issuance | |
| — | | |
| — | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net
Income (Loss) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| | | |
| | |
December 31, 2021 | |
| — | | |
| — | | |
| 711,915,750 | | |
$ | 71,192 | | |
$ | 8,102,379 | | |
$ | (8,173,571 | ) | |
| | |
Shares Issuance/Cancellation | |
| | | |
| | | |
| (660,664,429 | ) | |
| (66,066 | ) | |
| 66,066 | | |
| | | |
| | |
Net
Income (Loss) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (24,163 | ) | |
| (24,163 | ) |
December
31, 2022 | |
| | | |
| | | |
| 51,251,321 | | |
$ | 5,125 | | |
$ | 8,168,446 | | |
$ | (8,197,734 | ) | |
$ | (24,163 | ) |
Shares Issuance/Cancellation | |
| 5 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net
Income (Loss), June 30, 2023 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,294 | ) | |
| (4,294 | ) |
June
30, 2023 | |
| 5 | | |
| | | |
| 51,251,321 | | |
$ | 5,125 | | |
$ | 8,168,446 | | |
$ | (8,202,028 | ) | |
$ | (28,457 | ) |
Sino
Bioenergy Corp. Statements
of Cash Flows For
the Six Months Ended June 30, 2023 and 2022 |
| |
2023 | |
2022 |
CASH
FLOWS FROM OPERATING ACTIVITIES | |
| | | |
| | |
Net
Income | |
$ | (4,294 | ) | |
$ | — | |
Adjustments
to reconcile Change in Net Assets to Net cash | |
| | | |
| | |
Provided
By (Used For) operating activities: | |
| | | |
| | |
Increase
in Current Liabilities | |
| 4,194 | | |
| — | |
Total
adjustments | |
| 100 | | |
| — | |
Net
cash provided (used) by operating activities | |
| — | | |
| — | |
CASH
FLOWS FROM INVESTING ACTIVITIES | |
| | | |
| | |
Net
cash provided (used) by financing activities | |
| — | | |
| — | |
CASH
FLOWS FROM FINANCING ACTIVITIES | |
| | | |
| | |
Capital
distributions | |
| — | | |
| — | |
Capital
contributions | |
| — | | |
| — | |
Net
cash provided (used) by financing activities | |
| — | | |
| — | |
Net
increase (decrease) in cash and equivalent | |
| 100 | | |
| — | |
CASH
& CASH EQUIVALENTS: at beginning of period | |
| 1,837 | | |
| — | |
CASH
& CASH EQUIVALENTS: June 30, 2023 | |
$ | 1,737 | | |
$ | — | |
Sino
Bioenergy Corp.
Notes
to Financial Statements
For
the Six Months Ended June 30, 2023
NOTE
1. GENERAL
Sino
Bioenergy Corp. (the “Company”, “we”, “us” or “our”), a Nevada corporation, is listed
on the OTC Pink Markets under the trading symbol SFBE, was incorporated on August 19, 1999. The Company was originally incorporated as
Pacific Rim Solutions Inc. to market and distribute an oxygen enriched water product called biocatalyst in the province of British Columbia. That
business purpose collapsed because of a dispute with the original license holder, which led to the discontinuance of all operations relating
to biocatalyst. On January 30, 2006, the Company changed it name to Sino Fibre Communication, Inc. and later on January 3, 2011, the
Company again changed it name to its current name, Sino Bioenergy Corp. The Company had acquired the rights to several domain names,
all related to the supplements industry including: VitaminSales.us VitaminsPrime.com, VitaminChoices.com, HerbsPrime.com, SupplementsPrime.com
and NewHealthReview.com, which would be the corporate online newsletter. Initially the Company worked as an online affiliated distributor
of existing Internet-based vitamin and other supplement sales companies. Management was not able to sustain this business and discontinued
operations in December 2005.
On
January 5, 2006, the two largest stockholders of the Company transferred their shares of the Company (approximately 93% of the then total
outstanding shares of Pacific Rim Solutions, Inc.) to a new stockholder group. Subsequent to the closing of this share transaction, the
new shareholder group appointed a new Board of Directors and changed the company's operating business and name. The new business operated
under the name of Sino Fibre Communications Inc., effective January 30, 2006. The Company planned to operate an optical fiber network
in China that would provide domestic and international backbone transmission and data network services such as synchronous digital hierarchy,
internet protocol wholesale, managed bandwidth and leased lines to other network operators, wholesale carriers and web-centric service
providers.
Sometime
after September 30, 2018, the Company abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets.
It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders
and pay its annual franchise tax from 2018 to 2022 which resulted in its Nevada charter being permanently revoked.
The
company incurred operating losses in from inception through 2018 resulting in accumulated deficit of $8,173,571 as at September 30, 2018.
After their September 30, 2018 reports filed November 4, 2018, the Company stopped all forms of making public report of its operation
and financial results.
On
April 5, 2022, Alpharidge Capital, LLC, a shareholder of the Company, served a demand to the Company, at last address of record, to comply
with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. On May 13, 2022, a petition was filed against the Company
in the District Court of Clark County, Nevada, entitled “In the Matter of SINO BIOENERGY CORP., a Nevada corporation” under
case number A-22-852552-P by Alpharidge Capital, LLC, along with an Application for Appointment of Custodian, after several attempts
to get prior management to revive the Company’s Nevada charter, which had been dissolved.
On
June 10, 2022, the District Court of Clark County, Nevada entered an Order
Granting Application for Appointment of Alpharidge Capital, LLC (the “Order”), as Custodian of the Company. Pursuant to the
Order, the Alpharidge Capital, LLC (the “Custodian”) has the authority to take any actions on behalf of the Company, that
are reasonable, prudent or for the benefit of pursuant to, including, but not limited to, issuing shares of stock and issuing new classes
of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to
meet the requirements under the Nevada charter.
On
June 10, 2022, pursuant to a Securities Purchase Agreement (SPA) the Custodian
granted to Alpharidge LLC. (Alpharidge), 5 Series A preferred shares (convertible at 1 into 200,000,000 common shares, and the converted
shares have 1/1 voting rights similar to all common stock) in exchange for $7,500 which the Company used to fund the settlement of the
Stock Transfer Agent’s balance. Alpharidge also undertook to reinstate the Company’s Charter with the State of Nevada, and
make all reasonable efforts to provide adequate current public information to meet the requirements under the Securities Act of 1933.
On
June 10, 2022, the Custodian appointed Frank I Igwealor, who is associated
to Alpharidge Capital, LLC., as the Company’s sole officer, secretary, treasurer and director. The purchaser of the 5 Series A
preferred shares has control of the Company through super voting rights over all classes of stock and the 5 Series A preferred shares
are convertible into 1,000,000,000 (5 Series A preferred shares multiplied by 200,000,000) shares of the Company’s common stock.
However, the court appointed control still remains with the Custodian until the Custodian files a petition with the District Court of
Clark County, Nevada to relinquish custodianship and control of the Company.
On
June 24, 2022, the Company filed a Certificate of Reinstatement with the
Secretary State of the State of Nevada, which reinstated the Company’s charter and appointed a new Resident Agent in Nevada.
The
company is currently engaged with forensic an assets recovery consultant to help recover the assets of the company from previous management
to make shareholders whole again. The Company intends to go after the Toxic lenders and predatory lenders that have been milking the
corporation and depriving the shareholders of stability because of the nonstop dilutions they had subjected the company to these past
years.
The
Company recently wrote down all of its assets to zero following a change of management because new management had doubts about the value
of each assets and their availability for the Company’s utilization. Following the management change, the Company has funded its
operation with advances from the new management. The company hopes to continue with this arrangement until it could raise sufficient
capital to stand on its own feet. The company has also engaged with forensic accountants and assets recovery consultants to help recover
the assets of the company from previous management and predatory lenders to make shareholders whole again.
On
April 1, 2023, the Company completed its new business plan and started implementation. On April 1, 2023, the Company restarted its business
as an online affiliated distributor of existing Internet-based vitamin and other supplement sales companies. Since April 1, 2023, in
accordance with its business plan, the Company has devoted substantial energy, time and resources reviewing and rewriting agreements
with partners, customers, vendors, and manufacturers, reviewing licenses and sublicense agreements with potential licensors, interviewing
and hiring employees, and conducting research and due diligence on potential partners, Joint-ventures, and acquisitions in the target
industry. We is also actively seeking additional acquisitions Internet-based vitamin and other supplement, food/nutrition/farm and food
technology operations as time and resources permits.
NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Accounting
The
Company has earned insignificant revenues from limited principal operations. Accordingly, the Company’s activities have been accounted
for as those of a “Development Stage Enterprise” as set forth in Financial Accounting Standards Board Statement No. 7 (“SFAS
7”). Among the disclosures required by SFAS 7 are that the Company’s financial statements be identified as those of a development
stage company, and that the statements of operations, stockholders’ equity (deficit) and cash flows disclose activity since the
date of the Company’s inception.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of financial statements and the reported amounts of revenues and disbursements during the reporting
period. Actual results could differ from those estimates.
Cash
and cash equivalents
For
purpose of the statement of cash flows, the Company considers all money market funds and highly liquid debt instruments purchased with
a maturity of three months or less when purchased to be cash equivalents.
Liabilities
Sino
Bioenergy Corp. maintains current liabilities with no related party payable carrying month to month. Sino Bioenergy Corp. maintains no
Long term liabilities on its assets.
Advertising
Costs
Advertising
costs associated with marketing the Company’s products and services are generally expensed as costs are incurred.
Revenue
Recognition
All
revenues are recorded in accordance with ASC 606, Revenue from Contracts with Customers, which is recognized when: (i) a contract with
a customer has been identified, (ii) the performance obligation(s) in the contract have been identified, (iii) the transaction price
has been determined, (iv) the transaction price has been allocated to each performance obligation in the contract, and (v) the Organization
has satisfied the applicable performance obligation over time or at a point in time.
Investments
Investments
with readily determinable fair values are reported at fair value based upon quoted market prices or published net asset values for alternative
investments with characteristics similar to a mutual fund. Other alternative investments (nontraditional, not readily marketable vehicles),
such as certain hedge funds, private equity, alternative hedged strategies and real assets are reported at net asset value, as a practical
expedient for estimated fair value, as provided by the investment managers of the respective funds. The reported values may differ from
the values that would have been reported had a ready market for these investments existed. All other investments are stated at fair value
based upon quoted market prices in active markets.
Fair
Value Measurements
The
Company determines the fair market value of its financial assets & liabilities based on the fair value hierarchy established in accordance
with U.S. generally accepted accounting principles.
Income
Taxes
The
Sino Bioenergy Corp. is subject to Corporate income and state income taxes in the state it does business. A deferred tax asset as a result
of net operating losses (NOL) has not been recognized due to the uncertainty of future positive taxable income to utilize the NOL. Due
to the recently enacted Tax Cuts and Jobs Act, any NOLs will be limited to 80% of taxable
income generated in future years.
Uncertain
Tax Provisions
Accounting
for uncertain income tax positions, relating to both federal and state income taxes, are required when a more likely than not threshold
is attained. If such positions result in uncertainties, then the unrecognized tax liability is estimated based on a cumulative probability
assessment that aggregates the estimated tax liability for all uncertain tax positions. With the adoption of these new rules, the Organization
assessed its tax positions in accordance with the guidance.
Property,
Plant and Equipment
Property,
plant and equipment are stated at cost, if purchased or fair value on date of contribution. Depreciation and amortization are computed
on a straight-line basis over the estimated useful life of the asset. Capitalization costs incurred in connection with ongoing capital
projects are recorded as systems and construction in progress. These costs will be reclassified into categories and depreciated once
placed in service. Expenditures for normal maintenance and repairs are charged to expense. The estimated useful lives by asset class
are as follows:
|
Years |
Buildings |
25-50 |
Buildings
improvements |
10 |
Vehicles |
5 |
Furniture
and office equipment |
5 |
Software
and computer equipment |
3-5 |
NOTE
3. SUBSEQUENT EVENTS
Management
has evaluated subsequent events through the date of filing the financial statements with OTC Markets, the date the financial statements
were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance sheet date that
would have a material effect on the financial statements thereby requiring adjustment or disclosure, other than those noted below:
Note
4. FAIR VALUE MEASUREMENT
The
Organization values its investments in accordance with GAAP and consistent with the FASB’s official pronouncement on Fair Value
Measurements for financial assets and liabilities. The pronouncement defines fair value as the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. GAAP establishes a hierarchy of valuation inputs based
on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent
of the reporting entity. Unobservable inputs reflect the entities own assumptions about how market participants would value an asset
or liability based on the best information available. Valuation techniques used to measure fair value utilize relevant observable inputs
and minimize the use of unobservable inputs.
The
three levels of the fair value hierarchy are as follows:
Level
1 Inputs are quoted prices or published net asset values (unadjusted), in active markets for identical assets or liabilities that
the Organization has the ability to access at the measurement date.
Level
2 Inputs are other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
Level
3 Inputs are unobservable inputs for the asset or liability.
A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. In determining fair value, organization utilizes valuation techniques that maximize the use of observable
inputs and minimize the use of unobservable inputs to the extent possible; as well as, considers nonperformance risk in its assessment
of fair value.
|
Fair
values of assets measured on a recurring basis at June 30, 2023 & 2022 are as follows: |
|
|
|
|
Quoted
Prices |
|
|
|
|
|
|
in
Active |
|
|
|
|
|
|
Markets |
|
|
|
|
|
|
for
identical |
Observables |
Unobservable |
|
|
|
|
Assets |
Inputs |
Inputs |
|
|
|
FMV |
(Level
1) |
(Level
2) |
(Level
3) |
|
|
June
30, 2023 |
$ 1,737 |
$ - |
- |
- |
|
|
June
30, 2022 |
$ - |
$ - |
- |
- |
|
NOTE
5. LITIGATION, COMMITMENTS AND CONTINGENCIES
Risks
and Uncertainties The Company’s operations are subject to significant risks
and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. The Company
has entered into no contracts during the year as follows:
Legal
and other matters In the normal course of business, the Company may become a party to litigation matters involving claims against
the Company. The Company's management is aware of a garnishment order that was previously served to the Company’s Stock Transfer
Agents. The Company’s attorneys are reviewing the garnishment order to ascertain its implication to the company’s financial
statements. Aside from the court order discussed above, The Company's management is unaware of any pending or threatened assertions and
there are no current matters that would have a material effect on the Company’s financial position or results of operations.
Note
6. SICK LEAVE, VACATION AND OTHER COMPENSATED ABSENCES
Sino
Bioenergy Corp. is in conformity with the state Labor Laws and Regulations, Family Care and
Medical Leave, and Prohibits Workplace Discrimination.
NOTE
7. CONCENTRATIONS OF CREDIT AND MARKET RISK
The
Sino Bioenergy Corp. maintains substantially all of their cash balances in deposit accounts that at times may exceed Federally insured
limits. The Sino Bioenergy Corp. has not experienced any losses in such accounts. The Sino Bioenergy Corp. believes they are not exposed
to any significant credit risk related to these deposit accounts. Financial instruments that potentially expose the Company to
concentrations of credit and market risk consist primarily of cash and cash equivalents. Cash and cash equivalents are maintained at
financial institutions and accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000.
At December 31, 2022, 2021 and June 30, 2023, Sino Bioenergy Corp. had $0, of uninsured balances at these institutions.
NOTE
8. RELATED PARTY TRANSACTIONS
The
Company is authorized to issue 8,000,000,000 shares of common stock, $0.001 par value and 50,000,000 preferred stocks, $0.001 par value.
Voting rights are not cumulative and, therefore, the
holders of more than 50% of the common stock could, if they chose to do so, elect all of the directors of the Company. As of June
30, 2023, there were 51,251,321 shares of common stock issued and outstanding. The company issued 335,000,000 shares of common stock
during twelve months ended December 31, 2021. So, there were 51,251,321 shares of common stock issued and outstanding as of June 30,
2023. As of June 30, 2023 and December 31, 2022, there were 50,000,000 share of preferred stock issued and outstanding held by 1 stockholder
of record.
NOTE
9. COVID 19
The
outbreak of Novel Coronavirus (COVID 19) continues to progress and evolve. Therefore, it is challenging now, to predict the full extent
and duration of its business and economic impact. The extent and duration of such impacts remain uncertain and dependent on future developments
that cannot be accurately predicted at this time, such as the transmission rate of the coronavirus and the extent and effectiveness of
containment actions taken. Given the ongoing economic uncertainty, a reliable estimate of the impact cannot be made at the date of authorization
of these financial statements. These developments could impact our future financial results, cash flows and financial condition however
the management of the Company was hopeful that it will not significantly impact the business of the Company.
NOTE
10. GOING CONCERN
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has no operations with
$8,202,028 accumulated loss as of June 30, 2023. The Company intends to commence operations as set out below and raise the necessary
funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with
the required funding. These factors, among others, raise substantial doubt about the Company’s ability to continue as a
going concern. The accompanying financial statements do not include any adjustments that
might result from the outcome of this uncertainty.
SUPPLEMENTAL
INFORMATION
Sino
Bioenergy Corp. SUPPLEMENTARY
SCHEDULE GENERAL
AND ADMINISTRATION EXPENSES For
the Six Months Ended June 30, 2023 |
| |
Six
Months | |
Six
Months |
| |
Ended | |
Ended |
| |
June
30, 2023 | |
June
30, 2022 |
General
and administrative expenses | |
| | | |
| | |
Automobile
expense | |
$ | 225 | | |
$ | — | |
Professional
& contracted Services | |
| 2,100 | | |
| — | |
Advertising | |
| 93 | | |
| — | |
Sec
filing | |
| — | | |
| — | |
Legal
Fee | |
| — | | |
| — | |
Insurance | |
| 142 | | |
| — | |
Computer
& related expenses | |
| 192 | | |
| — | |
Repairs
and maintenance | |
| — | | |
| — | |
Telephone | |
| 192 | | |
| — | |
Postage | |
| — | | |
| — | |
Office
Supplies | |
| 413 | | |
| — | |
Rent | |
| 625 | | |
| — | |
Depreciation | |
| — | | |
| — | |
Bank
Charges | |
| — | | |
| — | |
Other
Business Expenses | |
| 312 | | |
| — | |
Total
General and Administrative expenses | |
$ | (4,294 | ) | |
$ | — | |
Sino Bioenergy (CE) (USOTC:SFBE)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Sino Bioenergy (CE) (USOTC:SFBE)
Historical Stock Chart
Von Nov 2023 bis Nov 2024